NISHIYAMA Osamu

    Department of Medicine Associate Professor
Last Updated :2024/04/19

Researcher Information

Degree

  • MD, PhD(2001/12)

URL

Research funding number

  • 40568151

ORCID ID

J-Global ID

Research Interests

  • chronic obstructive pulmonary disease   pulmonary hypertension   pulmonary rehabilitation   interstitial lung disease   respiratory medicine   

Research Areas

  • Life sciences / Respiratory medicine

Education

  •        - 1993/03  Nagoya University  医学部  医学科

Association Memberships

  • European Respiratory Society   THE JAPANESE SOCIETY FOR TUBERCULOSIS   THE JAPAN BRONCHO-ESOPHAGOLOGICAL SOCIETY   JAPAN SOCIETY OF CLINICAL ONCOLOGY   日本臨床腫瘍学会   THE JAPAN LUNG CANCER SOCIETY   日本肺高血圧・肺循環学会   日本呼吸ケア・リハビリテーション学会   THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY   THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES   JAPANESE SOCIETY OF ALLERGOLOGY   THE JAPANESE RESPIRATORY SOCIETY   THE JAPANESE SOCIETY OF INTERNAL MEDICINE   American Thoracic Society   

Published Papers

  • Hiroki Mizusawa; Hisako Matsumoto; Masashi Shiraishi; Ryuji Sugiya; Yu Takeda; Masaya Noguchi; Tamotsu Kimura; Akira Ishikawa; Osamu Nishiyama; Yuji Higashimoto
    Respiratory investigation 62 (2) 234 - 239 2024/01 
    BACKGROUND: Decreased respiratory muscle strength and muscle mass is key in diagnosing respiratory sarcopenia. However, the role of reduced diaphragm activity, expressed as the maximal level of diaphragmatic excursion (DEmax), in diagnosing respiratory sarcopenia in patients with chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to characterize patients with COPD and low DEmax and maximal inspiratory pressure (MIP), a measure of inspiratory muscle strength, and assess the role of DEmax in respiratory sarcopenia. METHODS: Patients with COPD underwent spirometry, exercise tolerance (VO2peak) test, and MIP measurement. DEmax and sternocleidomastoid thickness at the maximal inspiratory level (TscmMIL) were assessed using ultrasound sonography. RESULTS: Overall, 58 patients with COPD (median age, 76 years; median %FEV1, 51.3 %) were included, 28 of whom showed a %MIP of ≥80 %, defined as having preserved MIP. Based on the %MIP of 80 % and median value of DEmax (48.0 mm) as thresholds, the patients were stratified into four groups: both-high (n = 18), %MIP-alone low (n = 11), DEmax-alone low (n = 10), and both-low (n = 19) groups. The both-low group exhibited the lowest %FEV1, Δinspiratory capacity, VO2peak, and TscmMIL, and these values were significantly lower than those of the both-high group. Except for %FEV1, these values were significantly lower in the both-low group than in the %MIP-alone low group despite adjusting DEmax level for body mass index. CONCLUSION: Measuring DEmax along with MIP can characterize patients with COPD, reduced exercise capacity, and decreased accessory respiratory muscle mass and can help diagnose respiratory sarcopenia.
  • iPPFE患者の横隔膜動態に着目した1例 臥位での運動療法による長期効果
    神吉 健吾; 白石 匡; 杉谷 竜司; 水澤 裕貴; 野口 雅矢; 武田 優; 木村 保; 西山 理; 松本 久子; 東本 有司
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 33 (Suppl.) 140s - 140s 1881-7319 2023/11
  • 吸気筋トレーニングがCOPD患者の横隔膜移動距離に与える効果
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 武田 優; 野口 雅也; 西山 理; 山崎 亮; 木村 保; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 33 (Suppl.) 152s - 152s 1881-7319 2023/11
  • 呼吸指導が著効したiPPFE患者の1例 呼吸指導介入による短期効果
    武田 優; 白石 匡; 杉谷 竜司; 水澤 裕貴; 野口 雅矢; 神吉 健吾; 木村 保; 西山 理; 松本 久子; 東本 有司
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 33 (Suppl.) 175s - 175s 1881-7319 2023/11
  • Masashi Shiraishi; Yuji Higashimoto; Ryuji Sugiya; Hiroki Mizusawa; Yu Takeda; Masaya Noguchi; Osamu Nishiyama; Ryo Yamazaki; Shintarou Kudo; Tamotsu Kimura; Yuji Tohda; Hisako Matsumoto
    ERJ Open Research European Respiratory Society (ERS) 00079 - 2023 2023/06 
    Background and objective Dynamic lung hyperinflation (DLH) can play a central role in exertional dyspnoea in patients with chronic obstructive pulmonary disease (COPD). Chest X-ray is the basic tool for assessing static lung hyperinflation in COPD. However, the predictive capacity of DLH using chest X-ray remains unknown. This study was conducted to determine whether DLH can be predicted by measuring the height of the right diaphragm (dome height) on chest X-ray. Methods This single-centre, retrospective cohort study included patients with stable COPD with pulmonary function test, cardiopulmonary exercise test, constant load test, and pulmonary images. They were divided into two groups according to the median of changes of inspiratory capacity (ΔIC=IC lowest − IC at rest). The right diaphragm dome height and lung height were measured on plain chest X-ray. Results Of the 48 patients included, 24 were classified as having high DLH (ΔIC≤−0.59 L from rest; −0.59 L, median of all) and 24 as having low DLH. Dome height correlated with ΔIC (r=0.66, p<0.001). Multivariate analysis revealed that dome height was associated with high DLH independent of %low attenuation area on chest computed tomography and %FEV1. Furthermore, the area under the receiver operating characteristic curve of dome height to predict high DLH was 0.86, with sensitivity and specificity of 83% and 75%, respectively, at a cutoff of 20.5 mm. Lung height was unrelated to ΔIC. Conclusion Diaphragm dome height on chest X-ray may adequately predict high DLH in patients with COPD.
  • Kensuke Kataoka; Osamu Nishiyama; Takashi Ogura; Yoshihiro Mori; Ryo Kozu; Shinichi Arizono; Tohru Tsuda; Hiromi Tomioka; Keisuke Tomii; Koji Sakamoto; Hiroshi Ishimoto; Michiko Kagajo; Hiroyuki Ito; Kazuya Ichikado; Hajime Sasano; Seiichirou Eda; Machiko Arita; Yasuhiro Goto; Osamu Hataji; Satoshi Fuke; Ryota Shintani; Hirotsugu Hasegawa; Masahiko Ando; Tomoya Ogawa; Masashi Shiraishi; Fumiko Watanabe; Koichi Nishimura; Takuma Sasaki; Shinjiro Miyazaki; Hideo Saka; Yasuhiro Kondoh
    Thorax 78 (8) 784 - 791 2023/04 [Refereed]
     
    BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterised by worsening dyspnoea and exercise intolerance. RESEARCH QUESTION: Does a long-term pulmonary rehabilitation improve exercise tolerance in patients with IPF treated with standard antifibrotic drugs, which are expected to reduce disease progression? METHODS: This open-label randomised controlled trial was performed at 19 institutions. Stable patients receiving nintedanib were randomised into pulmonary rehabilitation and control groups (1:1). The pulmonary rehabilitation group underwent initial rehabilitation which included twice-weekly sessions of monitored exercise training for 12 weeks, followed by an at-home rehabilitation programme for 40 weeks. The control group received usual care only, without pulmonary rehabilitation. Both groups continued to receive nintedanib. The primary and main secondary outcomes were change in 6 min walking distance (6MWD) and change in endurance time (using cycle ergometry) at week 52. RESULTS: Eighty-eight patients were randomised into pulmonary rehabilitation (n=45) and control (n=43) groups. Changes in 6MWD were -33 m (95% CI -65 to -1) and -53 m (95% CI -86 to -21) in the pulmonary rehabilitation and control groups, respectively, with no statistically significant difference (mean difference, 21 m (95% CI -25 to 66), p=0.38). Changes in endurance time were significantly better in the pulmonary rehabilitation (64 s, 95% CI -42.3 to 171)) than in the control (-123 s (95% CI -232 to -13)) group (mean difference, 187 s (95% CI 34 to 153), p=0.019). INTERPRETATION: Although pulmonary rehabilitation in patients taking nintedanib did not improve 6MWD in the long term, it led to prolonged improvement in endurance time. TRIAL REGISTRATION NUMBER: UMIN000026376.
  • Ryo Yamazaki; Osamu Nishiyama; Kazuya Yoshikawa; Yuji Tohda; Hisako Matsumoto
    Respiratory investigation 61 (3) 339 - 346 2023/03 [Refereed]
     
    BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) have a slowly progressive clinical course, although some develop acute exacerbations (AEs). An easily obtained composite score is desirable for predicting the survival rate in patients with AE of IPF (AE-IPF). We investigated the quick sequential organ failure assessment (qSOFA), originally developed to identify sepsis, as a predictor of mortality in patients with AE-IPF and compared it to other composite assessments. METHODS: Consecutive patients with IPF admitted for their first AE between 2008 and 2019 were recruited retrospectively. The association between the qSOFA score obtained at admission and mortality was investigated. RESULTS: During the study period, 97 patients with AE-IPF were hospitalized. The hospital mortality was 30.9%. Multivariate logistic regression analysis revealed that both the qSOFA and the Japanese Association for Acute Medicine (JAAM)-disseminated intravascular coagulation (DIC) scores were significant predictors of hospital mortality (odds ratio [OR] 3.86, 95% confidence interval [CI] 1.43-10.3; p = 0.007 and OR 2.71, 95% CI 1.56-4.67; p = 0.0004; respectively). Kaplan-Meier survival curves showed that both scores were consistently associated with survival. Furthermore, the sum of the two scores was a more effective predictor than the individual scores. CONCLUSIONS: The qSOFA score of patients admitted with AE-IPF was associated with both in-hospital and long-term mortality, which was also true for the JAAM-DIC score. The qSOFA score plus the JAAM-DIC score should be determined during the diagnostic evaluation of a patient with AE-IPF. Both scores combined may be more effective at predicting outcomes than individual scores.
  • 慢性閉塞性肺疾患患者における超音波画像診断装置を用いた吸気筋評価と最大吸気圧との関連について
    水澤 裕貴; 白石 匡; 杉谷 竜司; 武田 優; 野口 雅矢; 神吉 健吾; 木村 保; 石川 朗; 西山 理; 松本 久子; 東本 有司
    呼吸理学療法学 (一社)日本呼吸理学療法学会 3 (Suppl.) 116 - 116 2023
  • 慢性閉塞性肺疾患患者の動的肺過膨張と胸部単純X線による横隔膜ドーム高との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 武田 優; 野口 雅矢; 神吉 健吾; 西山 理; 山崎 亮; 木村 保; 東田 有智; 松本 久子
    呼吸理学療法学 (一社)日本呼吸理学療法学会 3 (Suppl.) 136 - 136 2023
  • 肺炎入院患者における骨格筋量・嚥下筋力の変化および再発との関係性について
    杉谷 竜司; 有薗 信一; 白石 匡; 田村 友美; 水澤 裕貴; 野口 雅矢; 神吉 健吾; 俵 祐一; 木村 保; 山崎 亮; 西山 理; 東本 有司
    呼吸理学療法学 (一社)日本呼吸理学療法学会 3 (Suppl.) 167 - 167 2023
  • 杉谷 竜司; 有薗 信一; 白石 匡; 水澤 裕貴; 俵 祐一; 木村 保; 西山 理; 東本 有司; 東田 有智; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 31 (1) 129 - 134 1881-7319 2022/12 
    【目的】本研究は,超音波画像診断装置(エコー)による胸鎖乳突筋(SCM)評価の信頼性および関連する指標を調査する.【方法】対象は,健常成人男性30名(31.6±7.5歳).背臥位での左側SCMの筋厚,筋輝度を評価した.鎖骨内側~側頭骨乳様突起の中点にて短軸像でのSCMを描出し,繰り返しの測定による信頼性と,枕の有無による差異を検証した.また体組成,吸気筋力との関連を調査した.【結果】Bland-Altman解析より,1回目・3回目での測定,枕の有無について,両者ともに信頼性は高く,系統誤差も認めなかった.筋厚は骨格筋量(r=0.453,p=0.012),除脂肪量(r=0.392,p=0.032)と正の相関関係,筋輝度は年齢との負の相関関係(r=0.467,p=0.009)を認めた.いずれの指標も,吸気筋力と相関を認めなかった.【考察】SCMのエコー評価は,信頼性が高く,臨床応用可能な指標といえる.(著者抄録)
  • Masashi Shiraishi; Yuji Higashimoto; Ryuji Sugiya; Hiroki Mizusawa; Yu Takeda; Shuhei Fujita; Osamu Nishiyama; Shintarou Kudo; Tamotsu Kimura; Kanji Fukuda; Yuji Tohda
    Respiration; international review of thoracic diseases 102 (1) 1 - 10 2022/11 [Refereed]
     
    BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have difficulties inhaling as the diaphragm becomes flattened and weakened due to lung hyperinflation. This weakened respiratory function is compensated for by the increased activity of the accessory respiratory muscles, such as the sternocleidomastoid muscle (SCM). OBJECTIVES: This study aimed to evaluate the difference in the SCM thickening fraction (SCM TF) of each respiratory phase (end-expiration, resting inspiration, and end-inspiration), as measured using ultrasonography (US), between patients with COPD and control subjects. We also evaluate the correlation between the SCM TF of each respiratory phase and exercise tolerance in patients with COPD. METHODS: Patients with COPD (n = 44) and age-matched controls (n = 20) underwent US for determination of the SCM TF. Ventilation parameters, including the peak oxygen uptake (peak VO2) and the change in the inspiratory capacity, were measured during cardiopulmonary exercise testing. The SCM thickness and TF was measured during end-expiration, resting breathing, and end-inspiration. RESULTS: The SCM was significantly thinner in patients with COPD than in controls at end-expiration. The increase in the SCM TF from end-expiration to end-inspiration in patients with COPD did not differ significantly from that in control subjects. In contrast, the SCM TF from end-expiration to resting inspiration was significantly greater in patients with COPD than in control subjects. The peak VO2 was strongly positively correlated with the SCM TF from end-expiration to end-inspiration in patients with COPD (r = 0.71, p < 0.01). CONCLUSIONS: The SCM may be thinner in patients with COPD than in controls. The SCM TF may also be associated with exercise tolerance.
  • COPD患者における胸鎖乳突筋の筋厚と運動耐容能,動的肺過膨張との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 武田 優; 野口 雅矢; 神吉 健吾; 西山 理; 木村 保; 松本 久子
    呼吸理学療法学 (一社)日本呼吸理学療法学会 8th.Meeting SE - 03 2022/11
  • COVID-19流行下における安定期COPD患者の身体活動量に関する研究
    水澤 裕貴; 白石 匡; 杉谷 竜司; 武田 優; 山崎 亮; 西山 理; 松本 久子; 石川 朗; 木村 保; 東本 有司
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 32 (Suppl.) 180s - 180s 1881-7319 2022/10
  • 特発性胸膜肺実質線維弾性症患者の姿勢変化による横隔膜移動距離に着目し運動療法を実施した1症例
    神吉 健吾; 白石 匡; 杉谷 竜司; 水澤 裕貴; 野口 雅矢; 山崎 亮; 西山 理; 木村 保; 松本 久子; 東本 有司
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 32 (Suppl.) 191s - 191s 1881-7319 2022/10
  • 肺疾患を伴う肺高血圧症患者に対するネーザルハイフローの効果
    西山 理; 吉川 和也; 白波瀬 賢; 山崎 亮; 高瀬 徹; 白石 匡; 杉谷 竜司; 水澤 裕貴; 東本 有司; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 32 (Suppl.) 184s - 184s 1881-7319 2022/10
  • 木本 祐太; 東本 有司; 白石 匡; 杉谷 竜司; 水澤 裕貴; 木村 保; 田平 一行; 西山 理; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (3) 355 - 359 1881-7319 2022/09 
    【目的】肺ランゲルハンス細胞組織球症(PLCH)は難治性希少疾患のため,治療法やリハビリテーションの効果は確立されていない.今回,肺高血圧症を合併したPLCH患者に対して高流量鼻カニュラ酸素療法(HFNCOT)を併用した運動療法を実施し,良好な成績が得られたため報告する.【症例紹介】肺高血圧増悪,心不全にて入院し,第4病日より理学療法開始した.運動時低酸素血症が顕著であり,運動負荷の調整に難渋した.経鼻カニュラとHFNCOTでの運動負荷試験の結果から,運動療法中にHFNCOTを用いることとした.【経過】HFNCOTにより低酸素血症は抑制され,十分な強度での運動療法が可能となり,独歩にて退院となった.【まとめ】HFNCOTはPLCH患者の運動時低酸素血症の抑制に有効であり,運動療法を安全かつ効果的に実践する一助となると考えられた.(著者抄録)
  • 木本 祐太; 東本 有司; 白石 匡; 杉谷 竜司; 水澤 裕貴; 木村 保; 田平 一行; 西山 理; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (3) 355 - 359 1881-7319 2022/09
  • Ryo Yamazaki; Osamu Nishiyama; Kazuya Yoshikawa; Yuji Tohda; Hisako Matsumoto
    Respiratory medicine 201 106933 - 106933 2022/09 [Refereed]
     
    BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is diagnosed incidentally in some patients with minimal or no respiratory symptoms. The clinical features of such patients are unknown. Herein we aimed to clarify the prevalence, clinical course, and prognostic factors of patients who were incidentally diagnosed with IPF. METHODS: The files of consecutive patients with newly diagnosed IPF were retrospectively reviewed to determine the methods involved in their diagnosis, and their outcomes. RESULTS: Among a total of 107 patients with newly diagnosed IPF, 35 (32.7%) were diagnosed incidentally, including 18 undergoing annual health check-ups and 17 undergoing assessment for other medical problems. The median survival from the time of diagnosis was 4.9 years for the 35 patients diagnosed incidentally, which was comparable to the median survival of 3.9 years for the 72 who were not diagnosed incidentally. The body mass index (BMI) was the sole independent predictor of survival (hazard ratio 0.78, 95% confidence interval 0.65-0.93, p = 0.006) in patients diagnosed incidentally. CONCLUSIONS: Nearly one third of patients with IPF were diagnosed incidentally, and their survival was still poor. Identifying patients during the earliest stage of IPF, particularly those with a low BMI, is warranted.
  • 西山 理; 藤田 貢; 吉川 和也; 西川 裕作; 大森 隆; 佐野 安希子; 東田 有智; 松本 久子
    日本呼吸器学会誌 (一社)日本呼吸器学会 11 (増刊) 300 - 300 2186-5876 2022/04
  • COPD患者の横隔膜移動距離と呼吸リハビリテーションによる運動耐容能の改善効果との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 西山 理; 木村 保; 福田 寛二; 東田 有智; 松本 久子
    日本呼吸器学会誌 (一社)日本呼吸器学会 11 (増刊) 285 - 285 2186-5876 2022/04
  • Takashi Matsuhira; Osamu Nishiyama; Yuji Tabata; Shinji Kurashimo; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    Biochemistry and biophysics reports 28 101118 - 101118 2021/12 [Refereed]
     
    Background: Idiopathic pulmonary fibrosis (IPF) is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, with a poor prognosis. We previously showed the antifibrotic effects of a novel phosphodiesterase 4 (PDE4) inhibitor, AA6216. In this study, we examined the effect of AA6216 on the pulmonary accumulation of segregated-nucleus-containing atypical monocytes (SatMs), which produce tumor necrosis factor (TNF)-α and are involved in murine lung fibrosis. Methods: Mice were treated with bleomycin intratracheally at day 0 and either 10 mg/kg AA6216, 100 mg/kg nintedanib, or vehicle orally once daily from day 0 to 8. On day 9, we isolated the bronchoalveolar lavage fluid and analyzed the SatM ratio. In addition, we evaluated the effect of AA6216 on TNF-α production from SatMs isolated from murine bone marrow. Results: AA6216, and not the antifibrotic agent nintedanib, significantly suppressed the pulmonary accumulation of SatMs (AA6216: 68.3 ± 5.4%, Nintedanib: 129.8 ± 19.7%). Furthermore, AA6216 dose-dependently inhibited the production of TNF-α by SatMs. Conclusions: AA6216 suppresses pathogenic SatMs in the lung, which contributes to its antifibrotic effects.
  • Masashi Shiraishi; Yuji Higashimoto; Ryuji Sugiya; Hiroki Mizusawa; Yu Takeda; Shuhei Fujita; Osamu Nishiyama; Shintarou Kudo; Tamotsu Kimura; Yasutaka Chiba; Kanji Fukuda; Yuji Tohda; Hisako Matsumoto
    Respiratory research 22 (1) 271 - 271 2021/10 [Refereed]
     
    BACKGROUND: In patients with chronic obstructive pulmonary disease (COPD), the maximum level of diaphragm excursion (DEmax) is correlated with dynamic lung hyperinflation and exercise tolerance. This study aimed to elucidate the utility of DEmax to predict the improvement in exercise tolerance after pulmonary rehabilitation (PR) in patients with COPD. METHODS: This was a prospective cohort study. Of the 62 patients with stable COPD who participated in the outpatient PR programme from April 2018 to February 2021, 50 completed the programme. Six-minute walk distance (6MWD) was performed to evaluate exercise tolerance, and ultrasonography was performed to measure DEmax. Responders to PR in exercise capacity were defined as patients who demonstrated an increase of > 30 m in 6MWD. The receiver operating characteristic (ROC) curve was used to determine the cut-off point of DEmax to predict responses to PR. RESULTS: Baseline levels of forced expiratory volume in 1 s, 6MWD, maximum inspiratory pressure, DEmax and quadriceps muscle strength were significantly higher, and peak dyspnoea of modified Borg (mBorg) scale score was lower in responders (n = 30) than in non-responders (n = 20) to PR (p < 0.01). In multivariate analysis, DEmax was significantly correlated with an increase of > 30 m in 6MWD. The area under the ROC curve of DEmax to predict responders was 0.915, with a sensitivity and specificity of 83% and 95%, respectively, at a cut-off value of 44.9 mm of DEmax. CONCLUSION: DEmax could adequately predict the improvement in exercise tolerance after PR in patients with COPD.
  • 超音波画像診断装置による胸鎖乳突筋評価の信頼性について
    杉谷 竜司; 有薗 信一; 白石 匡; 水澤 裕貴; 俵 祐一; 木村 保; 西山 理; 東本 有司; 福田 寛二; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 31 (Suppl.) 160s - 160s 1881-7319 2021/10
  • 慢性過敏性肺炎患者に対して包括的介入により生活範囲の拡大を認めた1例
    武田 優; 東本 有司; 白石 匡; 杉谷 竜司; 水澤 裕貴; 西山 理; 木村 保; 松本 久子; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 31 (Suppl.) 165s - 165s 1881-7319 2021/10
  • 超音波画像診断装置による胸鎖乳突筋評価の信頼性について
    杉谷 竜司; 有薗 信一; 白石 匡; 水澤 裕貴; 俵 祐一; 木村 保; 西山 理; 東本 有司; 福田 寛二; 松本 久子
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 31 (Suppl.) 160s - 160s 1881-7319 2021/10
  • 慢性過敏性肺炎患者に対して包括的介入により生活範囲の拡大を認めた1例
    武田 優; 東本 有司; 白石 匡; 杉谷 竜司; 水澤 裕貴; 西山 理; 木村 保; 松本 久子; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 31 (Suppl.) 165s - 165s 1881-7319 2021/10
  • Yasuhiro Kondoh; Shigeki Makino; Takashi Ogura; Takafumi Suda; Hiromi Tomioka; Hirofumi Amano; Masaki Anraku; Noriyuki Enomoto; Takao Fujii; Tomoyuki Fujisawa; Takahisa Gono; Masayoshi Harigai; Hidenori Ichiyasu; Yoshikazu Inoue; Takeshi Johkoh; Hideto Kameda; Kensuke Kataoka; Yasuhiro Katsumata; Yasushi Kawaguchi; Atsushi Kawakami; Hideya Kitamura; Noboru Kitamura; Tomohiro Koga; Kazuhiro Kurasawa; Yutaro Nakamura; Ran Nakashima; Yasuhiko Nishioka; Osamu Nishiyama; Masaki Okamoto; Fumikazu Sakai; Susumu Sakamoto; Shinji Sato; Toshimasa Shimizu; Noboru Takayanagi; Reoto Takei; Tamiko Takemura; Tohru Takeuchi; Yuko Toyoda; Hidehiro Yamada; Hideaki Yamakawa; Yasuhiko Yamano; Yoshioki Yamasaki; Masataka Kuwana
    Respiratory investigation 59 (6) 709 - 740 2021/09 
    The prognosis of patients with connective tissue disease (CTD) has improved significantly in recent years, but interstitial lung disease (ILD) associated with connective tissue disease (CTD-ILD) remains a refractory condition, which is a leading cause of mortality. Because it is an important prognostic factor, many observational and interventional studies have been conducted to date. However, CTD is a heterogeneous group of conditions, which makes the clinical course, treatment responses, and prognosis of CTD-ILD extremely diverse. To summarize the current understanding and unsolved questions, the Japanese Respiratory Society and the Japan College of Rheumatology collaborated to publish the world's first guide focusing on CTD-ILD, based on the evidence and expert consensus of pulmonologists and rheumatologists, along with radiologists, pathologists, and dermatologists. The task force members proposed a total of 27 items, including 7 for general topics, 9 for disease-specific topics, 3 for complications, 4 for pharmacologic treatments, and 4 for non-pharmacologic therapies, with teams of 2-4 authors and reviewers for each item to prepare a consensus statement based on a systematic literature review. Subsequently, public opinions were collected from members of both societies, and a critical review was conducted by external reviewers. Finally, the task force finalized the guide upon discussion and consensus generation. This guide is expected to contribute to the standardization of CTD-ILD medical care and is also useful as a tool for promoting future research by clarifying unresolved issues.
  • Yuji Higashimoto; Masashi Shiraishi; Ryuji Sugiya; Hiroki Mizusawa; Osamu Nishiyama; Yamazaki Ryo; Takashi Iwanaga; Yasutaka Chiba; Yuji Tohda; Kanji Fukuda
    Respiratory care 66 (9) 1458 - 1468 2021/09 [Refereed]
     
    BACKGROUND: A recent paper reported that low muscle mass in the erector spinae muscles (ESM) was strongly associated with poor prognosis and declining muscle mass over time in subjects with COPD. However, effects of pulmonary rehabilitation (PR), if any, on ESM mass have not been reported. We hypothesized that PR reduces the annual decline in ESM mass. METHODS: This was a retrospective cohort study. Thirty-nine subjects with COPD who received PR and underwent chest computed tomography before and after PR were evaluated (rehabilitation group). We also evaluated 39 age-matched subjects with COPD who did not receive PR (nonrehabilitation group). Data were collected from August 2010 until March 2020 in both groups. The ESM cross-sectional area (ESMCSA) was measured using axial computed tomography images, and annual changes were calculated. The 6-min walk distance (6MWD) was measured before and after PR; the minimum clinically important difference was defined as 30 m. RESULTS: ESMCSA declined in the nonrehabilitation group over time (-116.0 ± 141.2 mm2/y) but increased in the PR group (51.0 ± 95.3 mm2/y; P < .001). The annual increase in ESMCSA was significantly higher among subjects with an increase in 6MWD that exceeded the minimum clinically important difference compared with nonresponders in the rehabilitation group. The annual change in ESMCSA was negatively correlated with comorbidity index, and triple therapy (long-acting β2-agonist/long-acting muscarinic antagonist/inhaled corticosteroid) had a favorable effect on annual change in ESMCSA. Multiple regression analysis revealed that only PR was an independent factor for annual change in ESMCSA. CONCLUSIONS: ESM mass was shown to decline yearly in subjects with COPD. The annual decline in muscle mass was reduced by PR.
  • Osamu Nishiyama; Kensuke Kataoka; Masahiko Ando; Shinichi Arizono; Akira Morino; Koichi Nishimura; Tomoya Ogawa; Akira Shiraki; Fumiko Watanabe; Ryo Kozu; Takashi Ogura; Yasuhiro Kondoh
    ERJ open research 7 (3) 2021/07 [Refereed]
     
    Background: Pulmonary rehabilitation causes short-term improvement in exercise capacity, dyspnoea and health-related quality of life in idiopathic pulmonary fibrosis (IPF); however, long-term maintenance of the improvement is difficult. Nintedanib, an antifibrotic drug, has been shown to delay the worsening of pulmonary function in IPF. Therefore, the concomitant use of nintedanib with pulmonary rehabilitation is anticipated to contribute to the long-term maintenance of the pulmonary rehabilitation effects. The long-term effect of pulmonary rehabilitation under nintedanib treatment in IPF (FITNESS) study is a multicenter, randomised, prospective, parallel-group, open-label trial. Methods: The study will enrol 84 patients with IPF who have been treated with nintedanib. Patients in the pulmonary rehabilitation group will receive a programmed short-term induction pulmonary rehabilitation programme, followed by a maintenance home-based pulmonary rehabilitation programme, while patients in the control group will receive usual outpatient care. Patients in both groups will continue to receive nintedanib treatment throughout the study period. The primary end-point of the study is to compare the change in the 6-min walk distance from the baseline to 12 months between the pulmonary rehabilitation and control groups. The main secondary end-point is endurance exercise time, measured using a bicycle ergometer. Discussion: FITNESS is the first randomised controlled study to evaluate the long-term effects of pulmonary rehabilitation in IPF treated with nintedanib. This study will address the hypothesis that concomitant use of nintedanib contributes to the maintenance of long-term effects of pulmonary rehabilitation, thus leading to a comprehensive therapeutic approach of "nintedanib and pulmonary rehabilitation" in the antifibrotic era.
  • 岡島 聡; 前田 和成; 東本 有司; 本田 憲胤; 白石 匡; 杉谷 竜司; 岸本 英樹; 西山 理; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 29 (3) 365 - 368 1881-7319 2021/06 
    高齢慢性呼吸器疾患患者の日常生活訓練を実施する際,指導を正しく理解できないこと,自身の動作に固執することをしばしば経験する.高齢慢性呼吸器疾患患者の呼吸ケアを行う際に必要な高次脳機能障害及び認知機能障害に対する対処法を概説する.慢性閉塞性肺疾患や間質性肺炎などの慢性呼吸器疾患を有する患者は,呼吸器疾患の既往がない高齢者に比べて,認知機能が低下している.慢性呼吸器疾患患者で認知機能が低下する原因はまだ明らかにされていないが,慢性的な低酸素血症や全身性炎症が関連していると考えられている.また,その対策としては,運動療法や適切な酸素療法が有効であり,患者教育を行うためには行動変容を行うことが最も重要であると報告されている.(著者抄録)
  • 白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 西山 理; 工藤 慎太郎; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 29 (3) 453 - 459 1881-7319 2021/06 
    【はじめに・目的】呼吸リハビリテーションにおいて,吸気筋トレーニング(IMT)の有効性は確立されつつある.しかし,横隔膜の動きを考慮した適正負荷圧の設定方法は確立されていない.本研究の目的は,横隔膜のトレーニングにおいて最も効果的な,IMTの負荷圧を検証することである.【方法】対象は健常男性20名.クロスオーバーデザインで実施.IMT負荷圧を最大吸気圧(PImax)の30%,50%,70%に無作為割付け,1週間の間隔をあけて異なる負荷圧で計3回IMTを実施.超音波診断装置(M-mode)にて最大吸気位から最大呼気位までの横隔膜移動距離(Maximum Diaphragm excursion:DEmax)を測定した.【結果】30%PImaxによるIMT実施でDEmax(r=0.31,p<0.05),IC(r=0.64,p<0.05)に有意な増加を認めた.50%PImaxにおいてはDEmax(r=0.82,p<0.01),VC(r=0.34,p<0.05),IC(r=0.74,p<0.05)に有意な増加を認めた.【結論】健常者に対するIMTでは,中等度負荷が最も横隔膜に対して効果がある可能性が示唆された.(著者抄録)
  • 岡島 聡; 前田 和成; 東本 有司; 本田 憲胤; 白石 匡; 杉谷 竜司; 岸本 英樹; 西山 理; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 29 (3) 365 - 368 1881-7319 2021/06
  • 白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 西山 理; 工藤 慎太郎; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 29 (3) 453 - 459 1881-7319 2021/06
  • Ryuji Sugiya; Yuji Higashimoto; Masashi Shiraishi; Tomomi Tamura; Tamotsu Kimura; Yasutaka Chiba; Osamu Nishiyama; Shinichi Arizono; Kanji Fukuda; Yuji Tohda
    Dysphagia 2021/05 [Refereed]
     
    Dysphagia is frequently observed in patients with chronic obstructive pulmonary disease (COPD). Decreased tongue strength is one of the causes of dysphagia, and it is often observed in patients with sarcopenia. Sarcopenia is also frequently observed in COPD patients. We hypothesized that tongue strength is lower in COPD patients compared to normal subjects. This was a single-center, observational, cross-sectional study. Maximum tongue pressure (MTP) was measured in 27 patients with COPD and 24 age-matched control subjects. We also evaluated handgrip strength, gait speed, and appendicular skeletal muscle mass to define subjects as having sarcopenia. We used bioelectrical impedance analysis to assess body composition. The eating assessment test-10 was used to diagnose dysphagia. MTP was significantly lower in COPD patients than in control subjects (33.8 ± 8.4 vs 38.0 ± 5.3; p = 0.032). All measures of muscle and fat free body mass, handgrip strength, and gait speed were also significantly lower in COPD patients compared to control subjects (p < 0.01). The prevalence of sarcopenia in COPD patients was higher than that in control subjects (6/27 versus 0/24; p = 0.007), but the prevalence of dysphagia was not different between groups (COPD: 5/27, versus control: 1/24; p = 0.112). MTP was moderately correlated with skeletal muscle mass index (r = 0.56, p = 0.003) and handgrip strength (r = 0.43, p = 0.027) in COPD patients. Tongue strength was lower in COPD patients compared to normal subjects, and decreased tongue strength may be correlated with sarcopenia in COPD patients.
  • Osamu Nishiyama; Shigeki Shimizu; Koji Haratani; Kosuke Isomoto; Junko Tanizaki; Hidetoshi Hayashi; Ryo Yamazaki; Takashi Oomori; Yusaku Nishikawa; Akiko Sano; Kazuhiko Nakagawa; Yuji Tohda
    BMC pulmonary medicine 21 (1) 155 - 155 2021/05 [Refereed]
     
    BACKGROUND: The utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The purpose of this study was to examine the findings of bronchoalveolar lavage (BAL) analysis and transbronchial lung biopsy (TBLB) in non-small cell lung cancer (NSCLC) patients with ICI-related pneumonitis, and to elucidate the clinical significance of bronchoscopy for this health condition. PATIENTS AND METHODS: Consecutive NSCLC patients treated with ICIs, diagnosed with ICI-related pneumonitis after undergoing bronchoscopy between October 2015 and March 2019 were retrospectively screened. Findings of BAL fluid analysis and/or TBLB specimen histology were reviewed. RESULTS: Twelve patients underwent bronchoscopy for the diagnosis of ICI-related pneumonitis, ten of whom underwent BAL. An increase in the proportion of lymphocytes higher than 20% was observed in all ten patients. An increase in the proportion of neutrophils (> 10%) and eosinophils (> 10%) was observed in two and one patient, respectively. TBLB specimens were analyzed for eight patients. Major histologic findings included alveolitis in seven (87.5%) and organizing pneumonia (OP) in five (62.5%) patients. Other findings included acute lung injury and fibrosis. All twelve patients demonstrated favorable outcomes. CONCLUSION: A major characteristic of BAL analysis in ICI-related pneumonitis with NSCLC was an increased proportion of lymphocytes. The histologic features of lung tissue included alveolitis and/or OP. Acute lung injury and fibrosis were observed. Although the necessity of bronchoscopy should be determined on a case-by-case basis, it is necessary to assess these parameters when proper differential diagnosis is needed.
  • 外科的肺生検で診断されたIPFにおける肺動脈壁肥厚と予後の関連
    西山 理; 吉川 和也; 御勢 久也; 山崎 亮; 東田 有智; 須田 隆文
    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集 日本肺高血圧・肺循環学会・日本小児肺循環研究会 6回・27回 25 - 25 2021/05
  • COPD患者における胸鎖乳突筋と運動耐容能との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 武田 優; 藤田 修平; 西山 理; 木下 敬詩; 工藤 慎太郎; 木村 保; 福田 寛二; 東田 有智
    The Japanese Journal of Rehabilitation Medicine (公社)日本リハビリテーション医学会 58 (特別号) 2 - 6 1881-3526 2021/05
  • 吸気筋トレーニングにより横隔膜動態と運動耐容能が改善した安定期COPD患者の1症例
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 木下 敬詩; 藤田 修平; 木村 保; 西山 理; 福田 寛二
    The Japanese Journal of Rehabilitation Medicine (公社)日本リハビリテーション医学会 58 (特別号) 2 - 10 1881-3526 2021/05
  • COPD患者における胸鎖乳突筋と運動耐容能との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 武田 優; 藤田 修平; 西山 理; 木下 敬詩; 工藤 慎太郎; 木村 保; 福田 寛二; 東田 有智
    The Japanese Journal of Rehabilitation Medicine (公社)日本リハビリテーション医学会 58 (特別号) 2 - 6 1881-3526 2021/05
  • 吸気筋トレーニングにより横隔膜動態と運動耐容能が改善した安定期COPD患者の1症例
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 木下 敬詩; 藤田 修平; 木村 保; 西山 理; 福田 寛二
    The Japanese Journal of Rehabilitation Medicine (公社)日本リハビリテーション医学会 58 (特別号) 2 - 10 1881-3526 2021/05
  • 西山 理; 佐伯 翔; 御勢 久也; 吉川 和也; 東田 有智; 山崎 亮; 田中 伴典; 杉本 親寿; 澄川 裕充; 穗積 宏尚; 藤澤 朋幸; 須田 隆文
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (増刊) 225 - 225 2186-5876 2021/04
  • 西山 理; 藤田 貢; 國田 裕貴; 白波瀬 賢; 御勢 久也; 吉川 和也; 佐伯 翔; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (増刊) 191 - 191 2186-5876 2021/04
  • 佐野 安希子; 綿谷 奈々瀬; 西川 裕作; 國田 裕貴; 吉川 和也; 白波瀬 賢; 御勢 久也; 佐伯 翔; 大森 隆; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 原口 龍太; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (増刊) 162 - 162 2186-5876 2021/04
  • 西山 理; 藤田 貢; 國田 裕貴; 白波瀬 賢; 御勢 久也; 吉川 和也; 佐伯 翔; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (増刊) 191 - 191 2186-5876 2021/04
  • 西川 裕作; 佐野 安希子; 國田 裕貴; 吉川 和也; 白波瀬 賢; 御勢 久也; 佐伯 翔; 綿谷 奈々瀬; 西山 理; 山縣 俊之; 佐野 博幸; 原口 龍太; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (増刊) 271 - 271 2186-5876 2021/04
  • Nobuhiro Tanabe; Hiraku Kumamaru; Yuichi Tamura; Hiroyuki Taniguchi; Noriaki Emoto; Yoshihito Yamada; Osamu Nishiyama; Ichizo Tsujino; Hiroshi Kuraishi; Yoshihiro Nishimura; Hiroshi Kimura; Yoshikazu Inoue; Yoshiteru Morio; Yasuto Nakatsumi; Toru Satoh; Masayuki Hanaoka; Kei Kusaka; Mitsuhiro Sumitani; Tomohiro Handa; Seiicihiro Sakao; Tomoki Kimura; Yasuhiro Kondoh; Kazuhiko Nakayama; Kensuke Tanaka; Hiroshi Ohira; Masaharu Nishimura; Hiroaki Miyata; Koichiro Tatsumi
    Circulation journal : official journal of the Japanese Circulation Society 85 (4) 333 - 342 2021/03 [Refereed]
     
    BACKGROUND: There is limited evidence for pulmonary arterial hypertension (PAH)-targeted therapy in patients with pulmonary hypertension associated with respiratory disease (R-PH). Therefore, we conducted a multicenter prospective study of patients with R-PH to examine real-world characteristics of responders by evaluating demographics, treatment backgrounds, and prognosis.Methods and Results:Among the 281 patients with R-PH included in this study, there was a treatment-naïve cohort of 183 patients with normal pulmonary arterial wedge pressure and 1 of 4 major diseases (chronic obstructive pulmonary diseases, interstitial pneumonia [IP], IP with connective tissue disease, or combined pulmonary fibrosis with emphysema); 43% of patients had mild ventilatory impairment (MVI), whereas 52% had a severe form of PH. 68% received PAH-targeted therapies (mainly phosphodiesterase-5 inhibitors). Among patients with MVI, those treated initially (i.e., within 2 months of the first right heart catheterization) had better survival than patients not treated initially (3-year survival 70.6% vs. 34.2%; P=0.01); there was no significant difference in survival in the group with severe ventilatory impairment (49.6% vs. 32.1%; P=0.38). Responders to PAH-targeted therapy were more prevalent in the group with MVI. CONCLUSIONS: This first Japanese registry of R-PH showed that a high proportion of patients with MVI (PAH phenotype) had better survival if they received initial treatment with PAH-targeted therapies. Responders were predominant in the group with MVI.
  • Ryo Yamazaki; Osamu Nishiyama; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    Scientific reports 11 (1) 5782 - 5782 2021/03 [Refereed]
     
    Some patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were retrospectively recruited. Of 63 patients admitted for an AE-IPF and discharged alive, 9 (14.3%) developed a recurrence of AE within 1 year. The mean time to recurrence was 233 ± 103 days. Total doses (mg/month and mg/kg/month) of corticosteroids administered over day 1 to 30 after the AE were significantly higher in patients without recurrences of AE-IPF (5185 ± 2414 mg/month, 93.5 ± 44.0 mg/kg/month) than the doses in patients with recurrences (3133 ± 1990 mg/month, 57.2 ± 37.7 mg/kg/month) (p = 0.02 and p = 0.03, respectively). However, no differences were observed between the total doses of corticosteroids administered over days 31 to 60, 61 to 90, 91 to 120, and 151 to 180 after the AE. Furthermore, differences between the administration rates of immunosuppressive and antifibrotic treatments administered to the 2 patient groups were not significant. An increased total dose of corticosteroid administered over day 1 to 30 after an AE-IPF was associated with a decreased risk of subsequent recurrence of AE-IPF within 1 year after the first AE.
  • 安定期COPD患者における横隔膜移動距離と運動耐容能・肺機能との関連
    白石 匡; 東本 有司; 西山 理; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 工藤 慎太郎; 木村 保; 福田 寛二; 東田 有智
    理学療法学 (公社)日本理学療法士協会 47 (Suppl.1) OS3 - 15 0289-3770 2021/03
  • 超音波診断装置を用いた健常者における運動中の横隔膜動態ついての検討
    水澤 裕貴; 東本 有司; 白石 匡; 藤田 修平; 杉谷 竜司; 西山 理; 木村 保; 東田 有智; 福田 寛二
    理学療法学 (公社)日本理学療法士協会 47 (Suppl.1) PS3 - 16 0289-3770 2021/03
  • アスベスト肺の経過中に発症した多発血管炎性肉芽腫症の1例
    白波瀬 賢; 西山 理; 大森 隆; 佐伯 翔; 清水 重喜; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 10 (2) 178 - 182 2186-5876 2021/03 [Refereed]
     
    症例は84歳男性。アスベスト肺の経過観察中、胸部CTで両側下葉に新たにすりガラス影を伴った結節影(halo sign)を認めた。経気管支肺生検組織で小血管壁の好中球浸潤および弾性線維の破壊像を認めた。MPO-ANCA陽性であり、多発血管炎性肉芽腫症(granulomatosis with polyangiitis:GPA)と診断した。アスベスト肺にGPAを発症した報告はなく、粉塵曝露とANCA産生および血管炎発症との関連を考えるうえで貴重な症例と考えられた。(著者抄録)
  • Ryo Yamazaki; Osamu Nishiyama; Kazuya Yoshikawa; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    Scientific reports 11 (1) 3880 - 3880 2021/02 [Refereed]
     
    Some patients with idiopathic pulmonary fibrosis (IPF) require hospitalization due to pneumonia. Although predictive scoring tools have been developed and validated for community-acquired pneumonia (CAP), their usefulness in IPF is unknown. The Confusion, Urea, Respiratory Rate, Blood Pressure and Age (CURB-65) score and the Pneumonia Severity Index (PSI) are validated for CAP. The quick Sequential Organ Failure Assessment (qSOFA) is also reported to be useful. The aim of this study was to investigate the ability of these tools to predict pneumonia mortality among hospitalized patients with IPF. A total of 79 patients with IPF and pneumonia were hospitalized for the first time between January 2008 and December 2017. The hospital mortality rate was 15.1%. A univariate logistic regression analysis revealed that the CURB-65 (odds ratio 4.04, 95% confidence interval 1.60-10.2, p = 0.003), PSI (4.00, 1.48-10.7, 0.006), and qSOFA (5.00, 1.44-1.72, 0.01) scores were significantly associated with hospital mortality. There was no statistically significant difference between the three receiver operating characteristic curves (0.712, 0.736, and 0.692, respectively). The CURB-65, PSI, and qSOFA are useful tools for predicting pneumonia mortality among hospitalized patients with IPF. Because of its simplicity, the qSOFA may be most suitable for early assessment.
  • Ryo Yamazaki; Osamu Nishiyama; Kazuya Yoshikawa; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    Respiratory investigation 59 (4) 408 - 413 2021/02 [Refereed]
     
    BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) are at risk of acute exacerbations (AEs) that manifest as respiratory distress. However, the clinical course after AEs of IPF (AE-IPFs) has not been well described. Therefore, we aimed to elucidate the clinical course and prognosis in survivors of AE-IPFs. METHODS: Consecutive patients with IPF who presented to our institution with their first AE-IPFs between January 2008 and December 2019 were included in this study. Data were retrospectively collected, and the clinical course, survival, and cause of death were further analyzed. RESULTS: Ninety-seven patients were included in this retrospective study. Among them, 67 (69.1%) were discharged alive, with a median survival time after discharge of 1081 days. AE recurrence and pneumonia were the most common causes of death, each accounting for 22.2% of cases among survivors of AE-IPFs. AEs were the most frequent during the first 3 years after discharge, whereas pneumonia was more common thereafter. CONCLUSIONS: Survivors of AE-IPFs have a relatively favorable long-term prognosis. Among the survivors of first AE-IPFs, AE recurrence and pneumonia were the most common causes of death after discharge. Therefore, preventing AE recurrence and lung infections is crucial for prolonging survival in survivors of AE-IPFs.
  • COPD患者における舌圧とサルコペニアの関係について
    杉谷 竜司; 東本 有司; 白石 匡; 田村 友美; 藤田 修平; 木村 保; 西山 理; 福田 寛二; 東田 有智; 有薗 信一
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (Suppl.) 165s - 165s 1881-7319 2021/02
  • COPD患者の横隔膜移動距離と運動耐容能・動的肺過膨張との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 西山 理; 山崎 亮; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (Suppl.) 180s - 180s 1881-7319 2021/02
  • COPD患者における舌圧とサルコペニアの関係について
    杉谷 竜司; 東本 有司; 白石 匡; 田村 友美; 藤田 修平; 木村 保; 西山 理; 福田 寛二; 東田 有智; 有薗 信一
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (Suppl.) 165s - 165s 1881-7319 2021/02
  • COPD患者の横隔膜移動距離と運動耐容能・動的肺過膨張との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 西山 理; 山崎 亮; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 30 (Suppl.) 180s - 180s 1881-7319 2021/02
  • Ryo Yamazaki; Osamu Nishiyama; Kyuya Gose; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    BMC pulmonary medicine 21 (1) 5 - 5 2021/01 [Refereed]
     
    BACKGROUND: Some patients with idiopathic pulmonary fibrosis (IPF) develop pneumothorax. However, the characteristics of pneumothorax in patients with IPF have not been elucidated. The purpose of this study was to clarify the clinical course, actual management, and treatment outcomes of pneumothorax in patients with IPF. METHODS: Consecutive patients with IPF who were admitted for pneumothorax between January 2008 and December 2018 were included. The success rates of treatment for pneumothorax, hospital mortality, and recurrence rate after discharge were examined. RESULTS: During the study period, 36 patients with IPF were admitted with pneumothorax a total of 58 times. During the first admission, 15 patients (41.7%) did not receive chest tube drainage, but 21 (58.3%) did. Of the 21 patients, 8 (38.1%) received additional therapy after chest drainage. The respective treatment success rates were 86.6% and 66.7% in patients who underwent observation only vs chest tube drainage. The respective hospital mortality rates were 13.3% and 38.0%. The total pneumothorax recurrence rate after hospital discharge was 34.6% (n = 9). CONCLUSIONS: Pneumothorax in patients with IPF was difficult to treat successfully, had a relatively poor prognosis, and showed a high recurrence rate.
  • Ryo Yamazaki; Osamu Nishiyama; Kazuya Yoshikawa; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    PloS one 16 (1) e0245778  2021/01 [Refereed]
     
    BACKGROUND: Some patients with idiopathic pulmonary fibrosis (IPF) must be hospitalized because of heart failure (HF), including HF with preserved ejection fraction (HFpEF) and HF with reduced EF (HFrEF). The association between IPF and HF has not been clarified. We retrospectively investigated the clinical features and outcomes of patients with IPF who required nonelective hospitalization because of HF. METHODS: We examined data from IPF patients who required nonelective hospitalization for HF at the Kindai University Hospital from January 2008 to December 2018. We divided the patients into 3 groups: those with HFpEF without elevated right ventricular systolic pressure (RVSP), those with HFpEF and elevated RVSP, and those with HFrEF. The recurrence rates of HF after discharge and the 30- and 90-day mortality rates of the patients were evaluated. RESULTS: During the study period, 37 patients with IPF required hospitalization because of HF. Among the 34 patients included in the study, 17 (50.0%) were diagnosed with HFpEF without elevated RVSP, 11 (32.3%) with HFpEF and elevated RVSP, and 6 (17.6%) with HFrEF. Patients with HFrEF had significantly higher values for B-type natriuretic peptide (BNP) and left ventricular (LV) end-systolic and end-diastolic diameters than patients with the 2 types of HFpEF (BNP: P = 0.01 and P = 0.0004, LV end-systolic diameter: P <0.0001 and P <0.0001, and LV end-diastolic diameter: P = 0.01 and P = 0.0004, respectively). Notably, the difference between the LVEFs of the patients with 2 types of HFpEF was not significant. The patients with HFpEF without elevated RVSP had the lowest 30- and 90-day mortality rates (0%, P = 0.02 and 11.7%, P = 0.11, respectively). CONCLUSIONS: Among patients with IPF, HFpEF without elevated RVSP was the most common type of HF that required hospitalization. Patients with HFpEF without elevated RVSP survived longer than the patients with the other 2 types of HF.
  • 岩永 賢司; 國田 裕貴; 吉川 和也; 白波瀬 賢; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 原口 龍太; 東田 有智
    アレルギー (一社)日本アレルギー学会 69 (臨時増刊号) 308 - 308 0021-4884 2020/10
  • Masashi Shiraishi; Yuji Higashimoto; Ryuji Sugiya; Hiroki Mizusawa; Yu Takeda; Shuhei Fujita; Osamu Nishiyama; Shintarou Kudo; Tamotsu Kimura; Yasutaka Chiba; Kanji Fukuda; Yuji Tohda
    ERJ open research 6 (4) 2020/10 [Refereed]
     
    Background: Although the pathophysiological mechanisms involved in the development of dyspnoea and poor exercise tolerance in patients with COPD are complex, dynamic lung hyperinflation (DLH) plays a central role. Diaphragmatic excursions can be measured by ultrasonography (US) with high intra- and interobserver reliability. The objective of this study was to evaluate the effect of diaphragmatic excursions as assessed by US on exercise tolerance and DLH in patients with COPD. Methods: Patients with COPD (n=20) and age-matched control subjects (n=20) underwent US, which was used to determine the maximum level of diaphragmatic excursion (DEmax). Ventilation parameters, including the change in inspiratory capacity (ΔIC), were measured in the subjects during cardiopulmonary exercise testing (CPET). We examined the correlations between DEmax and the ventilation parameters. Results: The DEmax of patients with COPD was significantly lower than that of the controls (45.0±12.8 mm versus 64.6±6.3 mm, respectively; p<0.01). The perception of peak dyspnoea (Borg scale) was significantly negatively correlated with DEmax in patients with COPD. During CPET, oxygen uptake/weight (V'O2 /W) and minute ventilation (V'E) were significantly positively correlated with DEmax, while V'E/V'O2 and V'E/carbon dioxide output (V'CO2 ) were significantly negatively correlated with DEmax in patients with COPD. DEmax was also significantly positively correlated with ΔIC, reflecting DLH, and with V'O2 /W, reflecting exercise capacity. Conclusion: Reduced mobility of the diaphragm was related to decreased exercise capacity and increased dyspnoea due to dynamic lung hyperinflation in COPD patients.
  • Yusaku Nishikawa; Osamu Nishiyama; Shigeki Shimizu; Akiko Sano; Yuji Tohda
    Thorax 75 (9) 817 - 818 2020/09 [Refereed]
  • Takashi Matsuhira; Osamu Nishiyama; Yuji Tabata; Chizuko Kaji; Natsuki Kubota-Ishida; Yasutaka Chiba; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    European journal of pharmacology 885 173508 - 173508 2020/08 [Refereed]
     
    Idiopathic pulmonary fibrosis (IPF) is an intractable disease with poor prognosis, and therapeutic options are limited. While the pathogenic mechanism is unknown, cytokines, such as transforming growth factor (TGF)-β, and immune cells, such as monocytes and macrophages, that produce them, seem to be involved in fibrosis. Some phosphodiesterase 4 (PDE4) inhibitors reportedly have anti-fibrotic potential by acting on these disease-related factors. Therefore, we evaluated the effect of a novel PDE4 inhibitor, AA6216, on nonclinical IPF-related models and samples from IPF patients. First, we examined the inhibitory effect of AA6216 on the production of TGF-β1 from a human monocytic cell line, THP-1. Second, we analyzed the impact of AA6216 on TNF-α production by human alveolar macrophages collected from patients with IPF. Finally, we investigated the anti-fibrotic potency of AA6216 on bleomycin-induced lung fibrosis in mice. We found that AA6216 significantly inhibited TGF-β1 production by THP-1 cells. It also significantly suppressed TNF-α production by alveolar macrophages from patients with IPF. In the mouse model of bleomycin-induced pulmonary fibrosis, therapeutic administration of AA6216 significantly reduced fibrosis scores, collagen-stained areas, and TGF-β1 in bronchoalveolar lavage fluid. AA6216 may represent a new agent for the treatment of IPF with a distinct mechanism of action from that of conventional anti-fibrotic agents.
  • 佐野 博幸; 佐野 安希子; 西山 理; 山縣 俊之; 岩永 賢司; 原口 龍太; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 225 - 225 2186-5876 2020/08
  • 岩永 賢司; 國田 裕貴; 吉川 和也; 白波瀬 賢; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 原口 龍太; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 229 - 229 2186-5876 2020/08
  • 佐伯 翔; 西山 理; 山崎 亮; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 301 - 301 2186-5876 2020/08
  • 松平 崇; 西山 理; 山崎 亮; 佐伯 翔; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 239 - 239 2186-5876 2020/08
  • 西山 理; 山崎 亮; 佐伯 翔; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 249 - 249 2186-5876 2020/08
  • 山崎 亮; 西山 理; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 9 (増刊) 301 - 301 2186-5876 2020/08
  • 御勢 久也; 西山 理; 山崎 亮; 西川 裕作; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 42 (Suppl.) S164 - S164 0287-2137 2020/06
  • 西山 理; 清水 重喜; 御勢 久也; 山崎 亮; 西川 裕作; 綿谷 奈々瀬; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 42 (Suppl.) S304 - S304 0287-2137 2020/06
  • 佐野 安希子; 佐野 博幸; 西山 理; 岩永 賢司; 堀口 高彦; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 71 (2) s1 - s1 0029-0645 2020/04
  • 杉谷 竜司; 西山 理; 白石 匡; 藤田 修平; 水澤 裕樹; 大城 昌平; 東本 有司; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (3) 484 - 487 1881-7319 2020/04 
    慢性肺疾患患者に対する吸気筋訓練(inspiratory muscle training:IMT)の効果については、様々な疾患にて報告されているが、米国胸部医師学会/米国心血管・呼吸リハビリテーション学会(ACCP/AACVPR)ガイドラインでは、呼吸リハビリテーションの必須の構成項目としてルーチンに行う事を支持するエビデンスはないとしている。また小児に対するIMTの効果についても、有効性を示すエビデンスは乏しい。今回、我々は、横隔神経麻痺を合併した小児患者に対して労作時呼吸困難感の軽減を目的に、通常の理学療法に加えて4週間のIMTを行った。その結果、VC(vital capacity)、IC(inspiratory capacity)、PI max(maximum inspiratory pressure)が改善し、労作時呼吸困難感も改善を示した症例を経験したため報告する。(著者抄録)
  • 杉谷 竜司; 西山 理; 白石 匡; 藤田 修平; 水澤 裕樹; 大城 昌平; 東本 有司; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (3) 484 - 487 1881-7319 2020/04 [Refereed]
     
    慢性肺疾患患者に対する吸気筋訓練(inspiratory muscle training:IMT)の効果については、様々な疾患にて報告されているが、米国胸部医師学会/米国心血管・呼吸リハビリテーション学会(ACCP/AACVPR)ガイドラインでは、呼吸リハビリテーションの必須の構成項目としてルーチンに行う事を支持するエビデンスはないとしている。また小児に対するIMTの効果についても、有効性を示すエビデンスは乏しい。今回、我々は、横隔神経麻痺を合併した小児患者に対して労作時呼吸困難感の軽減を目的に、通常の理学療法に加えて4週間のIMTを行った。その結果、VC(vital capacity)、IC(inspiratory capacity)、PI max(maximum inspiratory pressure)が改善し、労作時呼吸困難感も改善を示した症例を経験したため報告する。(著者抄録)
  • Yuji Higashimoto; Akiko Sano; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Ryuta Haraguchi; Yasutaka Chiba; Kanji Fukuda; Yuji Tohda
    Allergology international : official journal of the Japanese Society of Allergology 69 (3) 453 - 454 2020/02 [Refereed]
  • デバイス別にみた喘息患者の吸入手技の比較検討
    岩永 賢司; 吉川 和也; 御勢 久也; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 西山 理; 佐野 博幸; 原口 龍太; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 109 (Suppl.) 249 - 249 0021-5384 2020/02
  • 御勢 久也; 西山 理; 佐伯 翔; 西川 裕作; 大森 隆; 佐野 安希子; 清水 重喜; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 42 (1) 91 - 91 0287-2137 2020/01
  • Ryo Yamazaki; Osamu Nishiyama; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    PloS one 15 (4) e0232212  2020 [Refereed]
     
    BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Chronic idiopathic interstitial pneumonia (c-IIP) is a group of lung diseases consisting mainly of fibrotic IIPs, and IPF is a type of c-IIP. Some patients with c-IIP undergo respiratory-related hospitalizations (RHs). With the hypothesis that the characteristics of patients who undergo RHs are related to the number of hospitalizations, we reviewed and investigated the RHs of patients with c-IIP. METHODS: We retrospectively examined the data of patients with c-IIP who were admitted to Kindai University Hospital between January 2008 and December 2018 for respiratory-related causes. RESULTS: During the study period, 243 patients with c-IIP were hospitalized a total of 544 times because of respiratory-related causes. The most common reasons for the first RH were acute exacerbation (48.1%) followed by pulmonary infection (32.5%). The most frequent reason for subsequent RHs was pulmonary infection. The in-hospital and 90-day mortality rate of patients with pulmonary infection increased with increasing numbers of RHs. Patients with multiple RHs had significantly worse long-term survival than patients hospitalized a single time. CONCLUSIONS: Pulmonary infection was the most frequent reason for repeated RHs. The proportion of all patients hospitalized for pulmonary infection at each RH increased with increasing numbers of RHs, along with the mortality rate of patients with pulmonary infections. Furthermore, repeated RHs were associated with poor survival.
  • 杉谷 竜司; 西山 理; 白石 匡; 藤田 修平; 水澤 裕貴; 工藤 慎太郎; 大城 昌平; 東本 有司; 木村 保; 東田 有智; 福田 寛二
    理学療法学 (公社)日本理学療法士協会 46 (6) 442 - 449 0289-3770 2019/12 
    【目的】慢性閉塞性肺疾患(Chronic Obstructive Pulmonary Disease;以下、COPD)増悪患者の運動時に非侵襲的陽圧換気療法(Noninvasive Positive Pressure Ventilation;以下、NPPV)を併用し、超音波画像診断装置にて横隔膜移動距離の変化を検証した。結果をもとに、理学療法時にNPPVを導入し、良好な転帰が得られたため報告する。【症例紹介】COPD増悪にて入院し、第5病日より理学療法を開始。呼吸困難感にて離床が困難であり、運動時のNPPV併用効果を検証した。【経過】NPPV併用による運動時間、呼吸困難感、横隔膜移動距離の改善を確認でき、理学療法にNPPVを導入した。日常生活動作の改善にて第25病日に退院した。【まとめ】COPD増悪患者の離床促進にNPPV導入が有効であり、横隔膜移動距離は動的肺過膨張の客観的な評価指標として有用であった。(著者抄録)
  • 杉谷 竜司; 西山 理; 白石 匡; 藤田 修平; 水澤 裕貴; 工藤 慎太郎; 大城 昌平; 東本 有司; 木村 保; 東田 有智; 福田 寛二
    理学療法学 (公社)日本理学療法士協会 46 (6) 442 - 449 0289-3770 2019/12 [Refereed]
     
    【目的】慢性閉塞性肺疾患(Chronic Obstructive Pulmonary Disease;以下、COPD)増悪患者の運動時に非侵襲的陽圧換気療法(Noninvasive Positive Pressure Ventilation;以下、NPPV)を併用し、超音波画像診断装置にて横隔膜移動距離の変化を検証した。結果をもとに、理学療法時にNPPVを導入し、良好な転帰が得られたため報告する。【症例紹介】COPD増悪にて入院し、第5病日より理学療法を開始。呼吸困難感にて離床が困難であり、運動時のNPPV併用効果を検証した。【経過】NPPV併用による運動時間、呼吸困難感、横隔膜移動距離の改善を確認でき、理学療法にNPPVを導入した。日常生活動作の改善にて第25病日に退院した。【まとめ】COPD増悪患者の離床促進にNPPV導入が有効であり、横隔膜移動距離は動的肺過膨張の客観的な評価指標として有用であった。(著者抄録)
  • 西山 理; 佐野 安希子; 林 秀敏; 西川 裕作; 谷崎 潤子; 原谷 浩司; 中川 和彦; 東田 有智
    肺癌 (NPO)日本肺癌学会 59 (6) 547 - 547 0386-9628 2019/11
  • 佐野 安希子; 清水 重喜; 西川 裕作; 大森 隆; 西山 理; 岩永 賢司; 原口 龍太; 東田 有智
    肺癌 (NPO)日本肺癌学会 59 (6) 886 - 886 0386-9628 2019/11
  • 西川 裕作; 西山 理; 佐野 安希子; 岩永 賢司; 原口 龍太; 東田 有智; 清水 重喜
    肺癌 (NPO)日本肺癌学会 59 (6) 886 - 886 0386-9628 2019/11
  • 脂肪肝による肝肺症候群と考えられた1例
    綿谷 奈々瀬; 西山 理; 山崎 亮; 吉川 和也; 御勢 久也; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 8 (6) 420 - 424 2186-5876 2019/11 [Refereed]
     
    症例は81歳男性。原因不明の低酸素血症で当科へ紹介となった。肝機能障害はないものの画像上脂肪肝があり、血流シンチグラフィで右左シャントを認め、脂肪肝による肝肺症候群と診断した。酸素療法を導入し禁酒と食事療法を指導したところ、脂肪肝、低酸素血症ともに改善し、酸素療法を中止した。肝機能障害のない脂肪肝のみで肝肺症候群と診断された例は報告されていない。また比較的短期間に改善を示しており興味深い症例と考える。(著者抄録)
  • COPD患者における横隔膜移動距離と換気応答・呼吸困難感との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 西山 理; 山崎 亮; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 29 (Suppl.) 166s - 166s 1881-7319 2019/10
  • 西山 理; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 清水 重喜; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (5) 540 - 540 0287-2137 2019/09
  • 佐伯 翔; 西山 理; 吉川 和也; 御勢 久也; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (5) 543 - 543 0287-2137 2019/09
  • 高濃度酸素投与下で運動療法を実施し、運動耐容能が改善した気腫合併特発性肺線維症の一症例
    水澤 裕貴; 東本 有司; 白石 匡; 杉谷 竜司; 釜田 千聡; 山縣 俊之; 西山 理; 木村 保; 東田 有智; 福田 寛二
    理学療法学 (公社)日本理学療法士協会 46 (Suppl.1) P - 37 0289-3770 2019/08
  • 西山 理; 山崎 亮; 御勢 久也; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (Suppl.) S223 - S223 0287-2137 2019/06
  • 西山 理; 清水 重喜; 御勢 久也; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (Suppl.) S224 - S224 0287-2137 2019/06
  • 御勢 久也; 西山 理; 山崎 亮; 綿谷 奈々瀬; 西川 祐作; 佐野 安希子; 佐野 博幸; 岩永 賢治; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (Suppl.) S323 - S323 0287-2137 2019/06
  • 山崎 亮; 西山 理; 御勢 久也; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (Suppl.) S340 - S340 0287-2137 2019/06
  • 食道癌患者における術前栄養状態が術後の身体特性や運動機能に与える影響について
    杉谷 竜司; 白石 匡; 藤田 修平; 水澤 裕貴; 東本 有司; 西山 理; 木村 保; 東田 有智; 福田 寛二
    大阪府理学療法学術大会学会誌 (公社)大阪府理学療法士会 31 81 - 81 1880-7631 2019/06
  • 吸気筋トレーニングにより、横隔膜動態と運動耐容能が改善したCOPD患者の1症例
    水澤 裕貴; 白石 匡; 藤田 修平; 杉谷 竜司; 工藤 慎太郎; 西山 理; 東本 有司; 木村 保; 福田 寛二
    大阪府理学療法学術大会学会誌 (公社)大阪府理学療法士会 31 53 - 53 1880-7631 2019/06
  • 健常者における吸気筋トレーニングの適正負荷圧の検討
    白石 匡; 西山 理; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 工藤 慎太郎; 木村 保; 東本 有司; 福田 寛二; 東田 有智
    大阪府理学療法学術大会学会誌 (公社)大阪府理学療法士会 31 82 - 82 1880-7631 2019/06
  • 佐野 安希子; 佐野 博幸; 綿谷 奈々瀬; 西川 裕作; 佐伯 翔; 西山 理; 岩永 賢司; 原口 龍太; 東田 有智
    アレルギー (一社)日本アレルギー学会 68 (4-5) 525 - 525 0021-4884 2019/05
  • 佐野 博幸; 佐野 安希子; 西川 裕作; 西山 理; 岩永 賢司; 東田 有智
    アレルギー (一社)日本アレルギー学会 68 (4-5) 498 - 498 0021-4884 2019/05
  • 西川 裕作; 岩永 賢司; 吉川 和也; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 原口 龍太; 東田 有智
    アレルギー (一社)日本アレルギー学会 68 (4-5) 575 - 575 0021-4884 2019/05
  • 御勢 久也; 岩永 賢司; 國田 裕貴; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 原口 龍太; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 68 (4-5) 610 - 610 0021-4884 2019/05
  • 佐野 安希子; 綿谷 奈々瀬; 御勢 久也; 吉川 和也; 佐伯 翔; 西川 裕作; 山崎 亮; 大森 隆; 西山 理; 佐野 博幸; 岩永 賢司; 原口 龍太; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 68 (4-5) 619 - 619 0021-4884 2019/05
  • COPD患者の自己管理能力と身体活動との関連
    白石 匡; 東本 有司; 澤田 優子; 杉谷 竜司; 水澤 裕貴; 釜田 千聡; 西山 理; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (1) 103 - 107 1881-7319 2019/05 [Refereed]
     
    【はじめに、目的】慢性閉塞性肺疾患(以下COPD)は、呼吸困難により身体活動量(以下PA)の減少をきたす。近年、COPD患者において自己管理の重要性が注目されている。本研究の目的はCOPD患者における自己管理能力とPAの関係を検討することとした。【方法】当院にて外来呼吸リハビリテーション(以下呼吸リハ)を実施した、GOLD stage 2〜4期の安定期のCOPD患者30例を対象とした。自己管理能力はLINQで評価し、PAは3軸加速度計で計測した。評価は呼吸リハ介入時と介入後12週以降に実施した。呼吸リハ前後でLINQの項目に改善が見られた群を改善群とし、改善が見られなかった群を非改善群とした。【結果】改善群・非改善群ともに、6MWDに改善を認めた(p<0.05)。改善群ではPAに改善を認めた(p<0.05)が非改善群ではPAが改善しなかった。【結論】身体活動を改善するためには運動療法のみではなく、自己管理能力を獲得させ、生活習慣を変えていくことが重要である。(著者抄録)
  • 西川 裕作; 西山 理; 吉川 和也; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 70 (2) s50 - s50 0029-0645 2019/04
  • Nishiyama O; Saeki S; Yamazaki R; Sano H; Iwanaga T; Kume H; Tohda Y
    Respiratory investigation 57 (5) 415 - 421 2212-5345 2019/04 [Refereed]
     
    BACKGROUND: The characteristics and significance of respiratory-related hospitalization in patients with idiopathic pulmonary fibrosis (IPF) in Asian countries remain unknown. The purpose of this study was to define the characteristics of respiratory-related hospitalization and to inspect the relationship between respiratory-related hospitalization and subsequent survival in patients with IPF in Japanese general practice. METHODS: Patients with IPF who underwent clinical evaluation between February 2008 and August 2017 were screened. Only those who had undergone evaluation within 1 year after the diagnosis of IPF were included in the study. The post-diagnosis pulmonary function tests were considered the registration point. We then performed a 6-month landmark analysis including only patients who were alive 6 months after the registration. The characteristics of respiratory-related hospitalizations during the 6 months after registration and the association between respiratory-related hospitalization and survival were investigated. RESULTS: A total of 106 patients with IPF were included in the study. The mean forced vital capacity (FVC) at registration was 80.2 ± 25.1% predicted. Seventeen patients (16.0%) had respiratory-related hospitalization during the 6 months after registration. Pneumonia was the most frequent reason for hospitalization (47.0%), followed by acute exacerbation of IPF (29.4%). In multivariate analysis, % predicted FVC (hazard ratio: 0.98, 95% confidence interval: 0.96-0.99, p = 0.004), 6-month decrease in % predicted FVC (1.05, 1.02-1.08, 0.005), and respiratory-related hospitalization (2.45, 1.24-4.85, 0.009) were significantly associated with survival. CONCLUSIONS: Pneumonia is the most frequent cause of respiratory-related hospitalization in Japanese IPF patients. Furthermore, respiratory-related hospitalization is significantly associated with subsequent poor survival.
  • 西山 理; 佐伯 翔; 山崎 亮; 佐野 安希子; 佐野 博幸; 岩永 賢司; 吉田 耕一郎; 原口 龍太; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 8 (増刊) 175 - 175 2186-5876 2019/03
  • 吉川 和也; 西山 理; 佐伯 翔; 山崎 亮; 西川 裕作; 大森 隆; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 8 (増刊) 307 - 307 2186-5876 2019/03
  • 佐野 博幸; 吉川 和也; 山崎 亮; 西川 裕作; 佐野 安希子; 西山 理; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 8 (増刊) 346 - 346 2186-5876 2019/03
  • 当科における移行期医療の実態
    岩永 賢司; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 西山 理; 佐野 博幸; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 108 (Suppl.) 238 - 238 0021-5384 2019/02
  • 御勢 久也; 西山 理; 佐野 安希子; 吉川 和也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 山縣 俊之; 佐野 博幸; 岩永 賢司; 原口 龍太; 久米 裕昭; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (1) 94 - 94 0287-2137 2019/01
  • 佐伯 翔; 西山 理; 佐野 安希子; 佐野 博幸; 岩永 賢司; 原口 龍太; 東田 有智; 清水 重喜; 伊藤 彰彦
    気管支学 (NPO)日本呼吸器内視鏡学会 41 (1) 96 - 96 0287-2137 2019/01
  • Yamazaki R; Nishiyama O; Saeki S; Sano H; Iwanaga T; Tohda Y
    PloS one 14 (8) e0212810  2019 [Refereed]
     
    BACKGROUND: Although evidence of a disseminated intravascular coagulation (DIC)-like reaction has been identified in the lung parenchyma of patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF), an association between DIC and IPF outcome has not been elucidated. Therefore, we retrospectively investigated the association between the Japanese Association for Acute Medicine (JAAM)-DIC score and mortality in patients with acute exacerbation of fibrosing idiopathic interstitial pneumonia (AE-fIIP). METHODS: Between January 2008 and December 2016, consecutive patients with chronic fIIP who were admitted for the first time for AE-fIIP were recruited into the study. Associations between clinical data and JAAM-DIC score at the time of admission and mortality were examined. RESULTS: During the study period, a total of 91 patients with fIIP (73.0±8.4 y.o.) were hospitalized for AE-fIIP for the first time. The 30-day and hospital mortality were 8.7% and 17.5%, respectively. A multivariate analysis showed that the JAAM-DIC score on admission was an independent predictor of 30-day mortality (odds ratio [OR] 2.57, 95% confidential interval [CI] 1.50-4.40, P = 0.0006). The APACHE II score (OR 1.29, 95% CI 1.01-1.63, P = 0.03) and the JAAM-DIC score (OR 3.47, 95% CI 1.73-6.94, P = 0.0004) were independent predictors of hospital mortality. CONCLUSIONS: The JAAM-DIC scoring system can predict survival in patients with AE-fIIP. The role of DIC in the pathogenesis of AE-fIIP merits further investigation.
  • Sugiya Ryuji; Tohda Yuji; Higashimoto Yuji; Shiraishi Masashi; Kamada Chisato; Nishiyama Osamu; Yamagata Toshiyuki; Kimura Tamotsu; Terada Katsuhiko; Fukuda Kanji
    The Journal of the Japan Society for Respiratory Care and Rehabilitation 一般社団法人 日本呼吸ケア・リハビリテーション学会 27 (3) 358 - 361 1881-7319 2018/11 [Refereed]
     
    <p>閉塞性細気管支炎(以下;BO)は,気管支領域を主病変とする慢性のびまん性肺疾患である.移植医療の進歩とともに疾患数が増加傾向である.しかし,BO患者に対する呼吸リハビリテ―ション(以下;呼吸リハ)のエビデンスは確立されていない.今回,BO患者に対する12週間の外来呼吸リハを施行し,運動療法中心の介入にて6分間歩行試験の歩行距離,等尺性膝伸展筋力,身体活動量が改善した1例を経験した.移植片対宿主病に伴うBO患者では,長期的なステロイド内服にて筋力低下が生じやすく,運動療法の重要性が高いと考える.今後は症例数を増やしてBOに対する呼吸リハのエビデンスを確立していく事が必要と考える.</p>
  • COPD患者における舌圧の評価
    釜田 千聡; 西山 理; 白石 匡; 田村 友美; 杉谷 竜司; 水澤 裕貴; 藤田 修平; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (Suppl.) 200s - 200s 1881-7319 2018/10
  • 横隔神経麻痺を合併した小児に対するIMTの効果について
    杉谷 竜司; 白石 匡; 釜田 千聡; 水澤 裕貴; 田村 友美; 藤田 修平; 西山 理; 木村 保; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (Suppl.) 235s - 235s 1881-7319 2018/10
  • COPD患者の自己管理能力と認知機能との関連
    武田 優; 白石 匡; 古澤 啓一; 小林 由佳; 杉谷 竜司; 釜田 千聡; 西山 理; 東田 有智; 木村 保; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 28 (Suppl.) 236s - 236s 1881-7319 2018/10
  • Sano H; Tomita K; Sano A; Saeki S; Nishikawa Y; Nishiyama O; Iwanaga T; Tohda Y
    Allergology international : official journal of the Japanese Society of Allergology 68 (2) 191 - 198 1323-8930 2018/10 [Refereed]
     
    BACKGROUND: We obtain summary estimates of the accuracy of additional objective tests for the diagnosis of adult asthma using systematic review and meta-analysis of diagnostic test accuracy studies. METHODS: Medline, Embase, and other relevant electronic databases were searched for papers published between January 1989 and December 2016. Studies were included if they evaluated the diagnostic accuracy of objective tests, including airway reversibility (AR), airway hyperresponsiveness (AHR), and fractionated exhaled nitric oxide (FeNO) for the diagnosis of adult asthma in patients with symptoms suggestive of asthma. If papers were assessed appropriate using the adapted QUADAS-2 tool, meta-analysis was conducted using the hierarchical bivariate model. This hierarchical model accounts for both within and between study variability. RESULTS: Sixteen studies reported the performance of the evaluated objective tests at presentation. For diagnosis of adult asthma, overall sensitivity and specificity for AR were 0.39 (95% confidence interval [CI] 0.18 to 0.66) and 0.95 (95% CI 0.86 to 1.00); for AHR, 0.86 (95% CI 0.61 to 1.00) and 0.95 (95% CI 0.77 to 1.00); for FeNO, 0.65 (95% CI 0.53 to 0.77) and 0.83 (95% CI 0.75 to 0.90). Comprehensive comparison of three diagnostic tools for adult asthma using the back-calculated likelihood rate (LR) showed that AR and AHR corresponded to a higher LR+, and AHR gave a lower LR-. CONCLUSIONS: In the current situation of no gold standard for diagnosis of adult asthma, AR and AHR are appropriate for ruling-in the true diagnosis, and AHR is superior for ruling-out a diagnosis. Since each objective test had a specific characteristic, it should be chosen depending on the situation, such as the capacity of the institution and the conditions of patients.
  • 佐伯 翔; 西山 理; 田中 伴典; 佐野 安希子; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (5) 342 - 346 2186-5876 2018/09 
    症例は58歳男性。前医で右鼠径リンパ節腫脹に対して生検を施行されたが診断がつかなかった。その際に胸部異常陰影も指摘されたが、自己判断で放置していた。その後、検診で胸部異常陰影、高ガンマグロブリン血症、脾腫を指摘され当科紹介となり診断のため外科的肺生検を施行した。生検の結果小葉間隔壁および周囲の肺胞隔壁に形質細胞の浸潤を認め、HHV-8染色でも陰性であった。前医のリンパ節生検でもリンパ濾胞周囲に形質細胞が認められ、多中心性キャッスルマン病と診断した。呼吸機能障害を認めず軽症の症例と考えられた。(著者抄録)
  • 胸腔鏡下肺生検で診断した軽症の多中心性キャッスルマン病の1例
    佐伯 翔; 西山 理; 田中 伴典; 佐野 安希子; 岩永 賢司; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (5) 342 - 346 2186-5876 2018/09 [Refereed]
     
    症例は58歳男性。前医で右鼠径リンパ節腫脹に対して生検を施行されたが診断がつかなかった。その際に胸部異常陰影も指摘されたが、自己判断で放置していた。その後、検診で胸部異常陰影、高ガンマグロブリン血症、脾腫を指摘され当科紹介となり診断のため外科的肺生検を施行した。生検の結果小葉間隔壁および周囲の肺胞隔壁に形質細胞の浸潤を認め、HHV-8染色でも陰性であった。前医のリンパ節生検でもリンパ濾胞周囲に形質細胞が認められ、多中心性キャッスルマン病と診断した。呼吸機能障害を認めず軽症の症例と考えられた。(著者抄録)
  • 御勢 久也; 佐野 安希子; 吉川 和也; 佐伯 翔; 綿谷 奈々瀬; 山崎 亮; 西川 裕作; 大森 隆; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 原口 龍太; 久米 裕昭; 吉田 耕一郎; 東田 有智
    日本職業・環境アレルギー学会雑誌 日本職業・環境アレルギー学会 26 (1) 103 - 103 1349-5461 2018/07
  • COPD患者に対するLife-Space Assessmentを利用した身体活動量評価の有用性の検討
    水澤 裕貴; 東本 有司; 白石 匡; 杉谷 竜司; 釜田 千聡; 東田 有智; 西山 理; 木村 保; 福田 寛二
    大阪府理学療法学術大会学会誌 (公社)大阪府理学療法士会 30 70 - 70 1880-7631 2018/07
  • Kume H; Nishiyama O; Isoya T; Higashimoto Y; Tohda Y; Noda Y
    International journal of molecular sciences 19 (7) 2018/07 [Refereed]
  • 佐野 博幸; 冨田 桂公; 佐野 安希子; 佐伯 翔; 山崎 亮; 西川 裕作; 西山 理; 岩永 賢司; 東田 有智
    アレルギー (一社)日本アレルギー学会 67 (4-5) 565 - 565 0021-4884 2018/05
  • 岩永 賢司; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 原口 龍太; 東田 有智
    アレルギー (一社)日本アレルギー学会 67 (4-5) 566 - 566 0021-4884 2018/05
  • 佐野 安希子; 佐野 博幸; 岩永 賢司; 綿谷 奈々瀬; 西川 裕作; 山崎 亮; 吉川 和也; 白波瀬 賢; 佐伯 翔; 西山 理; 山縣 俊之; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 67 (4-5) 575 - 575 0021-4884 2018/05
  • 西山 理; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 69 (2) s43 - s43 0029-0645 2018/04
  • 佐野 安希子; 西山 理; 佐野 博幸; 綿谷 奈々瀬; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 西川 裕作; 山縣 俊之; 東本 有司; 岩永 賢司; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 69 (2) s63 - s63 0029-0645 2018/04
  • びまん性肺胞出血にて発症した若年肺血管肉腫の一例
    西川 裕作; 西山 理; 清水 重喜; 綿谷 奈々瀬; 佐野 安希子; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (増刊) 341 - 341 2186-5876 2018/03
  • 大森 隆; 西山 理; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    結核 (一社)日本結核・非結核性抗酸菌症学会 93 (3) 133 - 133 0022-9776 2018/03
  • 岩永 賢司; 西川 裕作; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 原口 龍太; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (増刊) 177 - 177 2186-5876 2018/03
  • 佐野 安希子; 西山 理; 佐野 博幸; 綿谷 奈々瀬; 西川 裕作; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 山縣 俊之; 東本 有司; 岩永 賢司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (増刊) 327 - 327 2186-5876 2018/03
  • 西川 裕作; 西山 理; 清水 重喜; 綿谷 奈々瀬; 佐野 安希子; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 7 (増刊) 341 - 341 2186-5876 2018/03
  • Yasuhiro Kondoh; Hiroyuki Taniguchi; Kensuke Kataoka; Taiki Furukawa; Ayumi Shintani; Tomoyuki Fujisawa; Takafumi Suda; Machiko Arita; Tomohisa Baba; Kazuya Ichikado; Yoshikazu Inoue; Kazuma Kishi; Tomoo Kishaba; Osamu Nishiyama; Takashi Ogura; Keisuke Tomii; Sakae Homma
    PloS one 13 (3) e0193608  2018 [Refereed]
     
    BACKGROUND: Few studies have reported the diagnostic variability in patients with a possible usual interstitial pneumonia (UIP) pattern on high-resolution CT (HRCT) who underwent surgical lung biopsy (SLB), and the prognostic factors for these patients have not been fully evaluated. We retrospectively investigated the frequency of idiopathic pulmonary fibrosis (IPF) and prognostic factors in patients with possible UIP pattern on HRCT. METHODS: Consecutive patients who had a possible UIP pattern on HRCT, underwent SLB, and had a diagnosis of IIPs before SLB were retrospectively recruited from 10 hospitals. Diagnoses were made based on multidisciplinary discussion using the criteria for current IPF guidelines and multidisciplinary classification for IIPs in each hospital. RESULTS: 179 patients who underwent SLB were enrolled. The diagnoses were IPF in 91 patients (51%), unclassifiable IIPs in 47 (26%), idiopathic NSIP in 18 (10%), and chronic hypersensitivity pneumonia in 17 (9%). One-year FVC changes showed significant differences between IPF and non-IPF (-138.6 mL versus 18.2 mL, p = 0.014). Patients with IPF had a worse mortality than those with non-IPF (Logrank test, p = 0.025). Multivariable Cox regression analysis demonstrated that diagnoses of IPF (HR, 2.961; 95% CI, 1.183-7.410; p = 0.02), high modified MRC score (HR, 1.587; 95% CI, 1.003-2.510; p = 0.049), and low %FVC (HR, 0.972; 95% CI, 0.953-0.992; p = 0.005). CONCLUSIONS: About a half of patients with a possible UIP pattern on HRCT had diagnoses other than IPF, and patients with IPF had a worse mortality than those with an alternative diagnosis. We reaffirmed that multidisciplinary discussion is crucial in patients with possible UIP pattern on HRCT.
  • Osamu Nishiyama; Ryo Yamazaki; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    Respiratory Investigation Elsevier B.V. 56 (1) 57 - 63 2212-5353 2018/01 [Refereed]
     
    Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive impairment of lung function and degradation of daily activity however, this degradation has not been adequately elucidated. The objective of this study was to measure the physical activity of patients with IPF to determine its relationships with physiological parameters and survival rate. Methods: In total, 31 patients with IPF and 20 age-matched healthy participants were enrolled in this study. Physical activity was assessed using a physical activity monitor. The relationships among physical activity, physiological data, questionnaire-based patient-centered data, and survival were examined. Results: Physical activity, expressed as daily activity energy expenditure (AEE), was significantly lower, and the percentage of sedentary time was significantly longer in patients with IPF than in healthy participants. Moreover, AEE was moderately correlated with body-mass index, forced vital capacity, diffusing capacity of carbon monoxide, and partial arterial pressure of oxygen. Relatively strong correlation was also observed between AEE and the 6-min walk distance, but not with daily dyspnea, depression, and health-related quality of life scores. Prognostic analysis indicated that daily AEE was a significant predictor of survival. Conclusions: Patients with IPF were significantly inactive compared with age-matched healthy participants. In patients with more impaired physiological functions, the lower the physical activity was, the more was the sedentary time increased. Furthermore, lower daily physical activity resulted in significantly worse survival.
  • 肺および腹膜非結核性抗酸菌症の経過中に結核性胸膜炎を発症した1例
    大森 隆; 西山 理; 佐伯 翔; 山崎 亮; 佐野 安希子; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    結核 (一社)日本結核・非結核性抗酸菌症学会 92 (10) 617 - 617 0022-9776 2017/10
  • COPD患者に対するE-SASを利用した身体活動量評価の有用性の検討
    水澤 裕貴; 東本 有司; 白石 匡; 杉谷 竜司; 釜田 千聡; 山縣 俊之; 西山 理; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 27 (Suppl.) 196s - 196s 1881-7319 2017/10
  • COPD患者の自己管理能力と身体活動との関連
    白石 匡; 東本 有司; 杉谷 竜司; 水澤 裕貴; 釜田 千聡; 山縣 俊之; 西山 理; 木村 保; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 27 (Suppl.) 203s - 203s 1881-7319 2017/10
  • 西山 理; 吉川 和也; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 39 (5) 466 - 466 0287-2137 2017/09
  • 西川 裕作; 岩永 賢司; 佐野 安希子; 山縣 俊之; 西山 理; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本職業・環境アレルギー学会雑誌 日本職業・環境アレルギー学会 25 (1) 66 - 66 1349-5461 2017/06
  • MTX長期投与で発症したMTX関連リンパ増殖性疾患の1例
    佐野 安希子; 西山 理; 西川 裕作; 岩永 賢司; 東田 有智; 清水 重喜; 田中 伴典; 佐藤 隆夫
    肺癌 (NPO)日本肺癌学会 57 (3) 255 - 256 0386-9628 2017/06
  • Takashi Iwanaga; Takenori Kozuka; Junko Nakanishi; Koji Yamada; Osamu Nishiyama; Hiroyuki Sano; Takamichi Murakami; Yuji Tohda
    Pulmonary Therapy Springer Science and Business Media LLC 3 (1) 219 - 231 2364-1754 2017/06 [Refereed]
  • 西山 理; 山崎 亮; 西川 祐作; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 東田 有智; 中川 和彦
    気管支学 (NPO)日本呼吸器内視鏡学会 39 (Suppl.) S191 - S191 0287-2137 2017/05
  • 佐野 安希子; 西山 理; 佐野 博幸; 白波瀬 賢; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 山縣 俊之; 東本 有司; 岩永 賢司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 66 (4-5) 614 - 614 0021-4884 2017/05
  • 中西 雄也; 岩永 賢司; 白波瀬 賢; 御勢 久也; 佐伯 翔; 花田 宗一郎; 山崎 亮; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 68 (2) s72 - s72 0029-0645 2017/04
  • Osamu Nishiyama; Ryo Yamazaki; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    RESPIROLOGY WILEY 22 (3) 480 - 485 1323-7799 2017/04 [Refereed]
     
    Background and objective: Detailed body composition, such as fat-free mass, has not been examined in idiopathic pulmonary fibrosis (IPF). We investigated whether the fat-free mass index (FFMI), an index of lean body mass, predicted survival. Methods: Forty-four patients with IPF were enrolled in the study. Their body composition was assessed using direct segmental multi-frequency bioelectrical impedance analysis. The degree of correlation between variables of body composition and other variables such as forced vital capacity (FVC) and survival was examined. Results: There was a significant positive correlation between FFMI and FVC, diffusion capacity of the lung for carbon monoxide (DLCO) and 6-min walk distance, and a significant negative correlation with age. However, there was no significant correlation between FFMI and percentage predicted FVC or DLCO, with the degree of correlation being similar to that observed for BMI. The mean observation period in the survival analysis was 837.5 +/- 407.5 days. A univariate Cox proportional hazard model showed that several variables, but not BMI, were associated significantly with survival. FFMI (hazard ratio (HR): 0.64, 95% CI: 0.43-0.94, P = 0.02) and percentage predicted FVC (HR: 0.96, 95% CI: 0.93-0.99, P= 0.008) were significant factors in a multivariate model. Conclusion: We conclude that FFMI is a significant independent predictor of survival in patients with IPF.
  • 岩永 賢司; 佐野 博幸; 白波瀬 賢; 御勢 久也; 中西 雄也; 佐伯 翔; 花田 宗一郎; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 佐野 安希子; 西山 理; 山縣 俊之; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 6 (増刊) 176 - 176 2186-5876 2017/03
  • 佐野 博幸; 佐野 安希子; 山崎 亮; 西川 裕作; 西山 理; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 6 (増刊) 176 - 176 2186-5876 2017/03
  • 佐野 安希子; 佐野 博幸; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 西山 理; 山縣 俊之; 岩永 賢司; 東本 有司; 久米 裕昭; 吉田 耕一郎; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 6 (増刊) 304 - 304 2186-5876 2017/03
  • 西川 裕作; 岩永 賢司; 白波瀬 賢; 御勢 久也; 中西 雄也; 佐伯 翔; 花田 宗一郎; 山崎 亮; 綿谷 奈々瀬; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 6 (増刊) 305 - 305 2186-5876 2017/03
  • 当科通院中のCOPD患者における喘息合併の実態調査
    岩永 賢司; 佐野 博幸; 西川 裕作; 大森 隆; 佐野 安希子; 西山 理; 山縣 俊之; 東本 有司; 久米 裕昭; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 106 (Suppl.) 179 - 179 0021-5384 2017/02
  • Taiki Furukawa; Hiroyuki Taniguchi; Masahiko Ando; Yasuhiro Kondoh; Kensuke Kataoka; Osamu Nishiyama; Takeshi Johkoh; Junya Fukuoka; Koji Sakamoto; Yoshinori Hasegawa
    RESPIRATORY RESEARCH BIOMED CENTRAL LTD 18 1465-993X 2017/01 [Refereed]
     
    Background: It is unclear whether health related quality of life (HRQL) may have a predictive value for mortality in idiopathic pulmonary fibrosis (IPF). We investigated the relationship between HRQL assessed using the St. George's Respiratory Questionnaire (SGRQ) and survival time in patients with IPF, and tried to determine a clinical meaningful cut off value to predict poorer survival rates. Methods: We retrospectively analyzed consecutive patients with IPF who underwent an initial evaluation from May 2007 to December 2012. The diagnosis of IPF was made according to the 2011 international consensus guidelines. We used Cox proportional hazard models to identify independent predictors for mortality rate in patients with IPF. Results: We examined 182 eligible cases, average age was 66 years old, and 86% were male. Mean levels of percent predicted FVC, DLco, six-minute-walk test distance, and the SGRQ total score were around 80%, 58%, 580 m, and 34 points. On multivariate analysis, the SGRQ total score (hazard ratio [HR], 1.012; 95% confidence interval [CI] 1.001-1.023; P = .029) and percent predicted FVC (HR, 0.957; 95% CI 0.944-0.971, P < .001) were independent predictors for mortality rate. Moreover, a score higher than 30 points in the SGRQ total score showed higher mortality rate (HR, 2.047; 95% CI, 1.329-3.153; P = .001). Conclusions: The SGRQ total score was one of independent prognostic factors in patients with IPF. Total scores higher than 30 points were associated with higher mortality rates.
  • Toshiaki Matsuda; Hiroyuki Taniguchi; Masahiko Ando; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Koichi Nishimura; Osamu Nishiyama; Koji Sakamoto; Yoshinori Hasegawa
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 56 (13) 1637 - 1644 0918-2918 2017 [Refereed]
     
    Objective Depression is reported to be relatively common in idiopathic pulmonary fibrosis (IPF) patients. Thus far, however, whether or not depression independently determines the health-related quality of life (HRQOL) has not been evaluated exclusively in IPF patients. We designed this study to identify independent determinants of the St. George's Respiratory Questionnaire (SGRQ) score among various factors, including a depression scale, in IPF patients. Methods We retrospectively analyzed consecutive subjects with IPF who completed a systematic evaluation including pulmonary function tests, PaO2 at rest, 6-minute walk test (6MWT), SGRQ, Baseline Dyspnea Index (BDI), and Hospital Anxiety and Depression Scale (HADS). All eligible patients in the present study had newly diagnosed IPF and had not received any prior treatments, such as antidepressants, pirfenidone, corticosteroids, immunosuppressants, or long-term oxygen therapy. Results The 121 patients with IPF included 99 men. On the SGRQ, mild to moderate disturbance was observed in the total and each component score. According to the HADS, 27 patients (22.3%) had borderline or definite depression. In a univariate regression analysis, the forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLco), PaO2 at rest, BDI, HADS for Anxiety (HADS-A) and Depression (HADS-D), 6-minute walk distance (6MWD), and lowest SpO(2) during the 6MWT were significantly correlated with the SGRQ total score. In a stepwise multiple regression model, BDI, 6MWD, and HADS-D were selected as independent determinants of the total SGRQ score. The total variance in this model was 59% (p<0.001). Conclusion We concluded that depression was a significant determinant of the HRQOL or health status in patients with IPF.
  • Ryo Yamazaki; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    PLOS ONE PUBLIC LIBRARY SCIENCE 11 (12) e0168164  1932-6203 2016/12 [Refereed]
     
    Many patients with idiopathic pulmonary fibrosis (IPF) undergo hospitalizations due to pulmonary infections. We retrospectively investigated the characteristics of hospitalizations due to pulmonary infection in patients with IPF to elucidate causative pathogens and mortality. We reviewed patients with IPF who were admitted between January 2008 and December 2014 for pulmonary infections including pneumonia and bronchitis. The causative pathogen, the relationship between the site of pneumonia and existing IPF radiological patterns on high-resolution chest CT, and predictors of mortality were evaluated. Forty-eight IPF patients were hospitalized a totally of 81 times due to pulmonary infection during the study period. In the 48 first-time admissions after IPF diagnosis, causative pathogens were detected in 20 patients (41.6%). The most common pathogen was Haemophilus influenzae (14.5%) followed by Pseudomonas aeruginosa (4.1%), Staphylococcus aureus (4.1%), Branhamella catarrhalis (4.1%), and Klebsiella pneumoniae (4.1%). Among all 81 admissions, the most common pathogen was P. aeruginosa (12.3%), followed by H. influenzae (8.6%), S. aureus (6.1%) and Escherichia coli (4.9%). No relationship was observed between the detected pathogen and the site of pneumonia. The 30-day and hospital mortality rates were 14.5% and 18.7%, respectively. Pneumonia severity index on admission was significantly associated with both 30-day and hospital mortality. In conclusion, IPF patients hospitalized for pulmonary infections had high 30-day and hospital mortality. In contrast to community-acquired pneumonia, the causative pathogens mainly consisted of gram-negative bacteria. The PSI score may be a significant predictor of mortality. These results provide information for empiric antibiotic selection when treating IPF patients with pulmonary infections.
  • Akiko Sano; Osamu Nishiyama; Hiroyuki Sano; Koichiro Yoshida; Yuji Tohda
    Kekkaku : [Tuberculosis] 91 (9) 617 - 622 0022-9776 2016/09 
    A 52-year-old woman was referred to our hospital presenting with epigastric pain and weight loss. A contrast- enhanced abdominal computed tomography (CT) scan showed a low-density mass in the body of the pancreas, indicative of a malignancy. Endoscopic ultrasound-guided fine needle aspiration of the pancreatic mass was performed three times and showed no specific findings. A distal pancreatectomy was performed, and a pathological examination revealed epitheli- oid cell granulomas and necrosis. Ziehl-Neelsen staining did not reveal acid-fast bacilli in the pancreatic mass. A diagnosis of tuberculosis or sarcoidosis of the pancreas was con- sidered; however, the patient chose to undergo a follow-up examination without therapeutic intervention because the pancreatic mass had been removed completely and she had recovered well. Four months after the operation, the patient was readmitted to our hospital for insulin therapy for pancreatic diabetes. She presented with a fever and a productive cough, and a chest CT scan showed multiple nodules in both upper lobes. A bronchoscopy was performed and bronchoalveolar lavage fluid cultures for Mycobacterium tuberculosis were positive. The patient received antitubercular quadri-therapy and showed symptomatic and radiologic improvement. At the initial examination, we had been unable to establish the correct diagnosis; however, the detection of pulmonary lesions led to the time-delayed diagnosis of pancreatic tuber- culosis. Owing to its rarity, it is difficult to diagnose pancreatic tuberculosis using clinical symptoms and radiological imaging modalities; thus, pathologic and bacteriologic confirmation is essential. To avoid performing an unnecessary laparotomy in patients with pancreatic tuberculosis, increased vigilance and an accurate diagnostic approach are required.
  • 花田 宗一郎; 西山 理; 白波瀬 賢; 中西 雄也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 西川 裕作; 大森 隆; 佐野 安希子; 山縣 俊之; 岩永 賢司; 東本 有司; 佐野 博幸; 吉田 耕一郎; 久米 裕昭; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 38 (5) 449 - 449 0287-2137 2016/09
  • ICUでの早期離床が食道癌術後経過に与える影響
    杉谷 竜司; 東本 有司; 前田 和成; 白石 匡; 岡島 聡; 西山 理; 山縣 俊之; 東田 有智; 寺田 勝彦; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 26 (Suppl.) 156s - 156s 1881-7319 2016/09
  • 外来呼吸リハビリテーションを実施したCOPD患者の身体活動とセルフマネジメントとの関連
    白石 匡; 澤田 優子; 東本 有司; 前田 和成; 岡島 聡; 杉谷 竜司; 西山 理; 寺田 勝彦; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 26 (Suppl.) 178s - 178s 1881-7319 2016/09
  • 後期高齢者COPD患者に対する呼吸リハビリテーション効果の検討
    東本 有司; 山縣 俊之; 西山 理; 前田 和成; 白石 匡; 杉谷 竜司; 岡島 聡; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 26 (Suppl.) 185s - 185s 1881-7319 2016/09
  • 呼吸ケアカンファレンスに対する認識調査 多職種へのアンケートより
    宮田 紘世; 西山 理; 山崎 亮; 松林 輝代子; 若林 智恵美; 前田 和成; 白石 匡; 杉谷 竜司; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 26 (Suppl.) 221s - 221s 1881-7319 2016/09
  • 閉塞性細気管支炎症例に対する、外来呼吸リハビリテーションでの作業療法介入効果
    岡島 聡; 東本 有司; 前田 和成; 白石 匡; 杉谷 竜司; 小林 由佳; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 26 (Suppl.) 234s - 234s 1881-7319 2016/09
  • 佐野 安希子; 西山 理; 佐野 博幸; 吉田 耕一郎; 東田 有智
    結核 (一社)日本結核病学会 91 (9) 617 - 622 0022-9776 2016/09 
    52歳、女性。心窩部痛と体重減少を主訴に受診。腹部造影CTにて膵体部に腫瘤を認め、膵臓の悪性腫瘍が疑われた。EUS-FNAを3回施行したが診断に至らず、膵体尾部切除術を施行、病理組織診断にて壊死を伴う類上皮細胞肉芽腫を認めた。Ziehl-Neelsen染色で抗酸菌は証明されず、結核やサルコイドーシスが鑑別として考えられたが、腫瘤は完全に切除され、症状も改善していたため、経過観察となっていた。約4ヵ月後、膵性糖尿病に対してインスリン導入のため入院となった際に湿性咳嗽、発熱が出現。CTで両肺上葉に微細結節の集簇を認めた。気管支鏡検査を施行し、気管支洗浄液培養から結核菌陽性となった。抗結核薬4剤の治療を開始し、症状と画像所見の改善を認めた。初回検査時に診断が得られなかったが、後に肺結核の存在が判明したことにより、膵臓の病変は膵結核であったと考えられた。膵結核は稀な疾患であり、臨床所見や画像から診断することが困難であるため、病理学的、細菌学的確証が重要である。まず結核の可能性を疑って正確な診断アプローチを行うことが必要であり、それによって不要な外科的切除を避けることができる。(著者抄録)
  • Yuji Higashimoto; Toshiyuki Yamagata; Kazushige Maeda; Noritsugu Honda; Akiko Sano; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Yasutaka Chiba; Kanji Fukuda; Yuji Tohda
    GERIATRICS & GERONTOLOGY INTERNATIONAL WILEY-BLACKWELL 16 (8) 934 - 941 1444-1586 2016/08 [Refereed]
     
    Aim: To evaluate the influence of comorbidities and aging on pulmonary rehabilitation (PR) efficacy in patients with chronic obstructive pulmonary disease (COPD). Methods: This was a retrospective cohort study of patients with COPD attending an outpatient PR program. Comorbidity information was collected with the Charlson Index, BODE index and COPD-specific comorbidity test, and also included other common conditions not included in these indexes. The efficacy of PR was defined as a 54-m increase in 6-min walk distance or a four-point decrease in St. George's Respiratory Questionnaire score. Patients were divided into two age groups according to the median age of 72 years. Results: A total of 21 of 52 patients (40%) showed a clinically significant benefit by the 6-min walk distance, and 29 patients (55.8%) by the St. George's Respiratory Questionnaire score. PR efficacy was not different between the elderly group and the younger group by either parameter. A total of 98% of the patients had at least one chronic comorbidity. Hypertension was the most frequently reported comorbidity (28.5%). Higher body mass index, Hospital Anxiety and Depression Scale anxiety score and St. George's Respiratory Questionnaire total score were associated with a good response to PR by the 6-min walk distance. None of the individual comorbidities or indexes were correlated with the efficacy of PR. Multiple logistic regression analysis showed that body mass index was independently associated with the response to PR. Conclusions: PR is equally effective in elderly and younger patients with COPD, with efficacy influenced by body mass index and anxiety.
  • 佐伯 翔; 佐野 安希子; 西山 理; 中西 雄也; 山崎 亮; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本職業・環境アレルギー学会雑誌 日本職業・環境アレルギー学会 24 (1) 57 - 57 1349-5461 2016/06
  • 佐野 安希子; 佐野 博幸; 白波瀬 賢; 花田 宗一郎; 綿谷 奈々瀬; 西川 裕作; 西山 理; 山縣 俊之; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 65 (4-5) 570 - 570 0021-4884 2016/05
  • 中西 雄也; 岩永 賢司; 白波瀬 賢; 御勢 久也; 佐伯 翔; 花田 宗一郎; 山崎 亮; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 65 (4-5) 631 - 631 0021-4884 2016/05
  • 西山 理; 白波瀬 賢; 御勢 久也; 山崎 亮; 花田 宗一郎; 沖本 奈美; 西川 祐作; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 38 (Suppl.) S343 - S343 0287-2137 2016/05
  • Osamu Nishiyama; Yuji Tohda
    CHRONIC RESPIRATORY DISEASE SAGE PUBLICATIONS LTD 13 (2) 206 - 206 1479-9723 2016/05 [Refereed]
  • 御勢 久也; 岩永 賢司; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 花田 宗一郎; 忌部 周; 西川 裕作; 佐野 安希子; 山縣 俊之; 西山 理; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 67 (2) s80 - s80 0029-0645 2016/04
  • Hiroyuki Sano; Takashi Iwanaga; Osamu Nishiyama; Akiko Sano; Yuji Higashimoto; Katsuyuki Tomita; Yuji Tohda
    ALLERGOLOGY INTERNATIONAL JAPANESE SOCIETY ALLERGOLOGY 65 (2) 204 - 209 1323-8930 2016/04 [Refereed]
     
    Background: The characteristics of phenotypes of elderly patients with asthma are unknown. The aim of this study was to classify these phenotypes using lung function tests and images from high-resolution computed tomography (HRCT), and to identify associations between clinical characteristics and phenotypes. Methods: A cross-sectional study was conducted in 165 elderly patients (>65 years of age) who underwent a multidimensional assessment of clinical and functional status and comorbidity. The patients were divided into three phenotypes: (1) asthma-predominant, (2) asthma-obstructive airway disease (OAD) overlap without emphysema, and (3) asthma-OAD overlap with emphysema (asthma-emphysema overlap) based on chest HRCT. A receiver operating characteristic (ROC) curve was constructed to evaluate the cutoff for differentiating between the two OAD phenotypes. Multivariate analysis was also used to distinguish between these two phenotypes. Results: The phenotypes were asthma-predominant in 48 patients (29%), asthma-OAD without emphysema in 36 (22%), and asthma-emphysema in 81 (49%). Patients with asthma-emphysema were more frequent smokers. In multivariate analysis, smoking status (odds ratio 2.92: 95% CI 1.21-7.00, P = 0.03) and % predicted FEV1 <= 70% (odds ratio 3.18: 95% CI 1.13-8.92, P = 0.03) differed significantly between the asthma-emphysema and asthma-OAD without emphysema phenotypes. Conclusions: Half of elderly patients with asthma are characterized by asthma-emphysema overlap. Our results showed that elderly patients with asthma who are smokers and have moderate or severe OAD are also likely to have emphysema. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
  • 肺非結核性抗酸菌症における一般細菌性肺炎の発症予測因子に関する検討
    佐野 安希子; 佐野 博幸; 西山 理; 岩永 賢司; 吉田 耕一郎; 東田 有智
    感染症学雑誌 (一社)日本感染症学会 90 (臨増) 301 - 301 0387-5911 2016/03
  • IPFの診断と治療 呼吸器関連入院はIPF患者のFVC低下を加速させる
    西山 理; 山崎 亮; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 160 - 160 2186-5876 2016/03
  • IPFの診断と治療 IPF患者での身体活動量の評価
    西山 理; 山崎 亮; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 160 - 160 2186-5876 2016/03
  • 西山 理; 山崎 亮; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 237 - 237 2186-5876 2016/03
  • 佐野 博幸; 冨田 桂公; 佐野 安希子; 西山 理; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 249 - 249 2186-5876 2016/03
  • 岩永 賢司; 白波瀬 賢; 御勢 久也; 中西 雄也; 佐伯 翔; 花田 宗一郎; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 294 - 294 2186-5876 2016/03
  • 佐野 安希子; 佐野 博幸; 忌部 周; 西川 裕作; 西山 理; 山縣 俊之; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 5 (増刊) 339 - 339 2186-5876 2016/03
  • Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    CHRONIC RESPIRATORY DISEASE SAGE PUBLICATIONS LTD 13 (1) 40 - 47 1479-9723 2016/02 [Refereed]
     
    Emphysema on high-resolution computed tomography of the chest is the recent focus in the general practice in idiopathic pulmonary fibrosis (IPF). However, adequate attention has not been paid to obstructive disorder. Therefore, we retrospectively evaluated the association between the degree of airway obstruction and longevity in IPF subjects, with a hypothesis that lower forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) has an impact on prognosis. One hundred and fourteen consecutive IPF subjects who had been diagnosed with IPF and had undergone evaluation including pulmonary function test from January 2008 to May 2013 were included in the study. The relationship between baseline data and survival was examined. FEV1/FVC was widely distributed, ranging from 48.6% to 100%. On both univariate and multivariate Cox's regression analyses, lower FEV1/FVC was significantly associated with better survival (hazard ratio of 1.07 and 1.04 and 95% confidential interval of 1.03-1.10 and 1.01-1.08, respectively). Even on analysis with backward selection, FEV1/FVC remained a significant prognostic factor. FEV1/FVC is widely distributed and negatively predicts survival in IPF. A FEV1/FVC should be assessed in real-world general practice. Also, the effect of smoking on the clinical course of IPF should be investigated further.
  • 西山 理; 佐野 安希子; 白波瀬 賢; 御勢 久也; 山崎 亮; 花田 宗一郎; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 西川 裕作; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 38 (1) 60 - 60 0287-2137 2016/01
  • Mariko Morishita-Katsu; Koichi Nishimura; Hiroyuki Taniguchi; Tomoki Kimura; Yasuhiro Kondoh; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Shinichi Arizono; Osamu Nishiyama; Kazuhito Nakayasu; Kazuyoshi Imaizumi; Yoshinori Hasegawa
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE DOVE MEDICAL PRESS LTD 11 1543 - 1551 1178-2005 2016 [Refereed]
     
    Background: The chronic obstructive pulmonary disease (COPD) assessment test (CAT) is a short questionnaire that has facilitated health status measurements in subjects with COPD. However, it remains controversial as to whether the CAT can be used as a suitable substitute for the St George's Respiratory Questionnaire (SGRQ). This study investigated the reliability and score distributions of the CAT and SGRQ and evaluated which factors contributed to health status for each questionnaire. Methods: A total of 109 consecutive subjects with stable COPD from a single center were enrolled in this study. Each subject completed pulmonary function tests, exercise tests, and the following self-administered questionnaires: the Baseline Dyspnea Index, the Hospital Anxiety and Depression Scale, the CAT, and SGRQ. Results: Internal consistencies of CAT and SGRQ total scores were both excellent (Cronbach's alpha coefficients =0.890 and 0.933). Statistically significant correlations were observed between CAT and SGRQ total scores (R=0.668, P<0.001). Correlations of CAT scores with parameters related to pulmonary function, dyspnea, exercise performance, and psychological factors were inferior to correlations with those parameters with SGRQ total scores. Both multiple regression analyses and principal component analyses revealed that there were slight differences between SGRQ total scores and CAT scores. Conclusion: The CAT is similar to SGRQ in terms of discriminating health status. However, we demonstrated that what is assessed by the CAT may differ slightly from what is measured by SGRQ.
  • Osamu Nishiyama; Ryo Yamazaki; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    CANADIAN RESPIRATORY JOURNAL HINDAWI LTD 2016 3837182  1198-2241 2016 [Refereed]
     
    Background. Six-minute walk test (6MWT) has 3 measurement outcomes, which are walk distance, desaturation, and symptom. The aim of this study was to examine whether routinely measured right-heart catheter (RHC) data correlate with 6MWT outcomes in patients with interstitial lung disease (ILD). Methods. Between June 2010 and December 2012, consecutive patients with ILD who underwent evaluation, including pulmonary function test, hemodynamic studies with right-heart catheter, and 6MWT as routine general practice, were recruited. Correlates of 3 outcomes of 6MWT were examined to reveal significant predictors. Results. Forty-six patients consisting of 20 with idiopathic pulmonary fibrosis, 14 with collagen vascular disease associated ILD, and 12 with other idiopathic interstitial pneumonia were recruited (mean % predicted FVC: 76.7 +/- 17.1%). Several physiological variables, including mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR), were correlated with each 6MWT outcome. Stepwise multivariate regression analyses showed that % predicted FVC and % predicted DLco were independent predictors of walk distance (r(2) = 0.35, p = 0.0002). For SpO(2) at the end of 6MWT, % predicted DLco and PVR were selected as independent predictors (r(2) = 0.46, p < 0.0001). For dyspnea at the end of 6MWT, % predicted DLco was only one predictor (r(2) = 0.18, p = 0.005). Conclusion. Mean PAP had little impact on 6MWT outcomes in ILD patients who were nonselectively recruited, although PVR was one of predictors of desaturation.
  • 当院における呼吸器内科患者の栄養管理の変化 ケアカンファレンス開始後の動向
    宮田 紘世; 西山 理; 忌部 周; 山崎 亮; 杉谷 竜司; 東田 有智; 松林 輝代子; 若松 智恵美; 前田 和成; 白石 匡
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (3) 538 - 538 1881-7319 2015/12
  • 白石 匡; 東本 有司; 本田 憲胤; 前田 和成; 岡島 聡; 杉谷 竜司; 西山 理; 山縣 俊之; 寺田 勝彦; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (3) 384 - 388 1881-7319 2015/12 [Refereed]
     
    背景:慢性閉塞性肺疾患(以下COPD)の特徴として、労作時の呼吸困難のために日常生活が制限され、身体非活動性となりやすい。うつ・不安症状はCOPD患者に高頻度にみられ、身体活動量との関係が報告されている。本研究の目的は、COPD患者における、身体活動量とうつ・不安との関連について検討することである。対象と方法:COPD患者17名(男性15名/女性2名)を対象として、呼吸リハビリテーション(以下呼吸リハ)介入前後に諸指標の評価をした。身体活動量の評価は3軸加速度計を用いて計測し、うつ・不安の評価にはThe Hospital Anxiety and Depression Scale(以下HADS)を用いた。運動耐容能の評価は6分間歩行距離(6-min walk distance:以下6MWD)を、健康関連QOLの評価にはSt.Georges Respiratory Questionnaire(以下SGRQ)を用いた。結果:呼吸リハによる身体活動量変化は、呼吸リハ前のHADS(うつスコア)と正の相関がみられた。結論:うつ傾向のある人ほど、呼吸リハにより身体活動量は改善しており、積極的に呼吸リハを導入すべきことが示唆された。(著者抄録)
  • Yuji Higashimoto; Noritsugu Honda; Toshiyuki Yamagata; Akiko Sano; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Hiroaki Kume; Yasutaka Chiba; Kanji Fukuda; Yuji Tohda
    EUROPEAN RESPIRATORY JOURNAL EUROPEAN RESPIRATORY SOC JOURNALS LTD 46 (6) 1615 - 1624 0903-1936 2015/12 [Refereed]
     
    This study was designed to investigate the association of perceived dyspnoea intensity with cortical oxygenation and cortical activation during exercise in patients with chronic obstructive pulmonary disease (COPD) and exertional hypoxaemia. Low-intensity exercise was performed at a constant work rate by patients with COPD and exertional hypoxaemia (n=11) or no hypoxaemia (n=16), and in control participants (n=11). Cortical oxyhaemoglobin (oxy-Hb) and deoxyhaemoglobin (deoxy-Hb) concentrations were measured by multichannel near-infrared spectroscopy. Increased deoxy-Hb is assumed to reflect impaired oxygenation, whereas decreased deoxy-Hb signifies cortical activation. Exercise decreased cortical deoxy-Hb in control and nonhypoxaemic patients. Deoxy-Hb was increased in hypoxaemic patients and oxygen supplementation improved cortical oxygenation. Decreased deoxy-Hb in the pre-motor cortex (PMA) was significantly correlated with exertional dyspnoea in control participants and patients with COPD without hypoxaemia. In contrast, increased cortical deoxy-Hb concentration was correlated with dyspnoea in patients with COPD and hypoxaemia. With the administration of oxygen supplementation, exertional dyspnoea was correlated with decreased deoxy-Hb in the PMA of COPD patients with hypoxaemia. During exercise, cortical oxygenation was impaired in patients with COPD and hypoxaemia compared with control and nonhypoxaemic patients; this difference was ameliorated with oxygen supplementation. Exertional dyspnoea was related to activation of the pre-motor cortex in COPD patients.
  • Norihito Omote; Hiroyuki Taniguchi; Yasuhiro Kondoh; Naohiro Watanabe; Koji Sakamoto; Tomoki Kimura; Kensuke Kataoka; Takeshi Johkoh; Kiminori Fujimoto; Junya Fukuoka; Kyoko Otani; Osamu Nishiyama; Yoshinori Hasegawa
    CHEST AMER COLL CHEST PHYSICIANS 148 (6) 1438 - 1446 0012-3692 2015/12 [Refereed]
     
    BACKGROUND: Lung-dominant connective tissue disease (LD-CTD) is a disease concept for interstitial pneumonia; however, it has not been robustly validated. This study was conducted to elucidate the clinical, radiologic, and histologic features of LD-CTD. METHODS: We retrospectively reviewed 44 consecutive patients with serologically defined LD-CTD who underwent surgical lung biopsy. Patients were identified as having LD-CTD if they had specific autoantibodies but did not meet the criteria for connective tissue disease. We conducted a multidisciplinary diagnosis and evaluated major histologic patterns according to the current idiopathic interstitial pneumonias (IIPs) classification of 2013. Characteristic histologic features for LD-CTD (eg, prominent plasmacytic infiltration, lymphoid aggregates with germinal centers), high-resolution CT (HRCT) scan patterns, and prognosis were also assessed. RESULTS: The major histologic patterns were usual interstitial pneumonia (UIP) in 25 patients and nonspecific interstitial pneumonia (NSIP) in 13 patients. Two or more characteristic histologic features for LD-CTD were observed in 15 patients with histologic UIP (h-UIP) and 11 patients with histologic NSIP (h-NSIP). Fifteen patients with h-UIP (60%) showed an inconsistent UIP pattern on HRCT scan. Aft er multidisciplinary discussion (MDD), 18 patients with h-UIP were labeled as having unclassifiable IIP. The annual change in percent predicted FVC improved significantly in patients with h-NSIP (P = .002), who also had better survival than those with h-UIP (P = .031). In contrast, survival was not associated with HRCT scan pattern (P = .79). CONCLUSIONS: The major histologic patterns in LD-CTD were UIP followed by NSIP. Two-thirds of patients had characteristic histologic features for LD-CTD. A majority of patients with h-UIP were considered to have unclassifiable IIP based on MDD. Patients with h-UIP had worse survival than those with h-NSIP.
  • COPD患者の運動時脳皮質酸素化と呼吸困難感の関連
    東本 有司; 本田 憲胤; 杉谷 竜司; 白石 匡; 岡島 聡; 前田 和成; 沖本 奈美; 山縣 俊之; 西山 理; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 131s - 131s 1881-7319 2015/09
  • COPD患者における労作時低酸素血症が認知機能・脳循環動態に与える影響
    杉谷 竜司; 東本 有司; 前田 和成; 白石 匡; 岡島 聡; 山縣 俊之; 西山 理; 大城 昌平; 東田 有智; 福田 寛治
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 132s - 132s 1881-7319 2015/09
  • 病棟ケアカンファレンスを開始して
    忌部 周; 西山 理; 山崎 亮; 東本 有司; 東田 有智; 松林 輝代子; 若松 智恵美; 前田 和成; 白石 匡; 宮田 紘世
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 171s - 171s 1881-7319 2015/09
  • 抗癌剤治療後に食道がん切除術を行った患者の呼吸筋トレーニング効果の検討
    前田 和成; 東本 有司; 白石 匡; 杉谷 竜司; 寺田 勝彦; 山縣 俊之; 西山 理; 安田 卓司; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 188s - 188s 1881-7319 2015/09
  • 慢性呼吸器疾患患者の入浴動作方法の検討
    岡島 聡; 東本 有司; 前田 和成; 白石 匡; 杉谷 竜司; 小林 由佳; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 201s - 201s 1881-7319 2015/09
  • 当院における呼吸器内科患者の栄養管理の変化 ケアカンファレンス開始後の動向
    宮田 紘世; 西山 理; 忌部 周; 山崎 亮; 松林 輝代子; 若松 智恵美; 前田 和成; 白石 匡; 杉谷 竜司; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 25 (Suppl.) 202s - 202s 1881-7319 2015/09
  • Kensuke Kataoka; Hiroyuki Taniguchi; Yasuhiro Kondoh; Osamu Nishiyama; Tomoki Kimura; Toshiaki Matsuda; Toshiki Yokoyama; Koji Sakamoto; Masahiko Ando
    CHEST AMER COLL CHEST PHYSICIANS 148 (2) 436 - 443 0012-3692 2015/08 [Refereed]
     
    BACKGROUND: Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) presents as episodes of acute respiratory worsening closely associated with endothelial damage and disordered coagulopathy. Recombinant human soluble thrombomodulin (rhTM) regulates the coagulation pathway mainly by reducing thrombin-mediated clotting and enhancing protein C activation. We investigated the efficacy of rhTM for the treatment of patients with AE-IPF. METHODS: This historical control study comprised 40 patients with AE-IPF. Twenty patients treated with rhTM (0.06 mg/kg/d) for about 6 days (rhTM group) and 20 patients treated without rhTM (control group) were evaluated. The predictors of 3-month mortality (logistic regression model) were evaluated. RESULTS: There was no difference in baseline characteristics between the control group and the rhTM group. Three-month mortality of the rhTM group and control group was 30.0% and 65.0%, respectively. In univariate analysis, C-reactive protein and rhTM therapy were significant determinants for 3-month survival. In multivariate analysis, rhTM therapy (OR, 0.219; 95% CI, 0.049-0.978; P = 0.047) was an independent significant determinant for 3-month survival. CONCLUSIONS: We found that rhTM therapy improved 3-month survival of AE-IPF. The results observed here warrant further investigation of rhTM in randomized control trials.
  • 新規に喘息、COPDと診断した患者背景の比較
    忌部 周; 岩永 賢司; 佐野 安希子; 山縣 俊之; 西山 理; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 66 (2) s109 - s109 0029-0645 2015/04
  • 御勢 久也; 岩永 賢司; 中西 雄也; 佐伯 翔; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 64 (3-4) 485 - 485 0021-4884 2015/04
  • 岩永 賢司; 御勢 久也; 中西 雄也; 佐伯 翔; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 64 (3-4) 582 - 582 0021-4884 2015/04
  • 中西 雄也; 岩永 賢司; 御勢 久也; 佐伯 翔; 山崎 亮; 沖本 奈美; 綿谷 奈菜瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 185 - 185 2186-5876 2015/03
  • 西山 理; 山崎 亮; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 196 - 196 2186-5876 2015/03
  • 沖本 奈美; 西山 理; 中西 雄也; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 東本 有司; 山縣 俊之; 佐野 博幸; 岩永 賢司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 226 - 226 2186-5876 2015/03
  • 佐野 博幸; 岩永 賢司; 西山 理; 佐野 安希子; 山縣 俊之; 東本 有司; 中島 宏和; 久米 裕昭; 冨田 桂公; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 241 - 241 2186-5876 2015/03
  • 佐野 安希子; 佐野 博幸; 佐伯 翔; 御勢 久也; 中西 雄也; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 西山 理; 山縣 俊之; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 256 - 256 2186-5876 2015/03
  • 岩永 賢司; 御勢 久也; 中西 雄也; 佐伯 翔; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 4 (増刊) 291 - 291 2186-5876 2015/03
  • 高齢喘息患者の身体活動量と疾患コントロール、QOLとの関連性についての検討
    岩永 賢司; 佐伯 翔; 忌部 周; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 104 (Suppl.) 221 - 221 0021-5384 2015/02
  • 山崎 亮; 西山 理; 白波瀬 賢; 御勢 久也; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 37 (5) 609 - 609 2015
  • 沖本 奈美; 西山 理; 中西 雄也; 御勢 久也; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 忌部 周; 佐野 安希子; 東本 有司; 山縣 俊之; 佐野 博幸; 岩永 賢司; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 37 (1) 115 - 115 2015
  • 特発性肺線維症における肺炎・下気道感染症入院症例の検討
    西山 理; 山崎 亮; 佐野 安希子; 佐野 博幸; 岩永 賢司; 中島 宏和; 吉田 耕一郎; 東田 有智
    感染症学雑誌 (一社)日本感染症学会 88 (5) 733 - 733 0387-5911 2014/09
  • 食道癌術後患者の身体特性や運動機能に影響を与える因子について
    杉谷 竜司; 前田 和成; 白石 匡; 岡島 聡; 東本 有司; 山縣 俊之; 西山 理; 東田 有智; 大城 昌平; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 146s - 146s 1881-7319 2014/09
  • COPDの呼吸リハビリテーションの効果に関連する合併症と背景因子の検討
    東本 有司; 山縣 俊之; 沖本 奈美; 前田 和成; 白石 匡; 杉谷 竜司; 岡島 聡; 西山 理; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 166s - 166s 1881-7319 2014/09
  • 外来呼吸リハビリテーションを実施したCOPD患者の身体活動量の変化とうつスコアとの関連
    白石 匡; 東本 有司; 前田 和成; 岡島 聡; 杉谷 竜司; 西山 理; 山縣 俊之; 澤田 優子; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 168s - 168s 1881-7319 2014/09
  • 食道がん患者における術前呼吸筋トレーニング効果の検討
    前田 和成; 東本 有司; 白石 匡; 杉谷 竜司; 岡島 聡; 山縣 俊之; 西山 理; 寺田 勝彦; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 194s - 194s 1881-7319 2014/09
  • 癌治療歴のあるCOPD患者に対する外来呼吸リハビリテーションの効果の検討
    沖本 奈美; 東本 有司; 山縣 俊之; 西山 理; 前田 和成; 白石 匡; 杉谷 竜司; 岡島 聡; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 219s - 219s 1881-7319 2014/09
  • 慢性呼吸器疾患患者の入浴動作方法の検討
    岡島 聡; 東本 有司; 前田 和成; 白石 匡; 杉谷 竜司; 山縣 俊之; 西山 理; 寺田 勝彦; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 24 (Suppl.) 227s - 227s 1881-7319 2014/09
  • Atsushi Suzuki; Hiroyuki Taniguchi; Naohiro Watanabe; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Toshiaki Matsuda; Toshiki Yokoyama; Koji Sakamoto; Osamu Nishiyama; Yoshinori Hasegawa
    PLOS ONE PUBLIC LIBRARY SCIENCE 9 (9) e108339  1932-6203 2014/09 [Refereed]
     
    Background: Lung-dominant connective tissue disease (LD-CTD) is a new concept for classifying the subset of patients with interstitial pneumonia who have clinical features suggesting an associated CTD, but whose features fall short of a clear diagnosis of CTD under the current rheumatologic classification systems. The impact of mean pulmonary arterial pressure (MPAP) in LD-CTD has not been sufficiently elucidated. Objectives: To evaluate the survival impact of MPAP measured during the initial evaluation in patients with LD-CTD. Methods: We retrospectively analyzed the initial evaluation data of 100 LD-CTD patients undergoing pulmonary function test, 6-min walk test (6MWT), and right heart catheterization (RHC). Results: The mean MPAP was 16.2 +/- 4.4 mm Hg, and 18 patients had MPAP >= 20 mm Hg. A univariate Cox proportional hazard model showed that MPAP and several variables have a statistically significant impact on survival. With stepwise, multivariate Cox proportional analysis, MPAP (HR = 1.293; 95% CI 1.130-1.480; p<0.001) and mean forced vital capacity (FVC) % predicted (HR = 0.958; 95% CI 0.930-0.986; p = 0.004) were shown to be independent determinants of survival. Conclusions: Higher MPAP and lower % FVC at the initial evaluation were significant independent prognostic factors of LD-CTD. MPAP evaluation provides additional information of disease status and will help physicians to predict mortality in LD-CTD.
  • OKAJIMA SATOSHI; HIGASHIMOTO YUJI; HONDA NORITSUGU; MAEDA KAZUSHIGE; SHIRAISHI MASASHI; SUGIYA RYUJI; YAMAGATA TOSHIYUKI; NISHIYAMA OSAMU; TODA YUJI; FUKUDA KANJI
    日本呼吸ケア・リハビリテーション学会誌 The Japan Society for Respiratory Care and Rehabilitation 24 (2) 246 - 251 1881-7319 2014/08 [Refereed]
     
    【背景と目的】慢性呼吸器疾患患者の日常生活訓練を実施する際,指導を正しく理解できないことや,自身の動作に固執することをしばしば経験する.慢性閉塞性肺疾患(以下COPD)患者で前頭葉機能が低下していると報告はあるが,間質性肺炎(以下IP)患者の報告はない.そこで,IP患者を対象に前頭葉機能を検討し,COPD患者やコントロール患者と比較した.【対象と方法】当院で入院や外来通院しているIP患者20名,COPD患者48名,コントロール患者12名を対象とした.前頭葉機能検査はFrontal Assessment Battery(以下FAB)を用いて検討した.【結果】FAB合計点数はコントロール群(16.8±1.3点)と比較して,IP群(14.2±1.7点),COPD群(14.5±1.7点)ともに低値であった.FAB項目のなかでは,類似性,語の流暢性課題がIP群,COPD群ともに低値で,GO/NO-GO課題はCOPD群で低値であった.【結語】COPD患者と同様に,IP患者の前頭葉機能は低下していた.項目別でも,IP患者とCOPD患者の低下パターンは類似していた.
  • Shinichi Arizono; Hiroyuki Taniguchi; Koji Sakamoto; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Osamu Nishiyama; Koichi Nishimura; Ryo Kozu; Kazuyuki Tabira
    RESPIRATORY CARE DAEDALUS ENTERPRISES INC 59 (7) 1108 - 1115 0020-1324 2014/07 [Refereed]
     
    BACKGROUND: Although pulmonary rehabilitation (PR) has been reported to improve exercise capacity in patients with idiopathic pulmonary fibrosis, it is unknown which exercise measurement is the most responsive for evaluation of PR efficacy. The purpose of this study was to compare the responsiveness of 5 exercise measurements by evaluating the efficacy of PR in subjects with idiopathic pulmonary fibrosis. METHODS: We conducted a prospective observational study in which 53 subjects with idiopathic pulmonary fibrosis were enrolled. The PR group underwent a 10-week out-patient PR program. The control group was observed without any additional intervention, including PR. Five exercise measurements (endurance time [ET], peak work rate, peak oxygen consumption [(V) over dot(O2)] 6-min walk distance, and incremental shuttle walk distance) were evaluated at baseline and after 10 weeks. The effect size was used for the assessment of responsiveness. RESULTS: In each group, 24 subjects completed the 5 measurements at baseline and after 10 weeks. The changes in ET (PR: 181.6%; control: -8.2%), peak (V) over dot(O2) (PR: 7.6%; control: -5.4%), peak work rate (PR: 15.1%; control: -5.1%), 6-min walk distance (PR: 6.0%; control: -3.8%), and incremental shuttle walk distance (PR: 9.1%; control: -5.1%) were significantly different between the groups after 10 weeks (P < .05). In the PR group, ET showed the most striking improvement among the 5 measurements (P < .05), and its effect size was as large as 2.96, whereas those of the others were all < 0.5. CONCLUSIONS: ET is the most responsive exercise measurement for evaluating PR efficacy in patients with idiopathic pulmonary fibrosis.
  • 特発性肺線維症における肺炎・下気道感染症入院症例の検討
    西山 理; 山崎 亮; 佐野 安希子; 佐野 博幸; 岩永 賢司; 中島 宏和; 吉田 耕一郎; 東田 有智
    日本化学療法学会雑誌 (公社)日本化学療法学会 62 (Suppl.A) 226 - 226 1340-7007 2014/05
  • 正常もしくは軽度の気流障害を呈する成人喘息患者における呼吸抵抗の検討
    岩永 賢司; 佐伯 翔; 山崎 亮; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 西山 理; 佐野 博幸; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本気管食道科学会会報 (NPO)日本気管食道科学会 65 (2) s2 - s2 0029-0645 2014/04
  • Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 19 (2) 260 - 265 1341-9625 2014/04 [Refereed]
     
    Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.
  • 忌部 周; 岩永 賢司; 佐伯 翔; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 山藤 啓史; 佐野 安希子; 西山 理; 佐野 博幸; 東本 有司; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 3 (増刊) 173 - 173 2186-5876 2014/03
  • 佐野 博幸; 佐野 安希子; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 3 (増刊) 330 - 330 2186-5876 2014/03
  • 沖本 奈美; 東本 有司; 白石 匡; 佐伯 翔; 山崎 亮; 深井 有美; 忌部 周; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 山縣 俊之; 西山 理; 佐野 博幸; 岩永 賢司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 3 (増刊) 335 - 335 2186-5876 2014/03
  • 高齢者喘息患者の喫煙歴と気腫合併閉塞性換気障害の関係
    佐野 博幸; 西山 理; 岩永 賢司; 佐野 安希子; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 103 (Suppl.) 257 - 257 0021-5384 2014/02
  • 山崎 亮; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智; 吉田 耕一郎
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 36 (5) 570 - 571 2014
  • 忌部 周; 西山 理; 御勢 久也; 中西 雄也; 佐伯 翔; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 山藤 啓史; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 36 (5) 570 - 570 2014
  • 岩永 賢司; 佐野 博幸; 佐伯 翔; 山崎 亮; 深井 有美; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 山藤 啓史; 佐野 安希子; 西山 理; 山縣 俊之; 東本 有司; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 63 (3) 537 - 537 2014
  • 久米 裕昭; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 63 (3) 517 - 517 2014
  • 忌部 周; 西山 理; 佐野 博幸; 佐伯 翔; 山崎 亮; 沖本 奈美; 深井 有美; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 36 (1) 92 - 92 2014
  • Hiroshi Santo; Osamu Nishiyama; Hiroyuki Sano; Masanori Kitaichi; Hiroaki Kume; Yuji Tohda
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 53 (3) 275 - 277 0918-2918 2014 [Refereed]
     
    Retroperitoneal fibrosis (RPF) with positive antineutrophil cytoplasmic antibodies ( ANCA) has been reported in several cases. We herein present the case of a 52-year-old woman who was diagnosed with mediastinal fibrosis (MF) on a thoracoscopic surgical biopsy. The patient had positive myeloperoxidase ANCA and thereafter developed crescentic glomerulonephritis, which was considered to be a form of ANCA-related nephritis. Both the MF and crescentic glomerulonephritis favorably responded to immunosuppressive therapy. These findings suggest a common pathogenesis of these disorders involving ANCA positivity, as reported in patients with RPF.
  • Shu Taga; Satsuki Nakamura; Masanori Makita; Osamu Nishiyama
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 53 (4) 331 - 332 0918-2918 2014 [Refereed]
  • Naohiro Watanabe; Koji Sakamoto; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Kenzo Ono; Junya Fukuoka; Osamu Nishiyama; Yoshinori Hasegawa
    RESPIRATION KARGER 87 (6) 469 - 477 0025-7931 2014 [Refereed]
     
    Background: The optimal treatment method for interstitial pneumonia (IP) with connective tissue disease (CTD) remains controversial. In addition, a clinically meaningful end point to judge drug efficacy has not been fully investigated. Objectives: The aim of this study was to evaluate, from various aspects, the therapeutic benefit and tolerability of combined therapy with cyclosporin A (CsA) and low-dose prednisolone (PSL) for chronic fibrosing CTD-IP patients. Methods: A total of 26 CTD-IP patients diagnosed by surgical lung biopsy and subsequently treated with the above combination therapy were retrospectively reviewed. The therapeutic regimen comprised methylprednisolone induction therapy for 2-4 weeks, followed by a combined therapy of CsA with low-dose PSL for 1 year. Evaluation of the therapeutic benefit was based on not only pulmonary function but also exercise capacity, health-related quality of life and dyspnea. Results: After 1 year of therapy, clinically significant improvements in forced vital capacity (>= 10%), carbon monox-ide diffusing capacity of the lung ( >= 15%), 6-min walk distance ( >= 28 m), and St. George's Respiratory Questionnaire ( <= -7) were observed in 61.5, 69.2, 61.5 and 69.2% of the patients, respectively. All measurements showed statistically significant improvements compared with baseline values. The 1-year treatment did not need to be discontinued in any patients due to unacceptable toxicity, and no deaths occurred. Conclusions: Combined therapy with CsA and lowdose PSL for CTD-IP patients was well-tolerated and patients displayed a noteworthy response. (C) 2014 S. Karger AG, Basel
  • Yasushi Makino; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 53 (23) 2737 - 2739 0918-2918 2014 [Refereed]
     
    We herein present the case of a 64-year-old immunocompetent man with a diagnosis of pulmonary cryptococcosis who presented with cavitary nodules, one of which contained a fungus ball, on chest CT. The coincidence of cavitary cryptococcosis and an Aspergillus fungus ball was histologically confirmed on a thoracoscopic lung biopsy. Encapsulated round-to-oval yeasts (Cryptococcus) were observed throughout the entire specimen, including the cavity, cavity wall and lung parenchyma. In contrast, filamentous fungi (Aspergillus) were noted within the cavity only. The probable mechanism of this rare manifestation is that the Cryptococcus formed cavities, after which an Aspergillus fungus ball developed within one cavity.
  • COPD患者における身体活動量とうつ・不安との関連
    白石 匡; 本田 憲胤; 前田 和成; 東本 有司; 岡島 聡; 杉谷 竜司; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 23 (Suppl.) 213s - 213s 1881-7319 2013/09
  • 食道癌根治術施行患者に対する呼吸リハビリテーションの効果
    前田 和成; 本田 憲胤; 東本 有司; 白石 匡; 杉谷 竜司; 山縣 俊之; 安田 卓司; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 23 (Suppl.) 231s - 231s 1881-7319 2013/09
  • Osamu Nishiyama; Hiroyuki Miyajima; Yumi Fukai; Ryo Yamazaki; Ryuji Satoh; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Lwanaga; Yuji Higashimoto; Hirokazu Nakajima; Hiroaki Kume; Yuji Tohda
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 107 (8) 1241 - 1246 0954-6111 2013/08 [Refereed]
     
    Background and objective: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis (IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study was to assess the effect of ambulatory oxygen on dyspnea in IPF patients without resting hypoxemia but with desaturation on exertion. Methods: This was a double-blind, placebo-controlled, randomized crossover trial of ambulatory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial oxygen (PaO2) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at 4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests. Results: Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco) of 57.0 (13.3) %, and PaO2 of 72.5 (5.4) mm Hg were recruited. No significant differences in dyspnea were observed between ambulatory oxygen and air at each time point. However, some patients showed improvement in dyspnea with oxygen on an individual basis. Conclusions: Since oxygen provides no additional benefit over air in terms of exertional dyspnea for IPF patients without resting hypoxemia, routine prescription of ambulatory oxygen is not recommended. However, assessment on an individual basis is necessary. Trial registration. UMIN Clinical Trial Registry; No.:UMIN000005098; URL:http://www.umin.ac.jp/ctr/. (C) 2013 Elsevier Ltd. All rights reserved.
  • NISHIYAMA OSAMU; MIYAJIMA HIROYUKI; WATATANI NANASE; OKIMOTO NAMI; FUKAI YUMI; IMBE SHU; TSUKAMOTO KEIZO; SANTO KEISHI; ICHIHASHI HIDEO; MAKINO YASUSHI; SANO AKIKO; SATO RYUJI; YAMAGATA TOSHIYUKI; SANO HIROYUKI; IWANAGA TAKASHI; HIGASHIMOTO YUJI; NAKAJIMA HIROKAZU; TOMITA KATSUYUKI; KUME HIROAKI; TODA YUJI
    日本胸部臨床 克誠堂出版 72 (5) 545 - 552 0385-3667 2013/05
  • TSUKAMOTO Keizo; KUME Hiroaki; NISHIYAMA Osamu; IWANAGA Takashi; NAKAJIMA Hirokazu; TOHDA Yuji
    日本呼吸器学会誌 = Annals of the Japanese Respiratory Society 日本呼吸器学会 2 (3) 199 - 204 2186-5876 2013/05
  • Fumiko Watanabe; Hiroyuki Taniguchi; Koji Sakamoto; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Tomoya Ogawa; Shinichi Arizono; Osamu Nishiyama; Yoshinori Hasegawa
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 107 (4) 622 - 628 0954-6111 2013/04 [Refereed]
     
    Background and objective: It has been shown that peripheral muscle dysfunction is a critical factor in determining exercise intolerance in patients with several chronic lung diseases, including idiopathic pulmonary fibrosis. We hypothesized that exercise capacity would be, at least in part, determined by peripheral muscle dysfunction in patients with fibrotic nonspecific interstitial pneumonia (f-NSIP), another major subtype of fibrotic interstitial lung disease. The aim of the current study was to elucidate the relevance of peripheral muscle dysfunction and its contribution to exercise intolerance in f-NSIP. Methods: The six-minute walk test was evaluated in 30 consecutive patients with f-NSIP along with potential determinants of exercise capacity, including respiratory muscle force and peripheral muscle force. Results: Among 30 patients, the median age was 61 years, and 21 were female. Sixteen patients showed significantly decreased quadriceps force (QF), and 17 had significant decreases in maximum expiratory pressure. Exercise capacity and muscle power were clearly related to sex. Adjusted for sex, QF showed a significant relation to exercise capacity measured by six-minute walk distance (6MWD), whereas pulmonary function parameters such as vital capacity showed marginal correlations. In stepwise multiple regression analysis, only QF was an independent predictor of 6MWD. Conclusions: Quadriceps weakness is often observed in patients with f-NSIP. It seems that QF significantly contributes to exercise capacity in this population. (c) 2013 Elsevier Ltd. All rights reserved.
  • 佐野 博幸; 冨田 桂公; 佐野 安希子; 佐藤 隆司; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 2 (増刊) 139 - 139 2186-5876 2013/03
  • 久米 裕昭; 山崎 亮; 沖本 奈美; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 佐藤 隆司; 西山 理; 中島 宏和; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 2 (増刊) 174 - 174 2186-5876 2013/03
  • 深井 有美; 西山 理; 山崎 亮; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 佐藤 隆司; 牧野 靖; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 2 (増刊) 191 - 191 2186-5876 2013/03
  • Katsuyuki Tomita; Hiroyuki Sano; Yasutaka Chiba; Ryuji Sato; Akiko Sano; Osamu Nishiyama; Takashi Iwanaga; Yuji Higashimoto; Ryuta Haraguchi; Yuji Tohda
    PRIMARY CARE RESPIRATORY JOURNAL PRIMARY CARE RESPIRATORY SOC-PCRS UK 22 (1) 51 - 58 1471-4418 2013/03 [Refereed]
     
    Background: To predict the presence of asthma in adult patients with respiratory symptoms, we developed a scoring algorithm using clinical parameters. Methods: We prospectively analysed 566 adult outpatients who visited Kinki University Hospital for the first time with complaints of nonspecific respiratory symptoms. Asthma was comprehensively diagnosed by specialists using symptoms, signs, and objective tools including bronchodilator reversibility and/or the assessment of bronchial hyperresponsiveness (BHR). Multiple logistic regression analysis was performed to categorise patients and determine the accuracy of diagnosing asthma. Results: A scoring algorithm using the symptom-sign score was developed, based on diurnal variation of symptoms (1 point), recurrent episodes (2 points), medical history of allergic diseases (1 point), and wheeze sound (2 points). A score of >= 3 had 35% sensitivity and 97% specificity for discriminating between patients with and without asthma and assigned a high probability of having asthma (accuracy 90%). A score of 1 or 2 points assigned intermediate probability (accuracy 68%). After providing additional data of forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio <0.7, the post-test probability of having asthma was increased to 93%. A score of 0 points assigned low probability (accuracy 31%). After providing additional data of positive reversibility, the post-test probability of having asthma was increased to 88%. Conclusions: This pragmatic diagnostic algorithm is useful for predicting the presence of adult asthma and for determining the appropriate time for consultation with a pulmonologist. (C) 2013 Primary Care Respiratory Society UK. All rights reserved. K Tomita et al. Prim Care Respir J 2013; 22(1): 51-58 http://dx.doi.org/10.4104/pcrj.2013.00005
  • 成人気管支喘息診断における呼気一酸化窒素の有用性の検証
    佐野 博幸; 冨田 桂公; 佐野 安希子; 西山 理; 佐藤 隆司; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本内科学会雑誌 (一社)日本内科学会 102 (Suppl.) 228 - 228 0021-5384 2013/02
  • 牧野 靖; 佐野 博幸; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 佐藤 隆司; 佐野 安希子; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 35 S184  2013
  • 佐藤 隆司; 佐伯 翔; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (3) 394 - 394 2013
  • 岩永 賢司; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 西山 理; 佐野 博幸; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (3) 390 - 390 2013
  • 久米 裕昭; 佐伯 翔; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (9) 1300 - 1300 2013
  • 山藤 啓史; 岩永 賢司; 佐伯 翔; 山崎 亮; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 佐野 安希子; 西山 理; 佐野 博幸; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (9) 1389 - 1389 2013
  • 沖本 奈美; 東本 有司; 佐伯 翔; 山崎 亮; 綿谷 奈々瀬; 深井 有美; 宮嶋 宏之; 忌部 周; 山藤 啓史; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (9) 1390 - 1390 2013
  • Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
    RESPIRATION KARGER 85 (4) 326 - 331 0025-7931 2013 [Refereed]
     
    Background: Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown. Objectives: This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF. Methods: Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated. Results: Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9%. The median overall survival was 11.4 months, the 1-year survival rate was 28.6% and the median PFS was 5.4 months. Conclusions: This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy. Copyright (C) 2012 S. Karger AG, Basel
  • Motohiro Kimura; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Hiromichi Aso; Koji Sakamoto; Yoshinori Hasegawa
    RESPIRATION KARGER 85 (6) 456 - 463 0025-7931 2013 [Refereed]
     
    Objectives: To evaluate the survival impact of pulmonary artery pressure measured during the initial evaluation in patients with IPF. Methods: We retrospectively analyzed the initial evaluation data of 101 consecutive IPF patients undergoing right heart catheterization. Patients evaluated with supplemental oxygen were excluded. Predictors of 5-year survival were analyzed using the Cox proportional model. Results: The mean forced vital capacity (FVC) % predicted, diffusing capacity of the lung for carbon monoxide (D-LCO) % predicted, and mean pulmonary artery pressure (MPAP) were 70.2 +/- 20.1%, 47.9 +/- 19.5%, and 19.2 +/- 6.5 mm Hg, respectively. A univariate Cox proportional hazard model showed that the body mass index, % FVC, % D-LCO, baseline Pao(2), modified Medical Research Council score, 6-min walk distance, and lowest Spo(2) of the 6-min walk test were significantly predictive of survival. The MPAP and pulmonary vascular resistance of right heart catheterization were also significant. With stepwise, multivariate Cox proportional analysis, MPAP (HR = 1.064; 95% CI 1.015-1.116, p = 0.010) and % FVC (HR = 0.965, 95% CI 0.949-0.982, p < 0.001) were independent determinants of survival. Analysis of the receiver operating curve revealed MPAP>20 mm Hg to be optimal for predicting the prognosis. Conclusions: Higher MPAP and lower % FVC at the initial evaluation were significant independent prognostic factors of IPF. The current results suggested the importance of the initial evaluation of PH for patients with IPF. Copyright (C) 2012 S. Karger AG, Basel Background: The impact of pulmonary hypertension (PH) on survival has been demonstrated in severe cases with idiopathic pulmonary fibrosis (IPF) who were referred for transplantation. However, whether PH is a predictor of survival remains unclear in milder cases.
  • Naoki Takashima; Tomoki Kimura; Naohiro Watanabe; Takumi Umemura; Shinya Katsuno; Keiko Arakawa; Masahiro Fukatsu; Naoto Nakamura; Osamu Nishiyama; Kensuke Kataoka; Yasuhiro Kondoh; Hiroyuki Taniguchi
    ONKOLOGIE KARGER 35 (12) 747 - 752 0378-584X 2012/12 [Refereed]
     
    Background: Severe skin rash as toxicity of erlotinib has been reported in relation to better response and survival. However, some patients require dose reduction due to skin toxicities, and their prognosis remains uncertain. We retrospectively evaluated the clinical course of non-small cell lung cancer patients receiving erlotinib at a reduced dose because of skin rash. Patients and Methods: Among 76 patients treated with erlotinib, 55 patients who developed skin rash severer than grade 2 were divided into 2 groups: 24 patients treated with erlotinib with dose reduction because of skin rash (dose reduction group) and 31 patients without any dose reduction (non-dose reduction group). Results: The median progression-free survival in the dose reduction and non-dose reduction groups was 341 and 70 days, respectively, and the median overall survival was 566 and 202 days, respectively (p < 0.001). In the dose reduction group, no smoking history, female sex, epidermal growth factor receptor gene mutation, and grade 3 skin rash were significant baseline factors. Conclusions: Patients who received erlotinib at a reduced dose following skin rash showed better survival than those without reduction. In cases of intolerable skin rash, patients may benefit from continuous treatment with a reduced dose of erlotinib.
  • 本田憲胤; 東本有司; 西山理; 前田和成; 岡島聡; 白石匡; 杉谷竜司; 山縣俊之; 東田有智; 大城昌平; 福田寛二
    総合リハビリテーション (株)医学書院 40 (11) 1447 - 1451 0386-9822 2012/11 
    64歳女。6歳時に頸椎・胸椎カリエスのため手術を施行した。徐々に進行する労作時呼吸困難が出現し、精査目的で入院となった。5日間の入院で非侵襲的陽圧人工呼吸器(NPPV)が導入され、退院後外来で呼吸リハビリテーションが開始となった。外来通院で実施した呼吸リハビリテーションプログラムは、週2回、休憩も含め1回約90分実施した。退院後NPPVと同時に労作時は在宅酸素療法(HOT)を導入していたが、介入後2ヵ月でHOTの離脱が可能であった。週2回の外来呼吸リハビリテーションと夜間睡眠時のNPPV導入により呼吸機能や運動耐容能、夜間睡眠時のSpO2が改善し、さらに、労作時の酸素療法を中止できた。運動前に実施した全身調整訓練の目的は、胸郭コンプライアンスの改善や呼吸補助筋のリラクセーションを行うことで効率の良い呼吸を獲得することとした。呼吸機能や夜間のSpO2の改善を認めた。
  • 多賀収; 中村さつき; 石原敦司; 西山理
    日本呼吸ケア・リハビリテーション学会誌 The Japan Society for Respiratory Care and Rehabilitation 22 (2) 208 - 212 1881-7319 2012/10 
    安静時PaO2 70 Torr以上を呈し運動時SpO2低下をきたす未治療の臨床的特発性肺線維症患者8例を対象に経鼻カヌラ4 L/分酸素投与の6分間歩行試験における効果を検討した.患者背景は年齢74.0±8.8歳,男性7例,%FVC 77.1±17.6%,%DLco 72.7±19.6%,安静室内気PaO2 88.4±12.5 Torrなどであった.6分間歩行距離は401.1±100.6 mから438.4±90.4 mへ有意に延長し(P<0.01),延長量は37.3±22.6 m(最小11.0 m,最大75.0 m)であった.最大心拍数や最大呼吸困難感,最大下肢疲労感に有意な改善を認めなかったが,最低SpO2,最大呼吸数は有意に改善した.6分間歩行距離延長量と患者背景因子や最大心拍数,最低SpO2,最大呼吸数,最大呼吸困難感,最大下肢疲労感それぞれの変化量,そしてベースラインの6分間歩行距離との間にはいずれも有意な相関を認めなかった.特発性肺線維症患者における運動時酸素投与によって運動耐容能改善効果が得られる可能性が示唆されたが,その効果が得られる患者背景因子や機序は明らかにならなかった.
  • 外来呼吸リハビリテーションと非侵襲的陽圧換気療法により肺機能・運動耐容能が改善し酸素療法から離脱できた脊椎後側彎症の1例
    本田 憲; 東本 有司; 西山 理; 前田 和成; 岡島 聡; 白石 匡; 大城 昌平; 山縣 俊之; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 22 (Suppl.) 231s - 231s 1881-7319 2012/10
  • COPD患者の高次脳機能障害に関連する因子の検討
    岡島 聡; 東本 有司; 本田 憲胤; 前田 和成; 白石 匡; 杉谷 竜司; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 22 (Suppl.) 161s - 161s 1881-7319 2012/10
  • コンディショニング中心による介入にて6MWDに著明な改善を認めたCOPD症例
    杉谷 竜司; 前田 和成; 本田 憲胤; 岡島 聡; 白石 匡; 東本 有司; 西山 理; 山縣 俊之; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 22 (Suppl.) 163s - 163s 1881-7319 2012/10
  • 呼吸リハビリテーションによる活動量変化と6分間歩行試験、SGRQとの関連
    白石 匡; 本田 憲胤; 前田 和成; 東本 有司; 岡島 聡; 杉谷 竜司; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 22 (Suppl.) 196s - 196s 1881-7319 2012/10
  • 多賀収; 中村さつき; 伊藤雄二; 秋山崇; 吉原正; 西山理
    日本呼吸器学会誌 日本呼吸器学会 1 (4) 349 - 353 2186-5876 2012/05
  • 西山 理; 綿谷 奈々瀬; 宮嶋 宏之; 佐藤 隆司; 牧野 靖; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 1 (増刊) 174 - 174 2186-5876 2012/03
  • 宮嶋 宏之; 西山 理; 綿谷 奈々瀬; 佐藤 隆司; 牧野 靖; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 1 (増刊) 260 - 260 2186-5876 2012/03
  • 佐野 博幸; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 市橋 秀夫; 牧野 靖; 佐野 安希子; 佐藤 隆司; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 1 (増刊) 315 - 315 2186-5876 2012/03
  • 東本 有司; 山縣 俊之; 西山 理; 宮嶋 宏之; 市橋 秀夫; 佐野 安希子; 佐藤 隆司; 佐野 博幸; 岩永 賢司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    日本呼吸器学会誌 (一社)日本呼吸器学会 1 (増刊) 361 - 361 2186-5876 2012/03
  • Koji Sakamoto; Hiroyuki Taniguchi; Yasuhiro Kondoh; Kenji Wakai; Tomoki Kimura; Kensuke Kataoka; Naozumi Hashimoto; Osamu Nishiyama; Yoshinori Hasegawa
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 106 (3) 436 - 442 0954-6111 2012/03 [Refereed]
     
    Backgrounds: Bronchoalveolar lavage (BAL) is generally regarded as a safe diagnostic procedure. However, acute exacerbation after BAL is increasingly recognized as a specific complication for patients with idiopathic pulmonary fibrosis (IPF). So far little is known about the correlation between BAL and acute exacerbation of IPF (AE-IPF). Methods: A cohort of 112 IPF patients at a single institution was analyzed retrospectively. We defined BAL-related AE-IPF as development of AE-IPF within 30 days after the procedure. The incidence rate of AE-IPF per person-month during the post-BAL period was compared with that after the post-BAL period. The relative risk was estimated as the former rate divided by the latter. We also reviewed the previous literature. Results: Four AE-IPF cases occurred during the 201 person-month post-BAL period. The risk of AE-IPF was significantly elevated within 30 days after BAL (rate ratio = 4.12; 95% Cl = 1.03-12.2). None of the 111 initial BAL procedures were followed by AE-IPF within a month. In a post hoc analysis, the relative risk of developing AE after second or later BAL procedures was estimated to be considerably higher (rate ratio = 9.10; 95% CI = 2.27-26.98). Twelve cases of BAL-induced AE-IPF were found in our study and in the literature review. Among them, nine showed moderate to severe functional impairment, and eight had either findings of leukocytosis, positive C-reactive protein, or neutrophilia in BAL. Conclusions: These results suggest that IPF patients should be carefully monitored after BAL, especially those with functional impairment or active inflammation. (C) 2011 Elsevier Ltd. All rights reserved.
  • H. Kotani; R. Kishi; A. Mouri; T. Sashio; J. Shindo; A. Shiraki; T. Hiramatsu; S. Iwata; H. Taniguchi; O. Nishiyama; M. Iwata; R. Suzuki; H. Gonda; T. Niwa; M. Kondo; Y. Hasegawa; H. Kume; Y. Noda
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS WILEY-BLACKWELL 37 (1) 112 - 116 0269-4727 2012/02 [Refereed]
     
    What is known and Objective: Montelukast, a cysteinyl leukotriene receptor 1 antagonist, is safe and efficacious in patients with asthma. The mechanisms underlying the significant interpatient variability in response to montelukast are not clear but are believed to be, in part, because of genetic variability. Methods: To examine the associations between polymorphisms in candidate genes in the leukotriene pathway and outcomes in patients with asthma on montelukast for 4-8 weeks, we evaluated the changes in peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV10) and patients' subjective symptom before and after montelukast treatment. DNA was collected from 252 Japanese participants. Results and Discussion: Two single-nucleotide polymorphisms (SNPs) in the ALOX5 (rs2115819) and LTA4H (rs2660845) genes were successfully typed. There was no difference between members of the general population (n = 200) and patients (n = 52) in each genotype frequency. Significant associations were found between SNP genotypes in the LTA4H gene and changes in PEF and FEV10. The PEF and FEV10 responses to montelukast in the A/A genotypes (n = 4) for the LTA4H SNP were significantly higher than those in the G allele carriers (A/G+G/G) (n = 17). What is new and Conclusion: Despite the small sample size, our results suggest that genetic variation in leukotriene pathway candidate genes contributes to variability in clinical responses to montelukast in Japanese patients with asthma.
  • 岩永 賢司; 沖本 奈美; 忌部 周; 塚本 敬造; 山藤 啓史; 佐藤 隆司; 西山 理; 佐野 博幸; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (3) 484 - 484 2012
  • 佐藤 隆司; 冨田 桂公; 沖本 奈美; 深井 有美; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 市橋 秀夫; 佐野 安希子; 牧野 靖; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (3) 513 - 513 2012
  • 中島 宏和; 佐藤 隆司; 西山 理; 佐野 博幸; 東本 有司; 岩永 賢司; 冨田 桂公; 久米 裕昭; 中島 重徳; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (3) 546 - 546 2012
  • 山崎 亮; 岩永 賢司; 沖本 奈美; 深井 有美; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 佐野 博幸; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1460 - 1460 2012
  • 佐藤 隆司; 山崎 亮; 沖本 奈美; 深井 有美; 忌部 周; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 牧野 靖; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1464 - 1464 2012
  • 深井 有美; 西山 理; 宮嶋 宏之; 佐藤 隆司; 牧野 靖; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1479 - 1479 2012
  • 沖本 奈美; 東本 有司; 山崎 亮; 深井 有美; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1475 - 1475 2012
  • 宮嶋 宏之; 西山 理; 深井 有美; 佐藤 隆司; 牧野 靖; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1478 - 1478 2012
  • 忌部 周; 久米 裕昭; 牧野 靖; 佐藤 隆司; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 博幸; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1496 - 1496 2012
  • 西山 理; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1354 - 1354 2012
  • 中島 宏和; 牧野 靖; 佐藤 隆司; 西山 理; 佐野 博幸; 東本 有司; 岩永 賢司; 久米 裕昭; 中島 重徳; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1578 - 1578 2012
  • 山藤 啓史; 村木 正人; 大野 剛史; 花田 宗一郎; 忌部 周; 田村 光信; 澤口 博千代; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 吉田 耕一郎; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1576 - 1576 2012
  • 久米 裕昭; 塚本 敬造; 荒木 信泰; 山崎 亮; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1569 - 1569 2012
  • 佐野 安希子; 佐野 博幸; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 沖本 奈美; 深井 有美; 山崎 亮; 牧野 靖; 佐藤 隆司; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1573 - 1573 2012
  • 牧野 靖; 西山 理; 山崎 亮; 沖本 奈美; 深井 有美; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 佐藤 隆司; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 吉田 耕一郎; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 34 (5) 528 - 528 2012
  • O. Nishiyama; H. Taniguchi; Y. Kondoh; T. Kimura; K. Kataoka; K. Nishimura; T. Ogawa; F. Watanabe; S. Arizono; Y. Tohda
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES MATTIOLI 1885 29 (2) 113 - 118 1124-0490 2012 [Refereed]
     
    Background: Although health-related quality of life (HRQL) has recently been considered to be an important outcome in clinical trials of idiopathic pulmonary fibrosis (IPF), its relationship with survival is unknown. Objective: To determine the prognostic significance of HRQL scores in IPF assessed with the SGRQ. Design: Eighty-seven consecutive patients with IPF, who had undergone evaluations and completed the St. George's Respiratory Questionnaire (SGRQ) at diagnosis were included in this study, as is the general practice. Cox proportional hazards analyses were performed to examine the relationship between HRQL scores and survival. Results: The mean observation period was 44.2+/-29.6 mo, in the course of which 54 patients (62.0%) died. Univariate analysis revealed that the activity scores in the SGRQ (HR: 1.016, 95% CI: 1.004-1.029, P=0.01) were significantly predictive of survival, although the symptoms, impacts, and total scores were not significantly related to mortality from all causes. However, multivariate analysis revealed that only the forced vital capacity percent predicted was a significant predictor of survival, and that the activity score in the SGRQ was not significantly related to mortality. Conclusions: There was no significant relationship between HRQL evaluated with the SGRQ and the subsequent mortality in IPF. The present negative result might suggest that HRQL is measuring an aspect other than one from physiological and functional impairment or disability.
  • インダカテロール(新規超長時間作用性β2刺激薬)の薬理学的特性とそれに基づく臨床的有用性
    久米 裕昭; 忌部 周; 塚本 啓造; 沖本 奈美; 深井 有美; 山藤 啓史; 牧野 靖; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 東田 有智
    アレルギー・免疫 (株)医薬ジャーナル社 18 (12) 1858 - 1868 1344-6932 2011/11 
    新規の長時間作用性β2刺激薬(LABA)であるインダカテロールの薬理学的特性に関して、モルモット由来気道平滑筋における収縮抑制効果を指標として解析した。インダカテロール(≧30nM)は短時間作用性β2刺激薬(SABA)と同様、15分以内に最大効果を示した。10μMのメサコリン(MCh)による気道平滑筋の収縮に対してインダカテロールを累積投与した際、最大抑制率から算出した固有活性の値は72.3%であった。この薬物はパーシャルアゴニストに分類され、現在臨床使用される薬物の中で最も高い固有活性を有する。MCh収縮に対するインダカテロールの抑制率は、12時間経過した時点でも有意な減少は認められなかった。インダカテロールを10分間曝露した後のSABAの抑制効果は濃度依存的に減少したが、300nM未満ではSABAの抑制作用にほとんど影響しなかった。以上の結果より、インダカテロールは速効性を有する超長時間作用性のストロングパーシャルアゴニストであり、さらにβ2受容体の耐性化が起こり難いことが予想される。そのため、β2受容体の数や機能が低下している可能性のある慢性閉塞性肺疾患患者においても、本来の効果を減弱することなく作用を発揮することが期待され、質と安全性が保障された医療の提供を実現させることが推察される。(著者抄録)
  • 運動時低酸素をきたすCOPD患者の脳皮質酸素化ヘモグロビン濃度
    東本 有司; 本田 憲胤; 西山 理; 宮嶋 宏之; 市橋 秀夫; 佐野 安希子; 前田 和成; 山縣 俊之; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 148s - 148s 1881-7319 2011/10
  • 労作時呼吸困難と大脳皮質活性の関係 近赤外分光法を用いて
    本田 憲胤; 東本 有司; 前田 和成; 岡島 聡; 白石 匡; 山縣 俊之; 西山 理; 大城 昌平; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 148s - 148s 1881-7319 2011/10
  • 呼吸リハビリテーション患者における栄養評価と分岐鎖アミノ酸投与効果の検討
    湯川 紘世; 東本 有司; 山縣 俊之; 本田 憲胤; 前田 和成; 白石 匡; 西山 理
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 254s - 254s 1881-7319 2011/10
  • 間質性肺炎患者と慢性閉塞性肺疾患患者の前頭葉機能の比較 Frontal Assessment Batteryを用いて
    岡島 聡; 東本 有司; 本田 憲胤; 前田 和成; 白石 匡; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 299s - 299s 1881-7319 2011/10
  • COPDの増悪前のCAT点数の変動についての検討
    杉谷 竜司; 本田 憲胤; 前田 和成; 岡島 聡; 白石 匡; 東本 有司; 西山 理; 山縣 俊之; 福田 寛二; 東田 有智
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 305s - 305s 1881-7319 2011/10
  • 症例ごとの運動指導の評価における加速度計の活用
    白石 匡; 本田 憲胤; 前田 和成; 東本 有司; 岡島 聡; 杉谷 竜司; 山縣 俊之; 西山 理; 東田 有智; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 307s - 307s 1881-7319 2011/10
  • 肺切除術施行患者の2ヵ月後の身体活動量について
    前田 和成; 本田 憲胤; 白石 匡; 東本 有司; 廣畑 健; 南 憲司; 山縣 俊之; 西山 理; 松尾 善美; 福田 寛二
    日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 21 (Suppl.) 314s - 314s 1881-7319 2011/10
  • Osamu Nishiyama; Hiroyuki Taniguchi; Yasuhiro Kondoh; Kazuto Takada; Kenji Baba; Hiroshi Saito; Yasuteru Sugino; Masashi Yamamoto; Toshihiko Ogasawara; Masashi Kondo; Kazuyoshi Imaizumi; Yoshinori Hasegawa; Ryujiro Suzuki; Kaoru Shimokata
    ANTI-CANCER DRUGS LIPPINCOTT WILLIAMS & WILKINS 22 (8) 811 - 816 0959-4973 2011/09 [Refereed]
     
    Although S-1 has been shown to have activity against advanced nonsmall-cell lung cancer (NSCLC), its efficacy for elderly patients remains unclear. This phase II study evaluated the efficacy and safety of S-1 as a first-line treatment for elderly patients. Chemotherapy-naive patients aged 70 years or older with stages IIIB to IV or postoperative NSCLC and performance status 1 or lower were eligible. Patients received S-1 approximately equivalent to 80mg/m(2)/day for 2 weeks followed by a 1-week rest period every 3 weeks. The primary end point was the response rate. Secondary end points were toxicity, disease control rate, progression-free survival, and overall survival. Twenty-nine patients were eligible. The median age was 78 years (range, 70-85 years). The overall response rate and the disease control rate were 27.6 [95% confidence interval (CI), 11.3-43.9%] and 65.5% (95% CI: 48.2-82.8%), respectively. The median progression-free survival time was 4.0 months (95% CI: 4.0-9.8 months). The median overall survival was 12.1 months (95% CI: 13.8-25.5 months) and the 1-year survival rate was 53.6%. No grade 4 toxicities were observed. The only hematological toxicity of grade 3 was anemia in 6.9% of patients. The grade 3 nonhematological toxicities included hyponatremia, anorexia, nausea, oral mucositis, and diarrhea in 3.4% of patients and infection in 6.9% of patients. S-1 monotherapy was effective and well tolerated as a first-line treatment for elderly patients with advanced NSCLC. The results of this study warrant further investigations of this regimen, including a randomized controlled trial. Anti-Cancer Drugs 22:811-816 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
  • ADA低値結核性胸膜炎の診断法の検討
    宮良 高維; 綿谷 奈々瀬; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 佐野 博之; 岩永 賢司; 冨田 桂公; 中島 裕一; 久米 裕昭; 東田 有智
    感染症学雑誌 (一社)日本感染症学会 85 (4) 439 - 439 0387-5911 2011/07
  • 岩永 賢司; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 49 (増刊) 215 - 215 1343-3490 2011/03
  • 西川 裕作; 佐野 博幸; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 宮良 高維; 岩永 賢司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 49 (増刊) 274 - 274 1343-3490 2011/03
  • 宮良 高維; 綿谷 奈々瀬; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 佐野 博幸; 岩永 賢司; 冨田 桂公; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 49 (増刊) 301 - 301 1343-3490 2011/03
  • 佐野 博幸; 冨田 桂公; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 49 (増刊) 312 - 312 1343-3490 2011/03
  • ADA低値結核性胸膜炎の診断法の検討
    宮良 高維; 綿谷 奈々瀬; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 佐野 博之; 岩永 賢司; 冨田 桂公; 中島 裕一; 久米 裕昭; 東田 有智
    感染症学雑誌 (一社)日本感染症学会 85 (臨増) 152 - 152 0387-5911 2011/03
  • 佐野 博幸; 西川 裕作; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 啓之; 山藤 啓史; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 S172  2011
  • 山藤 啓史; 佐藤 隆司; 冨田 桂公; 沖本 奈美; 深井 有美; 宮嶋 宏之; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 市橋 秀夫; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1377 - 1377 2011
  • 久米 裕昭; 忌部 周; 塚本 敬造; 牧野 靖; 佐藤 隆司; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 冨田 桂公; 中島 宏和; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1374 - 1374 2011
  • 佐藤 隆司; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 市橋 秀夫; 佐野 安希子; 牧野 靖; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1381 - 1381 2011
  • 佐野 博幸; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 山藤 啓史; 市橋 秀夫; 佐野 安希子; 西山 理; 岩永 賢司; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1335 - 1335 2011
  • 冨田 桂公; 深井 有美; 沖本 奈美; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 川内 映理; 山片 重良; 市橋 秀夫; 佐藤 隆司; 牧野 靖; 佐野 安希子; 西山 理; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1333 - 1333 2011
  • 佐藤 隆司; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 川内 映理; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (3) 456 - 456 2011
  • 忌部 周; 佐藤 隆司; 綿谷 奈々瀬; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 川内 映理; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (3) 456 - 456 2011
  • 岩永 賢司; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 佐野 博幸; 宮良 高維; 東本 有司; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (3) 440 - 440 2011
  • Yuji Higashimoto; Noritsugu Honda; Toshiyuki Yamagata; Toshiki Matsuoka; Kazushige Maeda; Rhyuji Satoh; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Takayuki Miyara; Masato Muraki; Katsuyuki Tomita; Hiroaki Kume; Ichiro Miyai; Yuji Tohda; Kanji Fukuda
    RESPIRATION KARGER 82 (6) 492 - 500 0025-7931 2011 [Refereed]
     
    Background: Exertional dyspnea is the primary symptom that limits exercise in patients with chronic obstructive pulmonary disease (COPD). It is unknown which activated brain area is associated with this symptom in COPD patients. Objectives: To investigate the activation of cortical areas associated with dyspnea during exercise in COPD patients. Methods: COPD patients (n = 10) and age-matched controls (n = 10) performed mild-intensity constant work rate cycle exercise (40% of their symptom-limited peak work rates) for 10 min, while cerebral hemodynamics and oxygenation were measured by near-infrared spectroscopy (NIRS). Ventilatory responses (breathing pattern and pulmonary gas exchange) and Borg scale ratings of dyspnea and leg fatigue were measured during exercise. Three NIRS probes were placed over the prefrontal and temporoparietal cortical regions of the subjects' heads. Changes in cortical oxyhemoglobin (oxyHb), deoxyhemoglobin (deoxy-Hb), and total hemoglobin (total Hb) concentrations from baseline recordings were measured. Increased oxy-Hb (oxygenation) was assumed to reflect cortical activation. Results: Oxy-Hb concentration was significantly increased in the prefrontal region during exercise in both groups but not in the temporoparietal regions. The change in prefrontal oxy-Hb concentration of COPD patients was not different from that of controls. Dyspnea scores were positively correlated with changes in oxyHb concentrations of the prefrontal regions in both groups. Multivariate analysis showed that oxy-Hb concentration in the prefrontal region was the best predictor of dyspnea in both groups. Conclusions: Exertional dyspnea was related to activation (oxygenation) of the prefrontal cortex in COPD patients and control subjects. Copyright (C) 2011 S. Karger AG, Basel
  • Shinichi Arizono; Hiroyuki Taniguchi; Osamu Nishiyama; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Koichi Nishimura; Hideaki Senjyu; Kazuyuki Tabira
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 50 (21) 2533 - 2539 0918-2918 2011 [Refereed]
     
    Background and Objective The endurance time has been reported to be the most sensitive measure of improved exercise capacity in response to a variety of interventions for COPD. The aim of the present study was to determine whether the improvements in quadriceps force and measures obtained from a symptom-limited maximal test contributed to the improvements in endurance time following pulmonary rehabilitation. Methods Fifty-seven consecutive COPD subjects completed a 10-week pulmonary rehabilitation program. The subjects completed a symptom-limited incremental cycle ergometry test and a constant work rate test before and after pulmonary rehabilitation. Peripheral and respiratory muscle strength was also measured. The relationships between the change in endurance time and the changes obtained from the incremental test and muscle strength test were investigated. Results The endurance time showed the greatest improvement among the exercise capacity indices. The changes in endurance time were significantly correlated to changes in quadriceps force, peak work rate, anaerobic threshold and work efficiency on the incremental load test. In the multiple stepwise regression analysis, changes in quadriceps force and work efficiency measured on the maximal exercise test were selected. Conclusion These findings suggest that the improvements in endurance time after pulmonary rehabilitation may be explained by increased quadriceps force and improvements in peak work rate and work efficiency.
  • O. Nishiyama; H. Taniguchi; Y. Kondoh; T. Kimura; K. Kato; K. Kataoka; T. Ogawa; F. Watanabe; S. Arizono
    EUROPEAN RESPIRATORY JOURNAL EUROPEAN RESPIRATORY SOC JOURNALS LTD 36 (5) 1067 - 1072 0903-1936 2010/11 [Refereed]
     
    The prognosis in idiopathic pulmonary fibrosis (IPF) is poor. No therapy has been shown to prolong survival. The objective of this study was to examine the prognostic significance of dyspnoea in daily living at baseline in IPF using a simple assessment tool. 93 consecutive patients with IPF, who had undergone evaluation at diagnosis, were included. The level of dyspnoea was assessed using the modified Medical Research Council (MRC) scale. The relationship between data at baseline and survival was examined. A univariate Cox proportional-hazard model showed that forced vital capacity % predicted (hazard ratio (HR) 0.965, 95% CI 0.948-0.982; p<0.0001), diffusing capacity of the lung for carbon monoxide % predicted (HR 0.978, 95% CI 0.963-0.993; p=0.0041), baseline arterial oxygen tension (HR 0.963, 95% CI 0.938-0.989; p=0.0060) and modified MRC score (HR 2.402, 95% CI 1.495-3.858; p=0.0003) were significantly predictive of survival. All variables of the 6-min walk test, including walk distance (HR 0.995, 95% CI 0.992-0.998; p=0.0020), the lowest arterial oxygen saturation measured by pulse oximetry (Sp,O(2)) (HR 0.944, 95% CI 0.918-0.972; p<0.0001) and the Borg scale (HR 1.285, 95% CI 1.091-1.514; p=0.0027), were also significant. With stepwise, multivariate Cox proportional analysis, the modified MRC score (HR 2.181, 95% CI 1.333-3.568; p=0.0019) and the lowest Sp,O(2) during the 6-min walk test (HR 0.952, 95% CI 0.924-0.981; p=0.0014) were the most significant. Dyspnoea in daily living, assessed with the modified MRC scale at baseline, provides additional prognostic information for patients with IPF.
  • Y. Kondoh; H. Taniguchi; T. Katsuta; K. Kataoka; T. Kimura; O. Nishiyama; K. Sakamoto; T. Johkoh; M. Nishimura; K. Ono; M. Kitaichi
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES FONDAZIONE PNEUMOLOGIA U I P ONLUS 27 (2) 103 - 110 1124-0490 2010/07 [Refereed]
     
    Background: Although acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a well known clinical condition, predicting risk factors remain unknown. We evaluated the frequency, risk factors and impact on survival of AE-IPF. Methods: We retrospectively studied patients diagnosed with IPF based on the criteria of the ATS/ERS consensus statement and followed them for periods of more than 3 years except in dead cases. Initial characteristics including the level of dyspnoea, which was assessed with the modified Medical Research Council (MRC) scale, and decline of forced vital capacity (FVC) defined by at least 10% decline at 6 months, were evaluated as possible risk factors for AE. Results: Seventy-four patients with IPF were studied. One-year, two-year, and three-year incidence of AE were 8.6%, 12.6%, and 23.9%, respectively. Multivariate analysis revealed that higher body mass index (BMI) [hazard ratio (HR), 1.20; 95% confidence interval (CI), 1.03-1.40], higher modified MRC scale [HR, 2.93; 95% CI, 1.46-5.85], and a decline in FVC at 6 mounths [HR, 0.97-2.60 (per mo); 95% CI, 1.01-7.45] were independent risk factors for AE-IPF. The causes of death were assessed to be AE in 20 of 57 expired patients. A stepwise multivariate Cox regression model evaluating AE-IPF, adjusted for %FVC and decline in FVC, demonstrated a statistically significant impact on overall survival [HR, 2.79; 95% CI, 1.59-4.88; p<0.001]. Conclusion: These data suggest that initial high modified MRC scale, high BMI, and decline in FVC at 6 months were significant independent risk factors fin AE-IPF. AE was an independent prognostic factor in IPF. (Sarcoidosis Vase Diffuse Lung Dis 2010; 27: 103-110)
  • 抗酸菌感染症 当院におけるMycobacterium abscessus治療例の検討
    宮良 高維; 山口 逸弘; 戸田 宏文; 宮嶋 宏之; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 内藤 映理; 牧野 靖; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 村木 正人; 富田 桂公; 久米 裕昭; 東田 有智
    感染症学雑誌 (一社)日本感染症学会 84 (臨増) 255 - 256 0387-5911 2010/03
  • 西川 裕作; 冨田 桂公; 圖子 瞳; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 内藤 映理; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 久米 裕昭; 村木 正人; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 48 (増刊) 181 - 181 1343-3490 2010/03
  • 佐藤 隆司; 冨田 桂公; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (3) 378 - 378 2010
  • 内藤 映理; 冨田 桂公; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (3) 376 - 376 2010
  • 村木 正人; 山藤 啓史; 西川 裕作; 内藤 映理; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 佐野 博幸; 山縣 俊之; 宮良 高維; 岩永 賢司; 久米 裕昭; 冨田 桂公; 東本 有司; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (3) 385 - 385 2010
  • 宮良 高維; 西川 裕作; 山藤 啓史; 忌部 周; 塚本 敬造; 宮嶋 宏之; 内藤 映理; 佐藤 隆司; 牧野 靖; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 冨田 桂公; 村木 正人; 久米 裕昭; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 S108  2010
  • 藤田 悦生; 大江 洋介; 元村 正明; 桑山 真輝; 服部 英喜; 園部 奨太; 助永 親彦; 橋村 俊哉; 薮田 幸一; 蔵 昌宏; 小多田 英貴; 小川 義高; 清水 孝典; 鳥野 隆博; 星田 四朗; 長井 直子; 佐々木 洋; 西山 理; 東田 有智; 米田 正太郎
    アレルギー 一般社団法人 日本アレルギー学会 59 (3) 392 - 392 2010
  • 佐野 博幸; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 宮良 高維; 中島 宏和; 冨田 桂公; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1403 - 1403 2010
  • 岩永 賢司; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 川内 映理; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 中島 宏和; 久米 裕昭; 冨田 桂公; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1355 - 1355 2010
  • 圖子 瞳; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 川内 映理; 牧野 靖; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 宮良 高維; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1426 - 1426 2010
  • 佐藤 隆司; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 川内 映理; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1477 - 1477 2010
  • 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 川内 映理; 西川 裕作; 佐野 安希子; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 中島 宏和; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1382 - 1382 2010
  • 山藤 啓史; 冨田 桂公; 綿谷 奈々瀬; 忌部 周; 塚本 敬造; 宮嶋 宏之; 西川 裕作; 川内 映理; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 東本 有司; 佐野 博幸; 宮良 高維; 岩永 賢司; 中島 宏和; 久米 裕昭; 村木 正人; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 59 (9) 1440 - 1440 2010
  • Koji Sakamoto; Hiroyuki Taniguchi; Yasuhiro Kondoh; Takeshi Johkoh; Hiromitsu Sumikawa; Tomoki Kimura; Osamu Nishiyama; Keisuke Kato; Kensuke Kataoka; Kenzo Ono; Mansanori Kitaichi; Yoshinori Hasegawa
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 104 (1) 127 - 133 0954-6111 2010/01 [Refereed]
     
    Backgrounds: Fibrotic nonspecific interstitial pneumonia (f-NSIP) has been recognized as a distinct disease entity. KL-6 has been reported to be a useful serum marker in interstitial lung diseases. However, few previous reports evaluated the value of serum KL-6 exclusively in f-NSIP, as distinct from other subtypes of idiopathic interstitial pneumonia, therefore the associations of serum KL-6 with clinical. and radiologic findings in this population remain unclear. Methods: Serum KL-6 levels were measured in twenty-six consecutive patients with f-NSIP diagnosed by surgical lung biopsy. Pulmonary function testing, bronchoalveolar lavage, subjective measurement of dyspnea using baseline dyspnea index (BDI), and HRCT were performed in parallel. Two radiologists conducted independent visual. examinations of the pattern and extent of abnormalities on HRCT. Results: Serum KL-6 levels were elevated above the cut-off level. in all patients. In univariate analysis serum KL-6 levels showed negative correlations with BDI (rho = -0.52; p < 0.01). Serum KL-6 had positive correlations with the extent of several patterns of opacities (rho = 0.56-0.62; p < 0.01). Among them, only the extent of traction bronchiectasis in HRCT showed significant association with serum KL-6 in multivariate analysis (beta-coefficient = 0.043; p < 0.01). Conclusions: Serum levels of KL-6 were elevated in f-NSIP, and were correlated with the extent of fibrotic abnormalities on HRCT, suggesting a value of serum KL-6 as a marker for fibrosis in f-NSIP. (C) 2009 Elsevier Ltd. All rights reserved.
  • Toshiki Yokoyama; Yasuhiro Kondoh; Hiroyuki Taniguchi; Kensuke Kataoka; Keisuke Kato; Osamu Nishiyama; Tomoki Kimura; Ryuichi Hasegawa; Keishi Kubo
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 49 (15) 1509 - 1514 0918-2918 2010 [Refereed]
     
    Background and Objective The outcome of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is usually very poor, and it has been suggested that mechanical ventilation does not benefit AE-IPF patients. Noninvasive ventilation (NIV) has attracted attention as a means to avoid intubation in acute respiratory failure, including acute respiratory distress syndrome (ARDS). This study describes the outcome of patients with AE-IPF who were treated with NIV. Methods Patients included in the study were those who fulfilled the criteria for AE-IPF during the periods between April 1998 and June 2004 at Tosei General Hospital, and in whom NIV was introduced. Clinical data were obtained retrospectively from patient records. Results This study included 11 patients. The initial NIV settings were continuous positive airway pressure (CPAP) mode in 6 patients (mean 10.1 +/- 2.5 cmH(2)O) and Spontaneous/Timed mode in 5 (mean inspiratory positive airway pressure/expiratory positive airway pressure; 15.0 +/- 3.3/10.2 +/- 2.9 cmH(2)O). Five patients avoided intubation and survived more than 3 months after AE-IPF. Six patients who failed NIV died within 3 months. In these 6 patients, 4 required intubation. The other 2 patients, who refused endotrachial intubation, died without intubation. Median survival time and 3-month survivals after acute exacerbation were 30 days, and 45.5%, respectively. Conclusion Considering extremely poor prognosis of AE-IPF, our findings suggest that NIV is a viable option for the respiratory management in AE-IPF, and should be studied in a large, well-controlled trial.
  • Hiromichi Aso; Yasuhiro Kondoh; Hiroyuki Taniguchi; Tomoki Kimura; Osamu Nishiyama; Keisuke Kato; Kensuke Kataoka; Yoshinori Hasegawa
    INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 49 (19) 2077 - 2083 0918-2918 2010 [Refereed]
     
    Background The efficacy of noninvasive ventilation (NIV) in acute exacerbation of pulmonary tuberculosis sequelae has not been fully studied. Methods We retrospectively reviewed 58 patients with acute exacerbation of pulmonary tuberculosis sequelae who were admitted to Tosei General Hospital and treated with NIV over a 9-year period. Results The 58 patients (mean age: 76.2 +/- 8.0) consisted of 39 males and 19 females. Arterial blood gas analysis on admission showed a mean pH of 7.28 +/- 0.07 and a mean PaCO(2) of 72.6 +/- 14.2 mmHg. After the start of NIV, significant improvement occurred in pH, to 7.32 +/- 0.06 after 2 h and 7.36 +/- 0.06 after 24 h, and in PaCO2, to 66.4 +/- 11.2 mmHg after 2 h and 61.6 +/- 11.3 mmHg after 24 h. The success rate in weaning from NIV was 86.2%. There were statistically significant differences in pH, body mass index (BMI), blood leukocyte count and serum potassium between patients successfully and unsuccessfully weaned from NIV. Conclusion We conclude that patients with acute exacerbation of pulmonary tuberculosis sequelae can be treated successfully with NIV. Lower pH, BMI, and serum potassium, and higher blood leukocyte count are related to NIV failure.
  • 佐藤 隆司; 冨田 桂公; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 牧野 靖; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 58 (8) 1211 - 1211 2009
  • 宮嶋 宏之; 岩永 賢司; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 内藤 映理; 牧野 靖; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 冨田 桂公; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 58 (8) 1282 - 1282 2009
  • 八木 光昭; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 片岡 健介; 村田 直彦
    アレルギー 一般社団法人 日本アレルギー学会 58 (3) 415 - 415 2009
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 片岡 健介
    アレルギー 一般社団法人 日本アレルギー学会 58 (3) 369 - 369 2009
  • 有薗信一; 小川智也; 渡辺文子; 寳門玲美; 平澤純; 近藤康博; 木村智樹; 西山理; 加藤景介; 千住秀明; 谷口博之
    日本呼吸ケア・リハビリテーション学会誌 日本呼吸ケア・リハビリテーション学会 18 (2) 160 - 165 1881-7319 2008/10
  • Osamu Nishiyama; Yasuhiro Kondoh; Tomoki Kimura; Keisuke Kato; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Shinichi Arizono; Koichi Nishimura; Hiroyuki Taniguchi
    RESPIROLOGY BLACKWELL PUBLISHING 13 (3) 394 - 399 1323-7799 2008/05 [Refereed]
     
    Background and objective: Although pulmonary rehabilitation is effective for patients with COPD, its efficacy in patients with IPF is unknown. The purpose of this study was to evaluate the effects of pulmonary rehabilitation in IPF. Methods: Thirty patients diagnosed with IPF, according to the consensus statement, were randomly assigned to the rehabilitation group or the control group. The pulmonary rehabilitation mainly consisted of a 10-week programme of exercise training. Pulmonary function, blood gas analysis, 6MWD, dyspnoea rating with the baseline dyspnoea index and health-related quality of life score on the St George's Respiratory Questionnaire were evaluated at baseline and after the programme. Results: Assessment of efficacy was carried out on 13 patients who completed the programme and 15 patients in the control group. There were no significant effects of the programme on measures of pulmonary function, values of arterial blood gas analysis or dyspnoea rating. Although there were some differences in the baseline 6MWD and total health-related quality of life score which were not statistically significant, marked improvements were observed in the 6MWD (mean difference 46.3 m (95% CI: 8.3-84.4), P < 0.05) and the total health-related quality of life score (-6.1 (95% CI: -11.7 to -0.5), P < 0.05). Conclusions: Pulmonary rehabilitation improves both exercise capacity and health-related quality of life in patients with IPF.
  • 木村 元宏; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 片岡 健介
    アレルギー 一般社団法人 日本アレルギー学会 57 (3) 436 - 436 2008
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 片岡 健介; 麻生 裕紀; 阪本 考司; 木村 元宏; 龍華 美咲
    アレルギー 一般社団法人 日本アレルギー学会 57 (3) 358 - 358 2008
  • 近藤 康博; 谷口 博之; 木村 智樹; 西山 理; 加藤 景介; 片岡 健介; 木村 元宏
    アレルギー 一般社団法人 日本アレルギー学会 57 (9) 1436 - 1436 2008
  • Osamu Nishiyama; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Keisuke Kato; Tomoya Ogawa; Fumiko Watanabe; Shinichi Arizono
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 101 (4) 833 - 838 0954-6111 2007/04 [Refereed]
     
    \The characteristics of dyspnoea in idiopathic pulmonary fibrosis (IPF) during a 6-min walk test are not clear. This study was designed to evaluate dyspnoea and desaturation during the 6-min walk test in IPF in comparison with that in chronic obstructive pulmonary disease (COPD), which is one of the most studied chronic lung diseases. The 41 consecutive patients with IPF included in this study were assessed by a 6-min walk test and concurrent measures of disease severity. Forty-one age-matched and resting PaO2 value-matched COPD patients who had undertaken the test during the same period were selected as the control. Only O-2 saturation at the end of the test was an independent predictor of dyspnoea in IPF (r(2) = 0.27, P = 0.0005), whereas forced expiratory volume in 1 s (FEV1) was the only predictor in COPD (r(2) = 0.16, P = 0.0096). Desaturation was significantly more severe in IPF (83.6+9.1% in IPF versus 88.0+5.9% in COPD, P < 0.001). In contrast, dyspnoea assessed with the Borg scale was significantly more severe in COPD (3.6 +/- 2.1 in IPF versus 4.6 +/- 1.9 in COPD, P < 0.05). O-2 saturation is an independent predictor of dyspnoea at the end of a 6-min walk test in IPF. In comparison with COPD, desaturation is more severe, although dyspnoea is milder. (c) 2006 Elsevier Ltd. All rights reserved.
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 片岡 健介; 麻生 裕紀; 阪本 考司
    アレルギー 一般社団法人 日本アレルギー学会 56 (8) 1070 - 1070 2007
  • 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 片岡 健介
    アレルギー 一般社団法人 日本アレルギー学会 56 (8) 1066 - 1066 2007
  • 加藤 景介; 横山 俊樹; 麻生 裕紀; 阪本 考司; 片岡 健介; 西山 理; 木村 智樹; 近藤 康博; 谷口 博之
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 29 (1) 77 - 77 2007
  • 渡邉 文子; 小川 智也; 有薗 信一; 寶門 玲美; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介
    日本理学療法学術大会 公益社団法人日本理学療法士協会 2006 D0796 - D0796 0289-3770 2007 
    【目的】
    呼吸リハビリテーションを継続しているCOPD患者を対象に運動耐容能,呼吸困難,健康関連QOLなどの各指標の経年的変化を検討する.
    【対象】
    呼吸リハビリテーションプログラムを施行し2年以上の観察期間があるCOPD患者で本研究参加の同意を得た48例,年齢69.3±7.0歳,FEV1(pred) 43.0±14.8%である.
    【方法】
    呼吸リハビリテーションは週2回・10週間の集中的なプログラムにて行い,以降は週1回の頻度で継続した.プログラムの内容は下肢トレーニング,上下肢筋力トレーニング,Threshold による吸気筋トレーニングからなる運動療法を主軸とした.評価は6MWD,6MWD時最低SpO2,呼吸困難 (BDI),健康関連QOL(SGRQ;西村浩一訳),呼吸筋力 (PImax),肺機能検査はFEV1(pred)とした.10週間前後と前より1年後および2年後で評価を行い,経年的変化は多変量分散分析にて検討した.
    【結果】
    6MWDは前後(447.6±100.9m→488.2±91.1m)で有意に改善し,1年後(472.7±106.3m)も維持されていた.2年後(459.5±111.5m)は前値に復する傾向にあった.6MWD時最低SpO2は前後(86.1±6.8→84.4±7.7%),1年後(82.3±8.2%),2年後(83.0±8.3%)で有意に悪化した.BDIは前後(6.9±1.6→7.8±1.5)で有意に改善し,1年後(7.5±1.5)も維持されていたが,2年後(6.8±1.6)は前値に復する傾向にあった.SGRQは前後(46.0±14.9→43.0±14.6)で有意に改善したが,1年後(47.5±16.1),2年後(48.0±16.3)には悪化する傾向にあった.PImaxは前後(62.4±28.1→74.7±27.8cmH2O),1年後(79.7±27.7cmH2O),2年後(83.0±29.0cmH2O)も有意に改善していた.FEV1(pred)は1年後(42.5±14.5%),2年後(42.6±16.3%)と悪化する傾向にあるが有意差はなかった.
    【考察】
    運動耐容能や呼吸困難の改善は1年後も維持されており,PImaxにおいては2年後も有意に改善していた.また運動耐容能や呼吸困難は2年後には前値に復する傾向にあり,6MWD時最低SpO2は経年的に有意に悪化していた.運動療法の継続により,1年後までは改善が維持できているものの,2年後には前値に復する傾向にあった.COPDは慢性疾患であり,長期的に運動耐容能や呼吸困難,健康関連QOLを維持していくには,再プログラムの実施を検討し,かつ酸素療法や薬物療法なども考慮にいれ包括的に管理していく必要があると考えられた.


  • 谷口 博之; 木村 智樹; 近藤 康博; 西山 理; 加藤 景介; 片岡 健介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 56 (3) 355 - 355 2007
  • 木村 元宏; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 片岡 健介
    アレルギー 一般社団法人 日本アレルギー学会 56 (3) 317 - 317 2007
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 片岡 健介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 56 (3) 319 - 319 2007
  • 指尾 豊和; 近藤 征史; 白木 晶; 武田 直也; 岩田 晋; 谷口 博之; 西山 理; 鈴木 隆二郎; 権田 秀雄; 松本 修一; 平松 哲夫; 進藤 丈; 安部 崇; 岩田 勝; 加藤 聡之; 久米 裕昭
    アレルギー 一般社団法人 日本アレルギー学会 56 (3) 333 - 333 2007
  • SAKAMOTO Koji; ASO Hiromichi; YOKOYAMA Toshiki; KATO Keisuke; NISHIYAMA Osamu; KIMURA Tomoki; KONDOH Yasuhiro; TANIGUCHI Hiroyuki
    Journal of the Japanese Association for Infectious Diseases The Japanese Association for Infectious Diseases 81 (4) 403 - 407 0387-5911 2007 
    We retrospectively reviewed 9 consecutive cases of primary pulmonary cryptococcosis having no comorbidity. At diagnosis, seven had no subjective symptoms and two had subtle symptom. Chest CT scan showed nodular shadows in 8, while 3 cases had infiltrative shadows. Eight of the nine were diagnosed with histopathology obtained by transbronchial lung biopsy or CT-guided needle aspiration biopsy. We also assessed PHA and Con A lymphocyte stimulation tests to measure cellular immune function in 6, four of whom showed decreased reaction of lymphocytes. We successfully treated seven of the nine with fluconazole alone and used fluconazole as a maintenance regimen in two. No relapse or treatment failure was seen after completion of antifungal treatment. Six cases were seropositive for serum cryptococcus antigen titer at diagnosis and only one showed seroconversion. We concluded that the duration of therapy for primary pulmonary cryptococcosis should not be necessarily determined by serum cryptococcus antigen seroconversion.
  • Osamu Nishiyama; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Keisuke Kato; Hiroaki Kume; Kaoru Shimokata
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY BLACKWELL PUBLISHING 33 (11) 1016 - 1021 0305-1870 2006/11 [Refereed]
     
    Although the clinical effects of the tulobuterol patch have been reported to include an increase in morning peak expiratory flow (PEF) values and a decrease of symptoms and the frequency of the rescue use of inhaled short-acting b(2)-adrenoceptor agonists, no trials comparing the efficacy of the tulobuterol patch to other standard inhaled long-acting b(2)-adrenoceptor agonists have yet been conducted. The aim of the present study was to compare the clinical effects of the patch formulation of tulobuterol with those of inhaled salmeterol in moderate to severe asthma. Fifty-four patients with moderate to severe asthma, whose conditions were suboptimally controlled despite receiving inhaled corticosteroids, were recruited. The study was a prospective, randomized trial of cross-over design comparing the effects of 4 weeks treatment with tulobuterol patch, 2 mg once daily, and salmeterol, 50 mg twice daily. The mean prebronchodilator morning PEF during the last 14 days of each treatment period and health-related quality of life (HRQoL) were the primary outcome variables. The HRQoL was assessed using the St George's Respiratory Questionnaire. Forty-four patients (81.5%) completed the trial and were included in the analysis. The mean morning PEF and HRQoL score were significantly improved in both the salmeterol (P < 0.0001 and P < 0.05, respectively) and the tulobuterol patch (P < 0.01 and P < 0.05, respectively) treatment periods compared with the run-in period. Although the mean morning PEF was significantly higher in the salmeterol-treated group than in the tulobuterol-treated group (P < 0.001), the HRQoL scores were comparable. The tulobuterol patch may be useful as a controller medication in addition to inhaled corticosteroids in moderate to severe asthma.
  • SAKAMOTO KOJI; YOKOYAMA TOSHIKI; ASO HIROMICHI; IWAKI MAI; NOMA SATOSHI; KATO KEISUKE; NISHIYAMA OSAMU; KIMURA TOMOKI; KONDO YASUHIRO; TANIGUCHI HIROYUKI
    日本呼吸器学会雑誌 44 (10) 675 - 680 1343-3490 2006/10
  • FUKATSU MASAHIRO; NISHIYAMA OSAMU; KIMURA TOMOKI; KATO KEISUKE; KONDO YASUHIRO; YOSHIKAWA HIDEO; TANIGUCHI HIROYUKI
    医療薬学 Japanese Society of Pharmaceutical Health Care and Sciences 32 (10) 1033 - 1037 1346-342X 2006/10 
    The purpose of this study was to evaluate the effect of gefitinib on quality of life (QOL) in patients with advanced non-small cell lung cancer in general practice. In order to do this, we retrospectively reviewed data of all patients who received a single course of treatment with gefitinib at Tosei General Hospital from July 2002 until May 2004, and evaluated their QOL based on The European Organization for Research and Treatment of Cancer's QLQ-C30 before and 4 weeks after initiation of treatment. Data for 45 patients were analyzed. Many QOL scores improved in patients who responded to treatment, though such improvement was not statistically significant. In addition many QOL scores improved in patients in whom the disease was stable, and many deteriorated in patients in whom it was progressing, though such changes were not statistically significant. In conclusion, a good response to gefitinib treatment can improve QOL in patients with advanced non-small cell lung cancer even if they have experienced a relapse or the disease has been refractory with 1 st or 2 nd line treatment. Pharmacists should take these findings into consideration when providing pharmaceutical advice to patients.
  • KATO KATSUHIRO; HASEGAWA RYUICHI; KATSUTA TOMOYA; TANIGUCHI HIROYUKI; KONDO YASUHIRO; KIMURA TOMOKI; NISHIYAMA OSAMU; KATO KEISUKE; NOMA SATOSHI; IWAKI MAI; SAKAMOTO KOJI; ASO HIROMICHI; YOKOYAMA TOSHIKI
    日本呼吸器学会雑誌 44 (10) 732 - 737 1343-3490 2006/10
  • 加藤 勝洋; 長谷川 隆一; 勝田 知也; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 野間 聖; 岩木 舞; 阪本 考司; 麻生 裕紀; 横山 俊樹
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 44 (10) 732 - 737 1343-3490 2006/10 
    症例は69歳男性。急性前立腺炎にて入院後、血痰及び両側上肺野に浸潤影が出現した。呼吸器内科転科時、PaO2 57.3Torr,BALではNeu 15.6%,Ly 33.6%,Eo 26.6%,Mφ 23.6%で定量培養陰性。急速に呼吸状態が悪化しARDSとなったため、非侵襲的・侵襲的人工呼吸管理、ステロイドパルス療法・好中球エラスターゼ阻害剤投与を行ったが改善せず、第8病日よりHFOVを開始した。HFOV管理後急速に酸素化の改善がみられ、第17病日には人工呼吸管理から離脱でき救命し得た。ARDSに対しHFOVが有効であった貴重な症例であると考え報告する。(著者抄録)
  • Yoshimasa Tanikawa; Hiroyuki Taniguchi; Osamu Nishiyama; Masahiro Aoyama; Yoshitaka Hibino; Takeshi Mizutani; Yasuhiro Kondoh; Tomoki Kimura; Keisuke Kato; Ryujirou Suzuki
    Japanese Journal of Lung Cancer 46 (6) 705 - 710 0386-9628 2006/10 
    Objective. We assessed the antitumor efficacy and safety of carboplatin and weekly paclitaxel and cyclooxygenase-2 (COX-2) inhibitor (meloxicam) combination therapy in patients with advanced non small-cell lung cancer (NSCLC). Subjects. Patients with stage IIIB, IV or relapsed NSCLC, aged between 20 and 80 with a PS of 0-2, were eligible. Each major organ function was adequate and cases with previous chemotherapy were not included. Methods. Patients received paclitaxel 70 mg/m2 weekly for 3 of 4 weeks with carboplatin (AUC 6) on day 1, as well as daily meloxicam (10 mg/day). Results. Twenty-six patients were treated: gender M/F 20/6, median age 63 yr (range, 45-78), stage IIIB/IV 11/15, PS 0/1/2 15/6/5, histology AD/SQ 22/4. Complete response was observed in 1 patient (4%) and partial response in 10 (38%), yielding an overall clinical response rate of 42%. Thirteen patients (50%) had stable disease. Five patients (19%) had grade 3 and one (4%) had grade 4 neutropenia. Two patients (8%) had grade 3 thrombocytopenia and one (4%) had grade 4. Grade 3 or more non-hematological toxicities observed included anorexia and vomiting in 2 (8%) and fever in 2 (8%). Grade 2 peripheral neuropathy was observed only in 2 (8%). No serious adverse events were recognized. Conclusions. Meloxicam in combination with carboplatin and weekly paclitaxel chemotherapy is an efficacious and feasible regimen in patients with advanced NSCLC. © 2006 The Japan Lung Cancer Society.
  • Yasuhiro Kondoh; Hiroyuki Taniguchi; Masanori Kitaichi; Toyoharu Yokoi; Takeshi Johkoh; Takashi Oishi; Tomoki Kimura; Osamu Nishiyama; Keisuke Kato; Roland M. du Bois
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 100 (10) 1753 - 1759 0954-6111 2006/10 [Refereed]
     
    Study objectives: Surgical Lung biopsy (SLB) plays an important role in the diagnosis of interstitial pneumonia, however, the occurrence of acute respiratory failure following SLB remains Largely unreported. We evaluated the incidence, clinical features, therapy and prognosis of acute exacerbation of interstitial pneumonia following SLB. Design: Retrospective study of consecutive patients who underwent SLB to establish a diagnosis of diffuse lung disease between May 1989 and April 2000. Patients with an acute exacerbation following lung biopsy were studied, and the HRCT images of the chest before and after surgery were reviewed. Measurements and results: Among the 236 consecutive patients with interstitial pneumonia who underwent a surgical Lung biopsy, five (2.1%) (IPF, 3; NSIP, 1; COP, 1) developed acute exacerbation of the diffuse lung disease in the course of 1-18 days after SLB. The extent of parenchymal involvement on HRCT before surgery was not significantly different between operated and contralateral nonoperated lung. Significantly increased regions of parenchymal involvement on HRCT were seen postoperatively compared with the preoperative CT in both the operated (20.7 +/- 12.5% versus 38.2 +/- 10.8%, P = 0.0431) and nonoperated lung (22.7 +/- 13.8% versus 70.5 +/- 24.4%, P = 0.0431), but the extent of the parenchymal involvement was significantly greater on the nonoperated side (P = 0.0251). Two of the 3 IPF patients died from the acute exacerbation. Conclusions: It is important to be aware of the possibility of acute exacerbation of interstitial pneumonia following SLB even after an apparently uneventful immediate postoperative course. The asymmetric image findings suggest that intraoperative respiratory management is a possible etiologic factor. (c) 2006 Elsevier Ltd. All rights reserved.
  • 渡邉文子; 小川智也; 有薗信一; 谷口博之; 近藤康博; 木村智樹; 西山理; 加藤景介
    日本呼吸管理学会誌 The Japan Society for Respiratory Care and Rehabilitation 15 (4) 473 - 476 0916-9253 2006/06 

    呼吸リハビリプログラムのなかで,運動療法は必須不可欠な項目であり,運動耐容能の改善やQOL(Quality of Life)の改善を目指している.しかしながら呼吸機能障害が高度な症例においては,運動療法の導入および遂行が困難な場合も多い.近年,慢性呼吸不全患者に非侵襲的陽圧換気法(noninvasive positive pressure ventilation: NPPV)が応用されているが,運動療法との関連では,運動療法中の換気補助目的にNPPVを装着する場合と,運動中ではなく夜間にNPPVを使う場合がある.今回,呼吸リハビリにおいて運動療法を行っていくうえでNPPVの併用について自験例を提示する.

  • NISHIYAMA OSAMU; TANIGUCHI HIROYUKI; KONDO YASUHIRO; KIMURA TOMOKI; KATO KEISUKE; NOMA SATOSHI; IWAKI MAI; ASO HIROMICHI; SAKAMOTO KOJI; SHIMIZU JUN'ICHI
    日本呼吸器学会雑誌 44 (5) 368 - 373 1343-3490 2006/05
  • ARIZONO SHIN'ICHI; OGAWA TOMOYA; WATANABE FUMIKO; HOMON REMI; KONDO YASUHIRO; KIMURA TOMOKI; NISHIYAMA OSAMU; KATO KEISUKE; TANIGUCHI HIROYUKI
    理学療法学 Japanese Physical Therapy Association (JPTA) 33 (2) 69 - 75 0289-3770 2006/04 
    The purposes of this study were: (1) to examine the short-term (10 weeks) and the long-term (1 year) effects of exercise training at high work rate on exercise tolerance in patients with chronic obstructive pulmonary disease, and (2) to detect the baseline physical conditions of patients who had shown decrease in exercise tolerance during the maintenance period. Fifty-seven patients underwent the exercise training, and were evaluated at baseline and 10 weeks and 1 year after the training. A significant improvement in 6-min walk distance was observed at 10 weeks and 1 year compared to the baseline. However, 6-min walk distance at 10 weeks was less than that at 1 year. Compare with patients who had not shown a decrease in 6-min walk distance, patients who had indicated the decrease (less than 54m) exhibited poorer pulmonary functions, less 6-min walk distance, and poorer ADL and Health Related QOL at baseline in the former group. Furthermore, there was a significant correlation between changes in 6-min walk distance and those in ADL score. The results suggest that poorer baseline physical condition may be an indicator of a decrease in 6-min walk distance during the maintenance period, although exercise training at high work rate improves 6-min walk distance. Moreover, a change in 6-min walk distance was significantly associated with a change in ADL score, which suggests that exercise training at the early stage can lead to long-term maintenance in improved in exercise tolerance.
  • K Kataoka; H Taniguchi; Y Hasegawa; Y Kondoh; T Kimura; O Nishiyama; K Imaizumi; T Kawabe; H Kume; K Shimokata
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 100 (4) 698 - 704 0954-6111 2006/04 [Refereed]
     
    Although pulmonary toxicity associated with gefitinib, an epidermal growth factor receptor inhibitor, has been reported recently, the accumulation of clinical information and the underlying mechanisms of gefitinib-induced interstitial lung disease (ILD) remain insufficient and unclear. After retrospectively reviewing the clinical records and chest X-rays of 489 lung cancer patients who were treated with gefitinib, we diagnosed four cases of gefitinib-induced ILD who underwent fiberoptic bronchoscopy and bronchoalveolar lavage (BAL). We found that the period of time from starting gefitinib to the onset of ILD was short, and concluded that a careful and close observation of a chest imaging study and a collection of respiratory symptoms was recommended. All four patients were treated with a high dose of corticosteroids, and ILD was resolved. We detected high levels of interferon-inducible protein-10 in BAL fluid, although we could not demonstrate the characteristic features of laboratory findings or BAL fluid cell analysis. We speculated that a Th1 type of lung tissue inflammation or lung injury might be involved as a part of mechanisms underlying gefitinib-induced ILD. (c) 2005 Elsevier Ltd. All rights reserved.
  • NOMA SATOSHI; NISHIYAMA OSAMU; IWAKI MAI; SAKAMOTO KOJI; ASO HIROMICHI; SHINDO YUICHIRO; KATO KEISUKE; KIMURA TOMOKI; KONDO YASUHIRO; TANIGUCHI HIROYUKI
    日本呼吸器学会雑誌 44 (1) 43 - 47 1343-3490 2006/01
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1191 - 1191 2006
  • 龍華 美咲; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1135 - 1135 2006
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1127 - 1127 2006
  • 村田 直彦; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 麻生 裕紀; 阪本 考司; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1210 - 1210 2006
  • 加藤 景介; 阪本 考司; 西山 理; 木村 智樹; 近藤 康博; 谷口 博之; 大石 尚史; 鈴木 隆二郎; 横井 豊治; 北市 正則; 片岡 健介; 下方 薫
    アレルギー 一般社団法人 日本アレルギー学会 55 (3) 416 - 416 2006
  • Fukatsu Masahiro; Nishiyama Osamu; Kimura Tomoki; Kato Keisuke; Kondoh Yasuhiro; Yoshikawa Hideo; Taniguchi Hiroyuki
    Japanese Journal of Hospital Pharmacy Japanese Society of Pharmaceutical Health Care and Sciences 32 (10) 1033 - 1037 1346-342X 2006 
    The purpose of this study was to evaluate the effect of gefitinib on quality of life (QOL) in patients with advanced non-small cell lung cancer in general practice. In order to do this, we retrospectively reviewed data of all patients who received a single course of treatment with gefitinib at Tosei General Hospital from July 2002 until May 2004, and evaluated their QOL based on The European Organization for Research and Treatment of Cancer's QLQ-C30 before and 4 weeks after initiation of treatment. Data for 45 patients were analyzed. Many QOL scores improved in patients who responded to treatment, though such improvement was not statistically significant. In addition many QOL scores improved in patients in whom the disease was stable, and many deteriorated in patients in whom it was progressing, though such changes were not statistically significant.In conclusion, a good response to gefitinib treatment can improve QOL in patients with advanced non-small cell lung cancer even if they have experienced a relapse or the disease has been refractory with 1 st or 2 nd line treatment. Pharmacists should take these findings into consideration when providing pharmaceutical advice to patients.
  • O Nishiyama; H Taniguchi; Y Kondoh; T Kimura; T Ogawa; F Watanabe; S Arizono
    QUALITY OF LIFE RESEARCH SPRINGER 14 (10) 2315 - 2321 0962-9343 2005/12 [Refereed]
     
    The purpose of this study was to reveal predictors for the long-term effects of pulmonary rehabilitation for chronic obstructive pulmonary disease (COPD) patients, in terms of health-related quality of life (HRQoL). We investigated the long-term effects of pulmonary rehabilitation in 53 COPD patients who had completed the outpatient program and could be evaluated continuously for 1 year. We also investigated factors related to long-term maintenance of HRQoL assessed by the St George's Respiratory Questionnaire (SGRQ). In the year following the program, the only items that retained a significant improvement compared with the pre-program levels were respiratory muscle strength and 6-min walking distance. Patients whose total SGRQ score showed improvements that were maintained above the minimal clinically important difference were placed in a maintained-improvements group (n=18, 34.0%), and the others in a non-maintained group (n=35, 66.0%). A comparison of the groups revealed that the maintained-improvements group had significantly lower forced vital capacity (FVC), inspiratory capacity (IC), and tidal volume (TV) at rest; higher PaCO2; greater initial impairments in HRQoL; and more frequent attendance in a maintenance program. In a multiple logistic regression model, only PaCO2 was identified as predictor for the maintenance of improvement in HRQoL over a long term. In conclusion, higher baseline PaCO2 is predictor of maintained, long-term improvement in HRQoL after pulmonary rehabilitation. Frequent attendance in a maintenance program is another predictor.
  • ARIZONO SHIN'ICHI; OGAWA TOMOYA; WATANABE FUMIKO; HOMON REMI; KONDO YASUHIRO; KIMURA TOMOKI; NISHIYAMA OSAMU; SENJU HIDEAKI; TANIGUCHI HIROYUKI
    理学療法学 Japanese Physical Therapy Association (JPTA) 32 (3) 110 - 114 0289-3770 2005/06 
    The purpose of this study was to determine whether supplemental oxygen can improve exercise capacity in chronic obstructive pulmonary disease (COPD) patients without exercise-induced hypoxemia. Ten stable COPD patients with resting PaO_2 more than 55 mmHg and exercise O_2 saturation not less than 88% were included in the study. The patients underwent constant load exercise tests without oxygen and receiving oxygen (4 L/min) in different days. Endurance time, breathlessness, leg fatigue, and the maximum heart rate were evaluated. As results, no improvements in all these variables were observed when oxygen was given. We conclude that supplemental oxygen does not improve exercise capacity in nonhypoxemic COPD patients.
  • O Nishiyama; H Taniguchi; Y Kondoh; T Kimura; T Ogawa; F Watanabe; S Arizono
    CHEST AMER COLL CHEST PHYSICIANS 127 (6) 2028 - 2033 0012-3692 2005/06 [Refereed]
     
    Study objective: In COPD, it has been shown that peripheral muscle dysfunction is a factor determining exercise intolerance. We examined the hypothesis that exercise capacity of patients with idiopathic pulmonary fibrosis (IPF) is, at least in part, determined by peripheral muscle dysfunction. Methods: Maximum oxygen uptake (VO(2)max) was evaluated in 41 consecutive patients with IPF, along with potential determinants of exercise capacity, both in the lungs and in the peripheral muscles. Results: Patients had reduced VO(2)max (893 +/- 314 mL, 46.0% predicted) and reduced quadriceps force (QF) [65% predicted]. Significant correlates of VO(2)max reduction were vital capacity (VC) [r = 0.79], total lung capacity (r = 0.64), diffusion capacity (r = 0.64), QF (r = 0.62), maximum expiratory pressure (r = 0.48), and PaO2 at rest (r = 0.33). In stepwise multiple regression analysis, VC and QF were independent predictors of VO(2)max. Furthermore, in subgroup analysis, QF was a significant contributing factor for VO(2)max in patients who discontinued exercise because of dyspnea and/or leg fatigue. Conclusions: We conclude that QF is a predictor of exercise capacity in IPF. Measures that improve muscle function might improve exercise tolerance.
  • O Nishiyama; H Taniguchi; Y Kondoh; T Kimura; T Ogawa; F Watanabe; K Nishimura
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 99 (4) 408 - 414 0954-6111 2005/04 [Refereed]
     
    The prognosis of patients with idiopathic pulmonary fibrosis (IPF) is generally considered to be poor. As the disease progresses, patients invariably become severely limited in their activities. Therefore, evaluating the health-related quality of life (HRQoL) in IPF patients is considered to be important. However, there have been few studies of this kind to date. We applied the St. George's Respiratory Questionnaire (SGRQ) to 41 consecutive IPF patients and examined various physiological variables to identify factors that were correlated with the HRQoL. Total lung capacity, transfer factor, arterial partial pressure of oxygen at rest, the lowest oxygen saturation during exercise test, and the baseline dyspnoea index (BDI) score were significantly correlated with the total SGRQ score. A similar tendency was observed in each component. Conversely, peak oxygen uptake, known as one of the important factors that determines HRQoL in chronic obstructive pulmonary disease (COPD), did not correlate with any SGRQ scores. In stepwise multiple regression analysis, the BDI score was selected as the only factor significantly contributing to the total SGRQ score. Dyspnoea was the most important factor determining HRQoL in IPF The types of other variables that correlated with the HRQoL in IPF patients were different from those in COPD. (c) 2004 Elsevier Ltd. All rights reserved.
  • Y Kondoh; H Taniguchi; T Yokoi; O Nishiyama; T Ohishi; T Kato; K Suzuki; R Suzuki
    EUROPEAN RESPIRATORY JOURNAL EUROPEAN RESPIRATORY SOC JOURNALS LTD 25 (3) 528 - 533 0903-1936 2005/03 [Refereed]
     
    The present study compared the efficacy of cyclophosphamide combined with low-dose prednisolone in the treatment of idiopathic pulmonary fibrosis (IPF) with efficacy in idiopathic fibrosing nonspecific interstitial pneumonia fibrosing (NSIP). A total of 27 patients with IPF and 12 patients with fibrosing NSIP were included in this study. All patients had undergone surgical lung biopsy. The diagnoses were made based on clinical, radiological and pathological findings. All patients were treated with intermittent pulse therapy with methylprednisolone for 4 weeks, followed by cyclophosphamide with low-dose prednisolone. According to pulmonary function tests, four of 27 patients with IPF had improved, 22 remained unchanged, and one had worsened at the completion of pulse therapy. After 1 yr of combination therapy, four of 27 patients had improved, 14 remained unchanged, and nine had worsened. After pulse therapy, four of 12 patients with fibrosing NSIP had improved, and eight remained unchanged. After 1 yr of combination therapy, eight of 12 patients had improved, four remained unchanged, and none had worsened. Median survival of IPF patients was 4.1 yrs, which is significantly worse than that of fibrosing NSIP patients. In conclusion, patients with fibrosing nonspecific interstitial pneumonia had a more favourable response to combination therapy and a better survival than those with idiopathic pulmonary fibrosis.
  • 野間 聖; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 阪本 考司
    アレルギー 一般社団法人 日本アレルギー学会 54 (3) 395 - 395 2005
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介
    アレルギー 一般社団法人 日本アレルギー学会 54 (3) 395 - 395 2005
  • 横山 俊樹; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介; 阪本 考司
    アレルギー 一般社団法人 日本アレルギー学会 54 (3) 345 - 345 2005
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 加藤 景介
    アレルギー 一般社団法人 日本アレルギー学会 54 (8) 979 - 979 2005
  • 岩木 舞; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介
    アレルギー 一般社団法人 日本アレルギー学会 54 (8) 1081 - 1081 2005
  • 近藤 康博; 阪本 考司; 谷口 博之; 北市 正則; 上甲 剛; 大石 尚史; 加藤 景介; 西山 理; 木村 智樹; 加藤 聡之; 横井 豊治
    アレルギー 一般社団法人 日本アレルギー学会 54 (8) 1104 - 1104 2005
  • Ono Kaoru; Taniguti Hiroyuki; Kondo Yasuhiro; Nishiyama Osamu; Kimura Tomoki
    The Journal of the Japan Society for Respiratory Care and Rehabilitation The Japan Society for Respiratory Care and Rehabilitation 14 (3) 442 - 447 2005 

    在宅NPPV療法では,患者が自ら機器の操作,管理を行うため,高い自己管理能力が求められる.患者がコンプライアンスを維持するためには訪問看護による継続的な看護介入が必要と考える.

    訪問看護では,患者の生活の場に立ち入ることにより,より個別的な生活に密着した問題解決方法が実践できる.また個別的なかかわりは,患者との距離を近づけ精神的支援を可能とする.これらのことから訪問看護は,チーム医療の一端として患者の在宅療養に密接にかかわり介入していくことで,在宅療養が困難と思われる患者であっても継続を可能にできることもある.しかし患者の高齢化で生活全般にわたり支援が必要なケースや,老人保健施設への入所困難など,訪問看護ではカバーできない問題もあり今後の課題と考える.

  • 近藤 康博; 谷口 博之; 木村 智樹; 西山 理; 加藤 景介; 岩木 舞
    日本呼吸ケア・リハビリテーション学会誌 一般社団法人 日本呼吸ケア・リハビリテーション学会 15 (1) 80_1 - 80_1 2005
  • Kimura Tomoki; Taniguchi Hiroyuki; Kondoh Yasuhiro; Nishiyama Osamu; Sakamoto Koji; Ogawa Tomoya; Watanabe Fumiko; Arizono Shin-ichi; Houmon Reimi
    The Journal of the Japan Society for Respiratory Care and Rehabilitation The Japan Society for Respiratory Care and Rehabilitation 14 (3) 342 - 342 2005
  • 渡辺 文子; 小川 智也; 有薗 信一; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 加藤 景介
    日本呼吸ケア・リハビリテーション学会誌 一般社団法人 日本呼吸ケア・リハビリテーション学会 15 (1) 74_2 - 74_2 2005
  • Osamu Nishiyama; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura
    Allergology International Blackwell Publishing 54 (2) 181 - 186 1323-8930 2005 [Refereed]
     
    Recently, in the field of asthma, there has been a substantial number of clinical trials which include health-related quality of life (HRQoL) as one of the outcomes. These studies employ two types of instruments for assessing HRQoL, generic and disease-specific instruments each being used individually or in combination. It has been proposed that treatments for patients aimed at increasing longevity, prevention of future morbidity, or making patients feel better. To achieve the last purpose, it is considered that HRQoL should be evaluated. Moreover, there are several reports demonstrating only weak to moderate correlations between physiological variables and HRQoL in patients with asthma. This is another reason for the importance of direct evaluation of HRQoL in conjunction with the conventional clinical indices. Pharmacological interventions based on guidelines seem to improve not only pulmonary function but also HRQoL in patients with asthma. However, all managements do not necessarily improve HRQoL, therefore assessing HRQoL is strongly recommended in clinical trials. However, the benefit of including HRQoL in evaluation of patients management is still unknown. It is valid that evaluation of HRQoL in clinical practice can both reveal patients problems that were not spontaneously identified by patients themselves and allow physicians focus on specific problems. Until such data are available, the benefit of assessing HRQoL in clinical practice will remain uncertain. Although conducting more clinical trials that prove efficacy in clinical practice is required, consideration of HRQoL in patients has recently been recognized as an important topic in the asthma field. It can be said that outcomes in health care for asthma will shift from the physiological aspect to humanistic aspect. ©2005 Japanese Society of Allergology.
  • O Nishiyama; H Taniguchi; Y Kondoh; T Kimura; T Katoh; T Oishi; S Matsumoto; T Yokoi; K Takagi; K Shimokata; T Johkoh; NL Muller
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LIPPINCOTT WILLIAMS & WILKINS 28 (4) 443 - 448 0363-8715 2004/07 [Refereed]
     
    Objective: The purpose of this study was to assess the high-resolution computed tomography (CT) findings of familial idiopathic pulmonary fibrosis (IPF). Methods: High-resolution CT scans obtained in 9 consecutive patients with biopsy-proven familial IPF were reviewed. The presence, distribution, and extent of various CT findings were evaluated. Results: All 9 patients had ground-glass opacities, intralobular reticular opacities, and irregular thickening of the interlobular septa; 7 (78%) had traction bronchiectasis, 7 (78%) had small foci of consolidation; and 3 (33%) had honeycombing. The abnormalities involved mainly the lower lung zones in 6 patients and the upper lung zones in 2 patients and had no zonal predominance in 1 patient. Follow-up CT showed increased extent of disease in 8 patients. Conclusions: The high-resolution CT findings of familial IPF resemble those of nonfamilial IPF. Familial IPF has a lower prevalence of honeycombing and a lower prevalence of predominant lower lung zone distribution than nonfamilial IPF, however.
  • O Nishiyama; H Kume; M Kondo; K Ito; M Ito; K Yamaki
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY BLACKWELL PUBLISHING ASIA 31 (3) 179 - 184 0305-1870 2004/03 [Refereed]
     
    1. Lysophosphatidylcholine (Lyso-PC), which is synthesized by phospholipase A(2), is generally considered to induce adhesion molecules. However, little is known about the involvement of Lyso-PC in the pathogenesis of bronchial asthma. The present study was designed to examine whether pre-exposure to Lyso-PC causes eosinophil recruitment and an increase in resistance in airways. 2. Eosinophils in bronchoalveolar lavage fluid (BALF) and the airway walls were enumerated after inhalation of 0.5 mg/mL Lyso-PC to guinea-pigs for 10 min. Respiratory resistance (R-rs) was recorded continuously over 6 h after inhalation of an equi-dose of Lyso-PC for an equivalent period. 3. The proportion of eosinophils was increased from 10.7 +/- 3.3 to 27.5 +/- 3.1% (P < 0.0001) in BALF 6 h after inhalation of Lyso-PC, whereas the proportion of neutrophils and lymphocytes was not increased. Histological examination also showed uniform distribution of eosinophils in the airway wall of bronchi and bronchioles 6 h after inhalation of Lyso-PC. The number of eosinophils (/10 h.p.f.) in the bronchi and bronchioles was increased from 43.5 &PLUSMN; 16.8 to 154.8 &PLUSMN; 21.7 (P < 0.0001) and from 34.8 +/- 0.7 to 106.0 +/- 26.6 (P < 0.01), respectively. This eosinophil infiltration was similarly observed 24 h later. 4. Next, we examined the effects of eosinophil infiltration induced by Lyso-PC on R-rs. Inhalation of Lyso-PC caused a slow increase in R, and the percentage increase in R-rs was 19.8 &PLUSMN; 1.9% (P < 0.0001) 6 h later. Eosinophil infiltration and an increase in R. did not occur after inhalation of physiological saline. These phenomena induced by Lyso-PC were diminished by pretreatment with dexamethasone (6 mug/kg per day for 3 days). 5. Lysophosphatidylcholine causes eosinophil infiltration and a subsequent increase in resistance in airways. Our results indicate that Lyso-PC may be involved in the pathophysiology of bronchial asthma.
  • 近藤 康博; 谷口 博之; 木村 智樹; 西山 理; 清水 淳市; 麻生 裕紀; 阪本 考司; 進藤 有一郎; 横山 俊樹
    アレルギー 一般社団法人 日本アレルギー学会 53 (2) 320 - 320 2004
  • 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 阪本 考司
    アレルギー 一般社団法人 日本アレルギー学会 53 (8) 885 - 885 2004
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 53 (8) 981 - 981 2004
  • 阪本 考司; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 53 (2) 343 - 343 2004
  • 麻生 裕紀; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 53 (2) 302 - 302 2004
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 阪本 考司; 小川 智也; 渡辺 文子; 有薗 信一; 寶門 玲美
    日本呼吸ケア・リハビリテーション学会誌 一般社団法人 日本呼吸ケア・リハビリテーション学会 14 (1) 65_1 - 65_1 2004
  • 谷口 博之; 近藤 康博; 西山 理; 松本 修一; 平松 哲夫; 権田 秀雄; 竹本 正興; 進藤 丈; 本多 康希; 谷川 吉政; 久米 裕昭; 長谷川 好規; 鈴木 隆二郎; 下方 薫
    肺癌 日本肺癌学会 43 (7) 921 - 921 0386-9628 2003/12 
    目的.paclitaxel (TXL)とdocetaxel (TXT)は同じtaxn系化合物であるが,完全な交差耐性を示さない薬剤であることが,基礎研究,臨床研究において報告されている.また,2nd lineのdocetaxel治療で約10%の奏効率が報告され,生存延長も期待されている.TXLの投与方法については3週間毎投与が標準治療とされているが,海外の報告ではweekly投与の場合,奏効率が単剤で30〜50%と優れ,また,3週間毎投与に比較し,骨髄毒性,脱毛,末梢神経障害,粘膜炎等の副作用が少ないとされている.今回は進行非小細胞肺癌症例に対するTXT+Carboplatin (CBDCA)併用化学療法の無効・再発症例に対し,Weekly TXL投与法の有効性と安全性について検討した.目的.Primary endpointは奏効率,有害事象発現率とし,secondary endpointはQOL・Survivalとした.方法.進行非小細胞肺癌症例に対するTXT+CBDCA併用化学療法(RTも含む)の無効・再発症例に対し,TXL80mg/m^2の毎週投与6コース終了後,2週間休薬しこれを1クールとした.結果.36症例が登録され,男女比は22/14,ECOG performance statusは0が19例,1が13例,2が4例,組織型は腺癌29例,扁平上皮癌6例,腺扁平上皮癌1例,IIIB8例IV28例.PR/SD/PD/NE : 5/20/9/2例で奏効率13.8%であった.G3 (MCI-CTC)以上の副作用は好中球減少が36%,血小板減少は0%,過敏反応(G2)を1例に認めた.QLQ C-30による健康関連QOLは痛みと食欲不振の項目が改善した.結論.TXLはTXTと同じタキサン系化合物であるが,TXT無効・再発症例にもTXLの毎週投与は有効であることが示唆された.
  • 西山 理; 谷口 博之; 近藤 康博
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 315 - 315 2003
  • 木村 智樹; 谷口 博之; 近藤 康博; 西山 理; 長谷川 隆一; 矢野 誠; 清水 淳一; 勝田 知也; 阪本 考司; 進藤 有一郎; 麻生 裕紀
    アレルギー 一般社団法人 日本アレルギー学会 52 (8) 850 - 850 2003
  • 勝田 知也; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 長谷川 隆一; 矢野 誠; 清水 淳一; 阪本 考司; 進藤 有一郎; 麻生 裕紀
    アレルギー 一般社団法人 日本アレルギー学会 52 (8) 927 - 927 2003
  • 進藤 有一朗; 谷口 博之; 近藤 康博; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 343 - 343 2003
  • 谷口 博之; 近藤 康博; 西山 理; 清水 淳市
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 344 - 344 2003
  • 片岡 健介; 谷口 博之; 近藤 康博; 西山 理; 久米 裕昭; 長谷川 好規; 下方 薫; 多賀 収
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 348 - 348 2003
  • 近藤 康博; 谷口 博之; 木村 智樹; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 52 (8) 814 - 814 2003
  • 谷口 博之; 近藤 康博; 木村 智樹; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 52 (8) 802 - 802 2003
  • 西山 理; 谷口 博之; 近藤 康博; 木村 智樹
    アレルギー 一般社団法人 日本アレルギー学会 52 (8) 770 - 770 2003
  • 矢野 誠; 谷口 博之; 近藤 康博; 木村 智樹; 西山 理; 清水 淳一; 長谷川 隆一; 進藤 有一郎; 阪本 考司
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 25 (6) 482 - 483 2003
  • O Nishiyama; K Kato; H Kume; Y Ito; R Suzuki; K Yamaki
    JOURNAL OF ASTHMA MARCEL DEKKER INC 40 (3) 281 - 287 0277-0903 2003 [Refereed]
     
    To evaluate the health status of patients with stable asthma and determine how disease severity affects the status, 68 consecutive patients were recruited from an outpatient clinic at an university hospital. Health status was assessed with the St. George's Respiratory Questionnaire and the Asthma Quality of Life Questionnaire (AQLQ). The results of the questionnaires revealed that the mean % predicted peak expiratory flow (PEF) in the preceding 2 weeks correlated most significantly with each total score for the two health status measures. We also found that, in the groups classified by mean % predicted PEF (mild, PEF greater than or equal to 80%; moderate, 60 to 79%; severe, < 60%), there were significant differences in all SGRQ scores (p < 0.05). In a subgroup analysis, the scores for moderate and severe patients were significantly worse than for mild patients in all four components (p < 0.05). Almost the same tendency was observed in the score distribution on the AQLQ. We conclude that mean % predicted PEF correlated most with the health status of the patients. Patients with PEF higher than 80% of predicted value generally maintained a better health status than did those with less than 80% of predicted PEF. Achieving higher than 80% of predicted PEF is important in managing asthma from the viewpoint of health status.
  • NISHIYAMA OSAMU; TANIGUCHI HIROYUKI; KONDO YASUHIRO; KIMURA MASAHIRO; SHIMIZU JUN'ICHI
    感染症学雑誌 日本感染症学会 76 (12) 1003 - 1009 0387-5911 2002/12
  • 前田 祐子; 谷口 博之; 近藤 康博; 西山 理; 片岡 健介; 多賀 収; 清水 淳市
    アレルギー 一般社団法人 日本アレルギー学会 51 (2) 250 - 250 2002
  • 片岡 健介; 谷口 博之; 近藤 康博; 西山 理; 多賀 収; 清水 淳市
    アレルギー 一般社団法人 日本アレルギー学会 51 (2) 250 - 250 2002
  • 谷口 博之; 近藤 康博; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 51 (2) 218 - 218 2002
  • 清水 淳市; 谷口 博之; 近藤 康博; 西山 理
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 912 - 912 2002
  • 木村 雅広; 谷口 博之; 近藤 康博; 西山 理; 片岡 健介; 清水 淳一; 矢野 誠; 前田 祐子; 多賀 収
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 1007 - 1007 2002
  • Osamu Nishiyama; Makoto Shimizu; Yasushi Ito; Hiroaki Kume; Ryujiro Suzuki; Toyoharu Yokoi; Kenichi Yamaki
    Respiratory Care 7 46 (7) 698 - 701 0020-1324 2001/07 [Refereed]
     
    We report on a 74-year-old man with an acute exacerbation of idiopathic pulmonary fibrosis (IPF) who was successfully treated with prolonged low-dose methylprednisolone, initiated at a loading dose of 2 mg/kg, followed by 2 mg/kg per day for 14 days. The dose was then tapered. The exacerbation observed on the chest radiograph and high-resolution computed tomography was found to have abated after the treatment. This successful case suggests the feasibility of this methylprednisolone treatment protocol for patients with IPF accompanied by accelerated deterioration. Furthermore, this case suggests possible similarities between acute exacerbation of IPF and late acute respiratory distress syndrome, as the same treatment protocol was previously proved to be beneficial for patients with late acute respiratory distress syndrome.
  • ITO YUKO; KUME HIROAKI; GOTO KUNIHIKO; ICHIKAWA MOTOSHI; NISHIYAMA OSAMU; KATO KEISUKE; ITO YASUSHI; SUZUKI RYUJIRO; YAMAKI KEN'ICHI
    日本呼吸器学会雑誌 39 (4) 287 - 292 1343-3490 2001/04
  • 西山 理; 加藤 景介; 伊藤 康; 久米 裕昭; 鈴木 隆二郎; 山木 健市
    アレルギー 一般社団法人 日本アレルギー学会 50 (2) 284 - 284 2001
  • O Nishiyama; H Taniguchi; Y Kondoh; K Nishimura; R Suzuki; K Takagi; K Yamaki
    RESPIRATORY MEDICINE W B SAUNDERS CO LTD 94 (12) 1192 - 1199 0954-6111 2000/12 [Refereed]
     
    The Visual Analogue Scale 8 (VAS8), consisting of eight linear scales, has been developed to measure health-related quality of life (HRQoL) in chronic obstructive pulmonary disease (COPD) patients. The purpose of this study was to examine the validity and responsiveness of the VAS8. First, HRQoL was assessed in a cross-sectional study with the VAS8 and the St George's Respiratory Questionnaire (SGRQ) in 46 COPD patients. Relationships between the VAS8 and various physiological parameters were examined. Second, in a longitudinal study. changes in HRQoL scores after pulmonary rehabilitation were evaluated in 29 COPD patients. The total VAS8 scores showed a weak correlation with vital capacity and maximal inspiratory pressure and a moderately strong correlation with 6-min walking distance and dyspnoea rating. The total VAS8 score showed a significant correlation with each SGRQ score. Furthermore, almost every VAS8 and SGRQ score improved significantly after pulmonary rehabilitation. The change in the total VAS8 value showed a strong correlation with that of the SGRQ. The VAS8 is well-suited to assess HRQoL in COPD patients. Visual analogue scales are generally useful in measuring HRQoL in COPD patients, and the VAS8 is particularly beneficial because or its case of use.
  • O Nishiyama; Y Kondoh; H Taniguchi; K Yamaki; R Suzuki; T Yokoi; K Takagi
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LIPPINCOTT WILLIAMS & WILKINS 24 (1) 41 - 46 0363-8715 2000/01 [Refereed]
     
    Purpose: The purpose of this work was to evaluate the radiographic and serial high resolution CT (HRCT) findings in patients with nonspecific interstitial pneumonia/fibrosis (NSIP). Method: We identified 15 patients with biopsy-proven NSIP. Radiography and initial and follow-up CT findings were reviewed. Results: Predominant radiographic findings were bilateral infiltrates distributing in the middle and lower lung zones and decreased lung volumes. At initial CT, predominant patterns were peribronchovascular interstitial thickening (n = 6), parenchymal bands (n = 8), intralobular interstitial thickening (n = 12), and traction bronchiectasis (n = 14). Mixed pattern of ground-glass opacity and consolidation (n = 11) were predominant findings of increased lung opacity. At follow-up CT in 14 cases, the abnormalities had disappeared completely in 3, improved in 9, persisted in 1, and worsened in 1. Conclusion: The pulmonary abnormalities observed in NSIP on HRCT can disappear or be diminished in most cases after corticosteroid therapy. Intralobular interstitial thickening and traction bronchiectasis, which have been considered to be indicators of irreversible fibrosis, also show favorable responses.
  • ITO SATORU; TANIGUCHI HIROYUKI; KONDO YASUHIRO; MIZUNO YASUNORI; NISHIYAMA OSAMU; WAKAYAMA HIDEO; NAKAGAWA TAKU; HAYASHI HIROKI; YAMAKI KEN'ICHI
    日本呼吸器学会雑誌 37 (5) 424 - 428 1343-3490 1999/05
  • 水谷 宏; 久米 裕昭; 伊藤 理; 西山 理; 小川 雅弘; 伊藤 康; 山木 健市; 鈴木 隆二郎; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 48 (2) 321 - 321 1999
  • KONDO YASUHIRO; TANIGUCHI HIROYUKI; NISHIYAMA; YOKOI TOYOJI; SUZUKI RYUJIRO; NODA YASUNOBU; KATO TOSHIYUKI; KANEKO MICHIE
    臨床放射線 44 (1) 93 - 98 0009-9252 1999/01
  • NISHIYAMA OSAMU; TANIGUCHI HIROYUKI; KONDO YASUHIRO; MIZUNO YASUNORI; ITO SATORU; WAKAYAMA HIDEO; NAKAGAWA TAKU
    アレルギー Japanese Society of Allergology 47 (12) 1258 - 1263 0021-4884 1998/12 
    To evaluate irreversible airflow limitation in asthmatics, we studied 168 patients admitted to our hospital with acute exacerbation of asthma. All patients were given intravenous methylprednisolone for at least 7 days to maximum 14 days and the best of PEF(% of predicted)was evaluated. In all subjects, the best of PEF showed significant correlations with both the patients'age(r=-0.411, p<0.0001)and the duration of asthma(r=-0.494, p<0.0001). A significant correlations between the best of PEF and the duration of asthma were also observed in both patients over 60 years old(r=-0.157, p<0.0001)and non-smokers(r=-0.568, p<0.0001). We conclude that asthma may develop irreversible airflow limitation in itself and the degree of impairment of lung function correlated with the duration of the disease.
  • 中川 拓; 谷口 博之; 近藤 康博; 三河 健一郎; 水野 裕文; 西山 理; 若山 英雄
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1095 - 1095 1998
  • 西山 理; 谷口 博之; 近藤 康博; 谷澤 誠; 水野 裕文; 伊藤 理; 若山 英雄; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 299 - 299 1998
  • 谷澤 誠; 谷口 博之; 近藤 康博; 西山 理; 水野 裕文; 伊藤 理; 若山 英雄; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 298 - 298 1998
  • 三河 健一郎; 谷口 博之; 近藤 康博; 西山 理; 水野 裕文; 若山 英雄; 中川 拓; 林 宏樹
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1040 - 1040 1998
  • 谷口 博之; 近藤 康博; 三河 健一郎; 水野 裕文; 西山 理; 若山 英雄; 中川 拓; 林 宏樹
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1037 - 1037 1998
  • 若山 英雄; 谷口 博之; 近藤 康博; 谷澤 誠; 水野 裕文; 西山 理; 伊藤 理; 中川 拓; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 349 - 349 1998
  • 水野 裕文; 谷口 博之; 近藤 康博; 谷澤 誠; 西山 理; 伊藤 理; 若山 英雄; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 348 - 348 1998
  • 渡辺 文子; 小川 智也; 小出 和美; 島田 政明; 土屋 紀元; 谷口 博之; 近藤 康博; 谷澤 誠; 西山 理
    理学療法学Supplement 公益社団法人 日本理学療法士協会 1998 452 - 452 1998
  • NISHIYAMA OSAMU; MATSUMOTO SHUICHI; HIRAMATSU TETSUO; AOYAMA MASAHIRO; KOJIMA EIJI
    気管支学 The Japan Society for Respiratory Endoscopy 20 (1) 17 - 20 0287-2137 1998/01 
    We reviewed the records of 823 patients who underwent fiberoptic bronchoscopy to determine the various causes of hemoptysis. Chest roentgenograms were normal in 559 patients (67.9%) and abnormal in 264 (32.1%). Specific diagnosis could be identified in 100 patients (17.9%) with normal chest roentgenograms and 196 patients (74.2%) with any abnormal findings on chest roentgenograms. Bacterial infection (54 patients, 9.7%), bronchiectasis (10 patients, 1.8%), and pulmonary vascular abnormalities (10 patients, 1.8%) accounted for the majority of hemoptysis of patients with normal chest roentgenograms. Malignant neoplasms were diagnosed in 5 patients (0.9%). In contrast, bronchogenic carcinoma (66 patients, 15.9%), mycobacterial infection (32 patients, 14.0%), old tuberculosis (33 patients, 12.5%), bacterial infection (32 patients, 12.1%), and bronchiectasis (19 patients, 7.2%) accounted for the majority of causes of hemoptysis of patients with any abnormal findings on chest roentgenograms. Malignant neoplasms were diagnosed in 50 patients (18.9%). All 5 patients with malignant neoplasms and normal chest roentgenograms were over 55 years old. But malignant neoplasms were diagnosed in even young patients under 40 years old with any abnormal findings on chest roentgenograms. We conclude that following patients with hemoptysis shoud be examined using fiberoptic bronchoscopy to rule out malignancy ; (1) all patients with abnormal findings on chest roentgenograms and (2) patients with higher age even without abnormal findings on chest roentgenograms.
  • KONDO YASUHIRO; TANIGUCHI HIROYUKI; TANIZAWA MAKOTO; NISHIYAMA OSAMU; MIZUNO HIROFUMI; ITO OSAMU; WAKAYAMA HIDEO; NAKAGAWA TAKU; TAKAGI KENZO
    日本呼吸管理学会誌 7 (2) 136 - 140 0916-9253 1997/12
  • 西山 理; 谷口 博之; 近藤 康博; 谷澤 誠; 伊藤 理; 若山 英雄; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 916 - 916 1997
  • 谷澤 誠; 谷口 博之; 近藤 康博; 西山 理; 伊藤 理; 若山 英雄; 高木 健三
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 828 - 828 1997
  • 谷口 博之; 近藤 康博; 谷澤 誠; 西山 理; 伊藤 理; 若山 英雄; 久米 裕昭; 高木 健三; 馬場 研二
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 822 - 822 1997

Books etc

  • 西山理 (ContributorVI びまん性肺疾患、1 間質性肺炎、(18) 放射線肺障害)日本臨牀社 2021/08 v, 463, 9p
  • 西山理 (Contributor4. 慢性呼吸不全の診断と治療へのアプローチ、(2) 肺高血圧症・右心不全への対応)医学書院 2021/04 9784260045926 xx, 496p
  • 西山理 (Contributor第10章 アレルギー145, 146)医学書院 2021/03 9784260042284 ix, 456p
  • 日本呼吸器学会; 日本リウマチ学会; 日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針2020作成委員会 (Contributor)日本呼吸器学会 : 日本リウマチ学会,メディカルレビュー社 (発売) 2020/04 9784779223686 ix, 227p
  • Respiratory Disease Series: Diagnosis Tools and Disease Managements. Advances in Asthma, Pathophysiology, Diagnosis and Treatment.
    Osamu Nishiyama (Joint workBronchial Thermoplasty: Japanese Experiences.)Springer 2019
  • インフォームドコンセントのための図説シリーズ、びまん性肺疾患と特発性間質性肺炎
    西山 理 (Joint workI章 総論、1. 病態、3. 治療、2) 呼吸リハビリテーション、在宅酸素療法)医薬ジャーナル社 2014
  • 呼吸器疾患のステロイド療法実践マニュアル
    西山 理 (Joint work各論 呼吸器疾患におけるステロイド療法の実践、III 特発性間質性肺炎、D. 特殊病態での使用法(高齢者・合併症・併存症など))南江堂 2014
  • 別冊・医学のあゆみ 呼吸器疾患―state of arts Ver.6
    西山 理 (Joint work第4章 主要疾患― 病態・診断・治療、アレルギー性肺疾患、Churg-Strauss症候群)医歯薬出版株式会社 2013
  • びまん性肺疾患の臨床 第4版
    西山 理 (Joint work各論14 ARDS、症例35 発熱、多関節痛を主訴に来院したサルコイドーシス症例)金芳堂 2012
  • プライマリケアのための喘息治療. 改訂版
    西山 理 (Joint work-外来マネジメント- V. ワンポイントアドバイス. G. 喘息と局所麻酔薬)医薬ジャーナル社 2011
  • 高齢者診療のツボCOPD
    西山 理 (Joint work安定期のCOPD 非薬物療法 肺炎・インフルエンザワクチンの接種、QOLの改善)日本医事新報社 2006
  • ナースが取り組む!COPDチームケアガイド、
    西山 理 (Joint work第3部 通院患者の看護と指導、1. 包括的呼吸リハビリテーション、2. 呼吸管理)メディカ出版 2006
  • 内科学レビュー2005 最新主要文献と解説
    西山 理 (Joint work呼吸器 3. 特発性間質性肺炎(IIPs))総合医学社 2005
  • 日常診療に役立つ喀痰染色アトラス
    西山 理 (Joint workIII. ガイドラインからみた市中肺炎の診断と治療)医療ジャーナル社 2002
  • 気管支鏡の読み
    西山 理 (Joint work治療 放射線療法が奏効した胆嚢癌肺転移気管支内浸潤例)丸善 2001
  • プラクティカル内科シリーズ5 気管支喘息
    西山 理 (Joint work第4章 治療へのアプローチ C.喘息急性増悪の治療 2.気管支拡張薬の位置づけ)南江堂 1999

MISC

Awards & Honors

  • 2015/10 The Japan Society for Respiratory Care and Rehabilitation superior presentation award
     
    受賞者: Osamu Nishiyama
  • 2012/11 The Japan Society for Respiratory Care and Rehabilitation encouragement award
     
    受賞者: Osamu Nishiyama
  • 2011/11 The Japan Society for Respiratory Care and Rehabilitation Superior presentation award
     
    受賞者: 西山 理

Research Grants & Projects

  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2023/04 -2026/03 
    Author : 西山 理; 藤田 貢; 松本 久子
  • 日本学術振興会:科学研究費助成事業 基盤研究(C)
    Date (from‐to) : 2022/04 -2025/03 
    Author : 松本 久子; 田辺 直也; 佐藤 晋; 西山 理; 佐野 安希子
     
    令和5年度は、喘息例での胸部CT所見(気管支拡張・細気管支炎像の有無,進展度)等と遺伝子多型との関係を中心に解析した。候補遺伝子としてびまん性汎細気管支炎や非若齢発症喘息のリスク遺伝子であり、分泌型ムチンをコードするHCG22遺伝子の一塩基多型(SNP)rs2523870に着目した。喘息106例において、rs2523870のgenotypeはTT 37名、CT 45名、CC 24名であった。リスクアレルのホモ接合体であるCC型と他との2群比較で、喘息発症年齢、呼吸機能、mReiff score(気管支拡張像の進展度)との関係はなかったが、CC型で好酸球性副鼻腔炎併存率、過去の血液好酸球数、過去の吸入ステロイド量、過去及び直近の胸部CTで細気管支炎罹患葉数が有意に多かった。IL4RA rs8832、IL13 rs20541についても解析を行ったが、mReiff scoreや細気管支炎の罹患葉数との関連は認めなかった。本研究でCC型での細気管支病変が、好酸球性か否かは確認できなかったが、好酸球性副鼻腔炎の併存率から推察すると一定の割合で好酸球性細気管支炎も存在すると考えられる。喘息の細気管支病変例で、好中球性気道炎症を呈するびまん性汎細気管支炎と同様のリスク多型が確認されたことは、分泌型ムチンの異常、気道クリアランスの障害が、炎症型を問わず細気管支病変の形成に寄与する可能性が推察される(J Allergy Clin Immunol 2023 Epub ahead of print)。
  • 肺疾患を伴う肺高血圧症患者における運動耐容能向上およびリハビリテーションの効果増強を目指したネーザルハイフローの応用
    公益財団法人 福田記念医療技術振興財団:2020年度共同研究助成
    Date (from‐to) : 2020/04 -2021/03 
    Author : 西山理; 東本有司; 高瀬徹
  • 慢性呼吸器疾患増悪入院後の訪問リハビリテーション介入による身体活動向上に関する効果の検証
    勇美記念財団:在宅医療研究への助成
    Date (from‐to) : 2018/08 -2019/07 
    Author : 西山 理

Teaching Experience

  • AllergyAllergy Kindai University, Faculty of Medicine
  • Respiratory MedicineRespiratory Medicine Kindai University, Faculty of Medicine
  • InfectionInfection Kindai University, Faculty of Medicine

Committee Membership

  • 2022/03 - Today   Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JPCPHS)   council member

Others

  • 2022/04 -2025/03  近畿大学学内研究助成金(21世紀研究開発奨励金(共同研究助成金)) 
    特発性肺線維症における下気道細菌叢 dysbiosisの病的機序の解明 (KD2206)
  • 2019/04 -2022/03  Research grant of Kindai University 
    Study on microbiome in lung disease
  • 2020/04 -2021/03  "オール近大"新型コロナウイルス感染症対策支援プロジェクト 研究助成(共同研究) 
    基礎疾患を有する患者における COVID19 重症化関連因子の探索
  • 2020/04 -2021/03  "オール近大"新型コロナウイルス感染症対策支援プロジェクト 研究助成 
    退院可能であった重症新型コロナウイルス肺炎患者の長期経過に関する検討


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.